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Abstract 
 
Introduction 
Sporadic Creutzfeldt-Jakob Disease (sCJD) remains the commonest type of prion disease 
with an incidence of approximately 1 per million and accounting for approximately 80% of 
cases.  The exact infectious mechanism is unknown.  However, the most widely accepted 
theory is the ‘protein-only hypothesis’ initially suggested by Prusiner and later developed 
over the years.  It has been proposed that prion diseases result from the post translational 
change of a normally expressed protein (PrP
C
) into a disease associated form (PrP
Sc
).  PrP
Sc
 is 
partially protease resistant and reserves the ability to self-propagate by inducing further PrP
C
 
to undergo conformational change thus producing more PrP
Sc
, a so called ‘seeding’ effect.  
PrP
Sc
 subsequently aggregates throughout the brain, producing the neuro-pathological hall 
mark of prion diseases which includes spongiform change, neuronal loss and astrocytic 
gliosis. 
 
Despite its rarity, the clinical presentation is well described and classically follows a 
characteristic course of rapid onset dementia with associated neurological decline that often 
includes cerebellar ataxia, myoclonus, eventually leading to a state of akinetic mutism and 
death within a period of 4-6 months.  Atypical presentations are less common but are well 
documented in the literature. 
 
Currently, there is not a disease specific ante-mortem test available for the diagnosis of sCJD 
with post mortem remaining the definitive means of diagnosis.  Current diagnostic criteria 
rely on clinical presentation in association with the MRI, EEG and CSF 14-3-3 protein.  
However, none of these investigations are specific for sCJD. Atypical presentations can be 
diagnostically challenging and there can be a delay in diagnosis which can be distressing for 
relatives.  This identified a need for a disease-specific, reliable diagnostic test that can 
provide an earlier and more accurate diagnosis. 
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A recently developed assay called real time quaking induced conversion (RT-QuIC) exploits 
the seeded conversion of normal prion protein to the abnormal form and therefore detects 
disease-associated prion protein in the cerebrospinal fluid.  Based on recent evidence, it has 
RT-QuIC has been reported to be highly sensitive and specific for diagnosing sporadic CJD 
and has the potential to identify cases that conventional diagnostic techniques such as 
electroencephalogram and MRI may miss, potentially contributing to an earlier and more 
accurate diagnosis.  This study aimed to provide a prospective analysis of the utility of RT-
QuIC in routine clinical practice. 
 
Aims of Thesis 
 
The aims of this work were: 
 
 To prospectively assess the diagnostic utility of RT-QuIC in routine clinical practice 
 
 To assess if certain clinical factors affect the RT-QuIC result, for example, codon 129 
genotype, age at onset, symptoms at onset and duration of disease. 
 
 To determine the value of RT-QuIC in cases where there is diagnostic uncertainty 
using current diagnostic techniques and establish whether it can provide an earlier 
diagnosis 
 
 To review the operational parameters (for example CSF volume, timing of lumbar 
puncture) of RT-QuIC throughout the course of the study and contribute to the 
optimisation and development of this new diagnostic test. 
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Methods 
 
162 suspected cases of sCJD were referred to the National CJD Research and Surveillance 
Unit (NCJDRSU) within the 18 month study period. 146 suspected cases underwent a lumbar 
puncture and 115 of the clinically suspected cases had 14-3-3 and RT-QuIC analysis 
performed. All cases were examined by the author where possible and the family were 
interviewed using a standardised questionnaire.  All cases were classified according to the 
current EuroCJD criteria pre and post review. MRI and EEG were reviewed where possible.  
Genetic testing and codon 129 were analysed following obtained consent. Brain tissue 
following post mortem examination was also reviewed where possible. 
 
Results 
 
44 cases were classified as pathologically confirmed sCJD.  Of these, 35 (79.9%) were RT-
QuIC positive. 36 (81.8%) were 14-3-3 positive, 14 (31.8%) were EEG positive and 24 
(54.5%) were MRI positive. 45 cases were classified as ‘probable’ according to WHO 
criteria, 38 (84.4%) were RT-QuIC positive, 40 (88.8%) were 14-3-3 positive, 14 (31.1%) 
were EEG positive and 27 (60.1%) were MRI positive. There were 5 cases classified as 
‘possible’ sCJD of which 3(60%) were RT-QuIC, 0 were 14-3-3, MRI or EEG positive. 7 
cases were classified as ‘unknown’ cases of sCJD of which 2(28.6%) were positive for both 
RT-QuIC and 14-3-3. 3(42.8%) had a positive MRI and 0 cases had a positive EEG. 
 
Overall, RT-QuIC has a sensitivity of 80% and specificity of 100% with a positive predictive 
value of 100%.  In comparison, 14-3-3 has a sensitivity of 82%, specificity of 82% and PPV 
of 95%.  EEG has a sensitivity of 32%, specificity of 91% and PPV of 93%.  MRI has a 
sensitivity of 55%, specificity of 100% and PPV of 100%.   
 
During the initial data period, 15µl of CSF was used to perform the RT-QuIC test although 
over the course of the study, it was found that 30µl gave better discrimination between 
positive and negative RT-QuIC results.  However, some CSF samples from cases of 
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suspected sporadic CJD had a negative RT-QuIC response at 30µl but a postive RT-QuIC 
response was obtained using 15µl.  Therefore, CSF samples were tested at both 15µl and 
30µl. 
 
Discussion 
 
In concordance with current literature, RT-QuIC is similar in sensitivity to 14-3-3 but more 
specific and has a greater positive predictive value.  It is considerably more sensitive than 
EEG and more specific. It is more sensitive than MRI but has equal specificity and positive 
predictive value. The 3 cases classified as ‘possible’ and RT-QuIC positive were highly 
suspected to be cases but died without a post-mortem.  The 2 cases classified as ‘unknown’ 
and RT-QuIC positive were both clinically suspected to be cases but also died without a post-
mortem.  However, since this study was started, based on further European and International 
research on RT-QuIC, the European diagnostic criteria for the diagnosis of sCJD has changed 
as of January 2017 to include RT-QuIC.  Therefore, based on the new criteria, all of these 
cases would now be considered likely cases of sCJD.  Overall, this is a highly sensitive, 
specific and reliable test for the diagnosis of sCJD, especially in cases where the diagnosis is 
difficult and when conventional tests may fail. This study supports the current literature. 
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Lay Summary 
 
Introduction 
Sporadic Creutzfeldt-Jakob Disease (sCJD) is a rare brain condition with an incidence of 1 
per million per annum.  It presents with a recognisable pattern of symptoms with rapidly 
progressive dementia frequently being a key feature.  The condition is unequivocably fatal 
and death usually ensues within 4-6 months of symptom onset. The cause of sCJD remains 
unknown.  The most widely accepted theory is based on a specific type of protein that we all 
have in our brains called the prion protein. Its exact function remains elusive although it is 
thought to play a part in our brains being able to function normally.  The prion protein is 
folded into a specific shape and this shape is important for it to work normally.  It has been 
hypothesised that in sCJD, this protein unfolds into a different shape and therefore is unable 
to work normally.  In addition, the abnormally folded protein then triggers other prion 
proteins to do the same, almost like a domino effect. This produces very characteristic 
changes in the brain tissue which can be seen under a microscope following post mortem.  
Post mortem remains the definitive means of diagnosing the condition. In life, there is no 
perfect test to make the diagnosis.  Diagnostic criteria was introduced and developed over the 
years and include the presence of a recognisable pattern of symptoms in addition to 
suggestive abnormalities on MRI brain scanning, specific abnormalities on a brain wave test 
(called and encephalogram or EEG) and the presence of protein in the fluid that bathes the 
brain (called 14-3-3). This is a different type of protein that the brain releases into the spinal 
fluid whenever there is a disease process affecting the brain.   
 
The difficulty with current tests is that they are not specific for sCJD and the changes 
observed on these tests can be seen in other neurological conditions that can affect the brain.  
In addition, atypical presentations of sCJD are well recognised which the conventional tests 
may miss.  This identified a need for a more disease specific test that was reliable and more 
accurate.  Over recent years a new type of spinal fluid test was introduced called real time 
quaking induced conversion or RT-QuIC for short. In this test, a synthetic form of prion 
protein is added to the spinal fluid of a person suspected of having sCJD. If the abnormal 
protein is present, it should start to convert the normal prion protein to an abnormal form.  
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Using a special fluorescent marker, this process can be monitored and gives rise to a positive 
result. If there is no fluorescent effect then the test is negative.  Current evidence has 
indicated that RT-QuIC can diagnose sCJD with higher accuracy and potentially identify 
cases that conventional tests may miss.  This study aims to assess the use of RT-QuIC in 
routine clinical practice. 
 
Aims of thesis 
 
The aims of this work was: 
 
 To assess the use of RT-QuIC in routine clinical practice 
 
 To identify whether any clinical factors such as age at onset, disease duration, 
underlying genetics influence the outcome of the test. 
 
 To ascertain whether RT-QuIC can diagnose atypical presentations that the 
conventional tests may miss 
 
 To contribute to the development of the test throughout the course of the study.  For 
example, what is the best volume of spinal fluid to use when completing the test 
 
Methodology 
The National CJD Research and Surveillance Unit (NCJDRSU) was established in 1990.  We 
rely on the referral of clinically suspected cases of CJD by clinicians from throughout the 
United Kingdom.  As part of surveillance, the unit has a number of other roles including 
analysis of 14-3-3 and RT-QuIC, review of MRI and EEG, genetic analysis and neuro-
pathological examination of brain tissue.  Suspected cases are offered a visit by a doctor from 
the unit.  In addition to patient assessment, surveillance data is obtained during an interview 
with families using a standardised questionnaire. 
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162 suspected cases of sCJD were referred to the NCJDRSU within the 18 month study 
period. 146 suspected cases underwent a lumbar puncture and 115 of the clinically suspected 
cases had 14-3-3 and RT-QuIC analysis performed. All cases were examined by the author 
where possible and the family were interviewed using a standardised questionnaire.  All cases 
were classified according to the current WHO criteria pre and post review. MRI and EEG 
were reviewed where possible.  Genetic testing was performed following obtained consent. 
Brain tissue following post mortem examination was also reviewed where possible. 
 
Results 
44 cases were classified as pathologically confirmed sCJD.  Of these, 35 (79.9%) were RT-
QuIC positive. 36 (81.8%) were 14-3-3 positive, 14 (31.8%) were EEG positive and 24 
(54.5%) were MRI positive. 45 cases were classified as ‘probable’ according to WHO 
criteria, 38 (84.4%) were RT-QuIC positive, 40 (88.8%) were 14-3-3 positive, 14 (31,1%) 
were EEG positive and 27 (60.1%) were MRI positive. There were 5 cases classified as 
‘possible’ sCJD of which 3(60%) were RT-QuIC, 0 were 14-3-3, MRI or EEG positive. 7 
cases were classified as ‘unknown’ cases of sCJD of which 2(28.6%) were positive for both 
RT-QuIC and 14-3-3. 3(42.8%) had a positive MRI and 0 cases had a positive EEG. 
 
Overall, RT-QuIC has a sensitivity of 80% (the percentage of cases that were correctly 
identified as positive) and specificity of 100% (the percentage of cases that were correctly 
identified as negative).  In comparison, 14-3-3 has a sensitivity of 82% and specificity of 
82%.  EEG has a sensitivity of 32% and specificity of 91%.  MRI has a sensitivity of 55%, 
specificity of 100% and PPV of 100%. 
 
Clinical factors including disease duration, age at onset, timing of lumbar puncture did not 
appear to influence the RT-QuIC result. 
 
During the initial data period, 15 microlitres of CSF was used to perform the RT-QuIC test 
although over the course of the study, it was found that 30 microlitres was better at 
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differentiating between positive and negative RT-QuIC results.  However, some CSF samples 
from cases of suspected sporadic CJD had a negative RT-QuIC response at 30 microlitres but 
a postive RT-QuIC response was obtained using 15microlitres.  Therefore, CSF samples were 
tested at both 15microlitres and 30microlitres. 
 
Discussion 
 
In concordance with current literature, RT-QuIC is similar in sensitivity to 14-3-3 but more 
specific.  It is considerably more sensitive than EEG and more specific. It is more sensitive 
than MRI but has equal specificity. The 3 cases classified as ‘possible’ and RT-QuIC positive 
were highly suspected to be cases but died without a post-mortem.  The 2 cases classified as 
‘unknown’ and RT-QuIC positive were both clinically suspected to be cases but also died 
without a post-mortem.  However, since this study was started, based on further European 
and International research on RT-QuIC, the European diagnostic criteria for the diagnosis of 
sCJD has changed as of January 2017 to include RT-QuIC.  Therefore, based on the new 
criteria, all of these cases would now be considered likely cases of sCJD.  Overall, this is a 
highly sensitive, specific and reliable test for the diagnosis of sCJD, especially in cases where 
the diagnosis is difficult and when conventional tests may fail. This study supports the recent 
literature. 
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Introduction 
 
1.1 Prion Diseases: an overview 
 
Creutzfeldt-Jakob Disease (CJD) belongs to a group of fatal neurodegenerative 
diseases collectively known as Prion Disease or Transmissible Spongiform 
Encephalopathies (TSEs).  Prion diseases affect both animals and humans and can 
occur in sporadic, acquired or inherited forms.  They are characterised by the fact 
that they are potentially transmissible and by their recognisable neuro-pathological 
and molecular features. 
The existence of acquired forms of prion disease and transmissibility support the 
presence of an infectious agent
1
.  However, the exact infectious mechanism remains 
unknown.  The most widely accepted theory is the ‘protein-only hypothesis’, initially 
suggested by Prusiner and later developed over the years
2
.  It has been proposed that 
prion diseases result from the post-translational change of a normally expressed 
protein, named the prion protein (PrP
C
) into a disease associated form (PrP
Sc
)
2,3
.  
PrP
C 
is found in abundance in many tissues throughout the body, although 
predominantly in the central nervous system
4
.  Its exact function remains unclear. It 
is not thought to be essential for life although, interestingly, studies on transgenic 
mice have demonstrated that PrP
C 
is essential for the transmission of prion disease
5
.  
PrP
Sc 
is partially protease resistant and has the ability to self-propagate by inducing 
further PrP
C
 to undergo conformational change thus producing more PrP
Sc
, a so 
called ‘seeding’ effect
5
.  PrP
Sc 
subsequently aggregates and is deposited throughout 
the brain producing the neuro-pathological hallmark of prion diseases along with 
spongiform change within the brain, along with neuronal loss and astrocytic gliosis
6
. 
Historically, epidemics of CJD have arisen in humans via the cannabalistic 
consumption of infectious body tissues during funerary practices in Papa New 
Guinea (termed Kuru) and more recently in the form of Variant CJD (vCJD)
7,8
.  
Variant CJD is a zoonosis that developed following the contamination of the human 
food chain by Bovine Spongiform Encephalopathy (BSE), a TSE affecting cattle
9,10
.  
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In addition, secondary transmission of vCJD by blood transfusion and the use of a 
blood product have also been reported
11-16
.  Iatrogenic CJD (iCJD) is the 
consequence of unintended transmission of CJD via certain medical/surgical 
procedures involving infectious human material or contaminated instruments
17
.  
Genetic prion diseases were initially described over a hundred years ago, when 
neurodegenerative diseases characterised by ataxia and dementia were observed in 
families across several generations
18-20
.  It is now known that this is due to mutations 
of the gene which encodes the normal cellular prion protein PrP
C 
(PRNP).  Although 
autosomal dominant in inheritance, cases of genetic disease have been reported in the 
absence of a family history of the condition
21
.
 
Currently, the commonest form of prion disease is CJD with sporadic CJD (sCJD) 
accounting for ῀80% of cases with an annual mortality rate of approximately 1-2 per 
million of the population in most countries
22
.  The exact aetiology of sCJD remains 
unknown.  Despite its rarity, the clinical presentation has been well described with 
rapidly progressive dementia being a central feature.  Death typically ensues within 
4-6 month of symptom onset
23, 24
.  However, clinical heterogeneity is well recognised 
in sCJD resulting in challenging and sometimes delayed diagnosis
25, 26
.  Early and 
accurate diagnosis of CJD is imperative for three reasons.  The differential diagnosis 
of rapidly progressive dementia is wide and diagnosing or excluding CJD early may 
negate the need for unnecessary investigations or empirical treatment
25, 27
. Secondly, 
there are the obvious public health implications and prevention of spreading the 
disease via iatrogenic means
28
.  Lastly, an earlier diagnosis has the potential to ease 
the distress of the families of patients suffering from the condition.  In addition, if 
treatments are developed, early diagnosis would allow early treatment, with 
potentially better therapeutic outcome.  Having spoken at the CJD Support Network 
charity conferences in 2013 and 2014, I learned that providing an earlier diagnosis, 
as well as identifying a treatment, were considered the main aspects of future 
research that were a priority to many families who have lost relatives to the 
condition. 
The early and accurate diagnosis has been a longstanding problem with standard 
diagnostic techniques lacking in specificity and not accounting for the clinical 
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heterogeneity of the condition
25
.  Here, I will provide a summary of prion diseases, 
concentrating on sCJD, the standard methods of diagnosis, their limitations and the 
emergence of newer, more disease specific diagnostic techniques. 
 
1.2 The Prion Protein and Protein-Only Hypothesis 
 
PrP
C
 is the normal cellular form of PrP
Sc
, the molecular hallmark of prion disease.  
The gene encoding this protein in humans is PRNP, located on chromosome 20.  In 
adults, PrP
C
 is highly expressed in the central nervous system (commonly located on 
the neuronal cell membrane) although its exact function remains unclear but it is 
thought to play a role in the development of the nervous system
21, 25
.   
The normal cellular protein is a glycophosphatidylinositol-anchored (GPI) 
glycoprotein with a largely α-helical C-terminal domain and an intrinsically 
disorganised N-terminal domain that binds copper and zinc
21, 25, 29
. The majority of 
PrP
C
 is produced in the endoplasmic reticulum and GOLGI apparatus. Thereafter it 
migrates to the cell surface where it is typically located attached by the GPI anchor 
and exposed to extracellular contents. However, during its lifecycle, PrP
C 
is 
internalised into endosomes and then re-cycled to the cell surface again
25, 29
.  PrP
C
 
can also be cleaved internally by endogenous proteases to produce N-terminal and C-
terminal fragments
25
.   
PrP
C 
is expressed in both the central nervous system and peripheral tissues, although 
it is found in abundance within neurons
25
.  Describing the role of PrP
C
 in healthy 
individuals has remained elusive.  Manipulation of PrP
C
 levels has been reported to 
alter a number of cellular functions including metal homeostasis, maintenance of the 
peripheral nerve myelin, synaptic plasticity, neuro-protection and cell signalling
30-36
. 
Prion proteins have become well known for their causative role in a range of 
neurodegenerative diseases in humans and animals.  Human prion diseases include 
sCJD, Gerstmann Strӓussler-Scheinker disease (GSS), Familial Fatal Insomnia (FFI), 
genetic CJD (gCJD), Kuru, Variably Protease Sensitive Prionopathy (VPSPr) and 
vCJD.  Animal prion diseases include Scrapie in sheep, goats and mouflon, 
The Diagnostic Utility of RT-QuIC for the Diagnosis of Sporadic Creutzfeldt-Jakob Disease   
 Introduction 4 
 
Transmissible Mink Encephalopathy (TME), Chronic Wasting Disease (CWD) in 
deer and Bovine Spongiform Encephalopathy (BSE) in cattle.  Over the years, 
extensive research has been conducted in attempt to establish the types of prion 
diseases and their infectious mechanisms. 
Prion diseases share a number of common histopathological characteristics and 
neurological symptoms.  These include spongiform degeneration of the central 
nervous system, formation of amyloid plaques, reactive gliosis and neuronal loss
6, 37-
39
.  When prion diseases arise as infections, they have a number of notable or atypical 
features: potentially long incubation periods, a lack of inflammation response and a 
lack of disease specific immune response
40
.  Initially these diseases were thought to 
be caused by a ‘slow virus’ due to their long incubation periods.  However, neither a 
virus nor nucleic acids have been detected to support this theory.  In addition, the 
‘viral hypothesis’ fails to account for the fact that up to 10-15% of cases are 
dominantly inherited genetic diseases and only a relative minority of cases 
(iatrogenic and variant CJD) have a clear infectious cause
40-42
.   
The most widely accepted theory regarding the infectious mechanism of prion 
diseases is the ‘protein-only hypothesis’ initially proposed by Griffith
2
, later 
developed over the years and now supported by a compelling body of evidence
40, 43-
46
.  Prusiner postulated that the infectious agent was not a virus but a ‘novel 
infectious entity’ consistent of protein alone and coined the phrase ‘prion’ to 
demonstrate the proteinaceous and infectious nature of the agent
3
.  This hypothesis 
suggests that prion diseases result from a post-translational conversion of the normal 
prion protein, PrP
C
, to a misfolded form, PrP
Sc
.  This newly formed abnormal protein 
then acts as a template to facilitate conversion of further PrP
C
 to PrP
Sc
 leading to 
further accumulation and aggregation within the central nervous system and 
ultimately resulting in disease
3, 40, 43, 44, 45
.  Of interest is that this process occurs 
regardless of the origin of PrP
Sc 39
.  For example, it will occur if the abnormal prion 
protein is acquired through an external source, as seen in vCJD. Alternatively, the 
source can be internal due to mutations in the PRNP gene as in GSS, FFI and genetic 
CJD.  In addition, it will also occur in cases of spontaneous conversion of PrP
C
 or 
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somatic mutation of PRNP as have been suggested as potential mechanisms in 
sporadic CJD
 42, 47
.   
Studies have demonstrated that the PrP
Sc
 is characterised not only by its misfolded 
shape with a high β sheet content, but also the fact that, unlike PrP
C
, it is insoluble 
and partially resistant to protease digestion
40, 45,
 
48, 49
 .  In contrast, PrP
C
 is a soluble 
protein high in α helix structure, low in β sheet content and highly susceptible to 
protease degradation
40, 45
.  This transition from predominantly α-helical to β sheet 
content appears to be a central event in prion propagation and pathogenesis although 
the exact mode by which it occurs remains unknown.  In prion disease, most, if not 
all, the α-helical structure is refolded into β sheets and the abnormal prion protein 
forms oligomers and then multimers that can then form amyloid fibrils
50
. Some 
researchers believe that it is the accumulation of PrP
Sc 
that results in the 
neurodegeneration within the brain
50
.  However, other groups believe that it is the 
process of conversion from PrP
C
 to PrP
Sc 
that causes the neuronal injury and cell 
loss
51, 52
. 
The accumulation of PrP
Sc
 in the central nervous system is a feature that is common 
to all prion diseases.  Studies have shown that the accumulation of PrP
Sc 
is a 
relatively late event which occurs shortly before the initial clinical symptoms and 
signs develop
53, 54
.  In variant CJD, but not other human prion disease, peripheral 
lymphoid tissues such as tonsil, appendix, spleen and lymph nodes show abnormal 
prion protein accumulation well before brain involvement and clinical signs are 
manifest
55
.  This obviously has public health implications where there is potential for 
transmission. 
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1.3 Prion Disease in Animals 
 
The main forms of animal prion disease include Scrapie in sheep, transmissible mink 
encephalopathy (TME), chronic wasting disease in cervids (CWD) and bovine 
spongiform encephalopathy (BSE) of cattle.  Some animal prion diseases have been 
transmitted through contaminated feed or via a contaminated environment
56, 57
. 
 
1.3.1 Scrapie 
 
Scrapie was the first TSE described and is considered the prototypic TSE. The first 
reported case of this neurodegenerative prion disorder affecting sheep, mouflon and 
goats occurred in the United Kingdom in 1732
57
.  The official name of Scrapie was 
used from 1853 and was derived from one of the principle signs of the condition 
where the animal compulsively scrapes their fleece against a hard surface due to an 
intense sensation of itching, frequently leading to wool loss
57
.  Classical and atypical 
forms of the condition are now recognised.  Other clinical signs of the classical form 
include behavioural change (head tremor, teeth grinding, hyper-responsive, 
agitation), increased thirst, excessive lip smacking, altered gait, incoordination and 
convulsions
58
.  In atypical forms of the condition, pruritis is usually absent and ataxia 
and incoordination are more pronounced
59, 60
.  It is a naturally occurring infectious 
disease with an estimated incubation time of 2-5 years and death usually ensues 
within 2 weeks to 6 months from the symptomatic onset
61
.   
Contamination of the environment was initially attributed to infectivity in the 
placenta from scrapie infected ewes
62
.  However, other sources of environmental 
contamination have now been established including urine, faeces and saliva
63-65
.  
This would explain cases of Scrapie where lambing had not occurred
66, 67
.  Scrapie 
PrP
Sc 
has been detected in a number of peripheral tissues including tonsils, spleen, 
lymph nodes, muscle and colon
68
.  Laboratory studies have demonstrated that PrP
Sc 
can attach to soil particles that remain near to the surface and are therefore accessible 
to grazing animals implicating soil as a plausible reservoir for Scrapie infectivity
69
.  
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In addition, abnormal prion PrP
Sc 
is able to persist in soil for years without losing its 
infectious properties
70
.  For example, there have been reports of sheep being infected 
in a building that had been unused for 16 years
71
.   
Detectable PrP
Sc 
has been reported in the faeces of sheep both in the early preclinical 
and end stages of the disease, suggesting that prions are likely to be shed into the 
environment throughout the course of the disease
64
.  It is invariably fatal and 
contagious resulting in the disease becoming endemic within flocks and remains a 
notifiable disease.  It is not thought to pose a threat to humans
72
. 
 
1.3.2 Transmissible Mink Encephalopathy (TME) 
 
TME is rare and affects ranch raised mink and is thought to have been acquired 
through contaminated feed although the exact origin of the infectious agent is 
unknown
61
.  Four outbreaks of TME were reported in the United States between 
1947 and 1985 and no cases have been documented since this time
73, 22
.  Many of the 
cases occurred in Wisconsin but ranches in Minnesota and Idaho were also 
affected
73
.  TME has also been reported in ranch raised mink in Canada, Finland, 
Germany and Russia
61, 73
.  The incubation period is thought to be approximately 6-12 
months with clinical onset to death usually between 2-8 weeks
74
.  The source of these 
outbreaks is unclear although epidemiological studies have suggested that Scrapie 
contaminated feed is the most plausible cause
74 
.   
The clinical phenotype is usually a gradual onset of behavioural change with 
increased aggression and hyperaesthesia, abnormal gait, compulsive biting, blindness 
and coma
61
.  Whether TME can survive long term in the environment remains 
unclear, but unlike Scrapie, TME does not seem to recur during subsequent years on 
the same farm.  However, like Scrapie, TME is contagious and outbreaks invariably 
lead to death of an entire herd
74
. 
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1.3.3 Chronic Wasting Disease (CWD) 
 
CWD is the only known prion disorder affecting free ranging wildlife including mule 
deer, white tailed deer, black tailed deer, elk and moose
75
.  It was initially recognised 
as a clinical ‘wasting’ syndrome in 1967 in captive mule deer in Colorado, USA.  It 
was later identified as a TSE by Williams in 1980 and has spread to free-range and 
captive populations in 23 US states and 2 Canadian provinces
76, 77, 78
. Following 
exportation of farmed cervids, cases were also detected in the Republic of Korea
79, 80
. 
In 2016, the first case of CWD in Europe was discovered in free ranging reindeer in 
Norway
81
.   
CWD is highly infectious and readily transmitted amongst cervids.  They continue to 
expand in prevalence and geographical range in North America since its initial 
discovery almost 50 years ago: it is considered the most contagious prion disease
82
.  
Presently, there is significant variation in the prevalence of CWD throughout North 
America, with levels ranging from 0-30% in wild populations
83
 and approaching 
80% in captive groups
84
.  
Factors that influence the variation in prevalence and geographical spread, remain 
incompletely understood.  The most convincing and leading hypothesis for the 
progressive spread of the condition in wild populations is the presence of CWD 
prions in bodily fluids
75, 85
. CWD prions has been identified in saliva, blood, faeces 
and urine in transgenic mice expressing cervid PrP
C 
with oral and nasal inoculation 
proving an efficient means of transmission
85
.  Transmission is therefore thought to be 
facilitated through exchange of bodily fluids between animals and the shedding of 
PrP
Sc 
into the environment and subsequent indirect transmission through ingestion of 
contaminated water, soil and plants
85
.   
The clinical hallmark of CWD is chronic weight loss and emaciation leading to 
death.  Other signs include behavioural changes including decreased interaction with 
other animals and loss of fear to humans, weakness, excessive salivation and 
bruxism, polydipsia, polyuria and tremors
86
. 
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Currently, there has been no evidence of transmission to humans but ongoing 
research and surveillance continues in order to assess the zoonotic potential.  
Transmission studies of CWD prions to humanised transgenic mice or non-human 
primates suggest a strong species barrier
87
.   However, in vitro studies have 
demonstrated that human PrP can be converted by CWD prions into PrP
Sc
 upon 
adaptation
88
.  Therefore the potential for zoonotic transmission cannot be fully 
excluded.  CWD is not transmissible to mice expressing human PrP
C 
although it is 
efficiently transmitted to mice expressing cervid PrP
C 75
.  It is thought that this 
difference is likely to reflect a species barrier, at least in part, likely to be the 
consequence of differences in amino acid sequences of the host cellular prion protein 
between species, thus demonstrating the importance of amino acid sequence in 
disease susceptibility
75
.  A recent systematic review investigating the current 
evidence of the transmissibility of CWD prions to humans found that five 
epidemiological studies, two studies on macaques and seven studies on humanised 
transgenic mice did not provide evidence to support transmission to humans
89
.  
Further work has been done by Race et al who also used cynomolgus macaque 
monkeys as a surrogate model for CWD transmission to humans
90
.  Following 
inoculation, a variety of highly sensitive disease screening assays were used to assess 
the presence of abnormal prion protein over a 13 year clinical observation period.  
There was no evidence of CWD transmission in the specimens examined
90
.  
However, there have been two studies on squirrel monkeys as well as several in vitro 
experiments that provided evidence that CWD prions can seed human prion protein 
to a misfolded state.  It was therefore concluded that transmission of CWD prions to 
humans cannot be ruled out as a possibility and therefore ongoing research and 
surveillance is important, particularly given the potential for long incubation 
periods
89
.  
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1.3.4 Bovine Spongiform Encephalopathy (BSE) 
 
Bovine spongiform encephalopathy (BSE) is a transmissible spongiform 
encephalopathy that occurs in cattle, initially recognised in the United Kingdom in 
1985
91
.  BSE has a long incubation period of 2.5-5 years and usually affects cattle of 
adult age.  Clinically it is characterised by an abnormal gait, paralysis of the hind 
legs, changes in behaviour, tremors and hyper-responsiveness to stimuli.  Other non-
specific symptoms include weight loss, decreased milk production and pacing.  
Death usually ensues within 2 weeks to 6 months from the development of 
symptoms
92
. 
BSE was most likely rose from infectivity in meat and bone meal (MBM) made from 
slaughtered cows and sheep as cattle feed.  From 1972, In the UK, cow intestines 
were used in MBM as a protein supplement which accelerated the occurrence of 
BSE
93
.  BSE has occurred in European countries that import MBM from the UK, 
however, most reported cases are from the UK, peaking in 1992
57
.   
The original source of the infectious material was at first suspected to be scrapie 
sheep but the possibility of a spontaneous bovine prion disease has not been 
excluded
57
.   
The compulsory notification and slaughter of cases of BSE (over 3 million cows) and 
a ban on MBM use was effective in controlling the epidemic
57, 94
.  Initial studies 
suggested that isolates from cases of BSE were homogeneous.  However, the 
possibility of a mixture of strains within BSE was later suggested and subsequent 
studies have provided strong evidence that this is the case.  Rarer variants of BSE 
have now been identified with isolates of PrP
Sc
 demonstrating profiles that differ in 
their biochemical and molecular properties.  Western Blot analyses identified types 
of PrP
Sc
 that had a different pattern of unglycosylated band migration compared to 
the classic form of BSE, known as ‘C type’.  Profiles that migrated to a higher (H 
Type) or lower (L Type) position were demonstrated.  A further study by Jacob et al 
also noted differences within molecular mass, antibody affinity binding, proteinase 
kinase digestion thus providing a strong argument for the presence of different 
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strains of BSE.  Histological features of the initial L type isolates also showed a 
proclivity for the forebrain in comparison to the classical form of BSE which has a 
higher density of PrP
Sc 
deposition in the brainstem
95
.  In addition, the PrP
Sc
 formed 
unusual amyloid plaques which led to the name Bovine Amyloidotic Spongiform 
Encephalopathy (BASE). 
96, 97
. 
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1.4 Prion Disease in Humans 
 
Human prion diseases currently recognised: Kuru; sCJD; vCJD; iCJD; VPsPr and the 
inherited forms which include GSS, FFI and genetic CJD (gCJD).  Sporadic CJD 
accounts for over 90% of prion disease.  The different forms of human prion disease 
share neuropathological features and the characteristic deposition of PrP
Sc
 in tissue, 
especially brain tissue: the identification of this remains the definitive means of 
diagnosis. 
 
1.4.1 Kuru 
 
Kuru is a prion disease that became an epidemic amongst the Fore and surrounding 
groups in Papa New Guinea in the late 1950s.  The term Kuru was derived from the 
Fore word Kuria or Guria which means ‘to shake’
98
.  It is now widely accepted that 
Kuru was transmitted and propagated among members of the Fore tribe of Papa New 
Guinea through ritualistic mourning cannibalism
98
.  Deceased family members of the 
tribe were traditionally cooked and eaten in order to demonstrate love and respect 
that was thought to help free the spirit of the dead
98
.  Females and children usually 
consumed the brain and spinal cord, the organs in which the infectious prions were 
most concentrated, thus allowing the transmission of Kuru.  This disease was 
subsequently more prevalent among women and children
98
.  In 1959, these funerary 
practices were banned by Australian authorities and no individual born after 1959 
has been diagnosed with the condition.  However, the mothers of these children 
continued to die suggesting that vertical transmission did not occur
98, 99
. Affected 
women who had married into neighbouring villages were shown to have contributed 
to the epidemic
98
.  Studies have suggested the epidemic may have started around 
1900 and it has been postulated that the origin was a sporadic case of CJD
100
.  This 
suggestion is supported by the fact that the molecular and biological properties 
between Kuru and sCJD are indistinguishable
101
. 
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The disease has lingered due to Kuru’s long incubation period from anywhere 
between 10 to over 50 years.  However, the epidemic has declined from over 200 
deaths per year in 1957 to no deaths in 2005
102
. 
The disease itself is characterised by progressive cerebellar ataxia and interestingly 
dementia was frequently late in the disease or did not occur at all.  The preclinical 
phase averages between 10-13 years but can be as short as 5 or as long as 50 years 
after initial exposure.  Symptoms start with cerebellar signs and gait ataxia, followed 
by severe tremors, emotional lability and later dysphagia, mutism and eventually 
death
102
.  Histologically, amyloid plaques containing PrP
Sc 
are seen in the 
cerebellum, accompanied by cerebellar atrophy, generalised astrocytosis and 
neuronal degeneration with relatively mild spongiform change
103
. 
 
1.4.2 Creutzfeldt-Jakob Disease (CJD) 
 
CJD is the most frequent of the human prion diseases although it remains rare.  The 
vast majority of CJD cases are sporadic (85-90%) although 5-15% are familial and 
1% iatrogenic, iCJD
104, 105
.  The annual mortality rate of sporadic CJD is 
approximately 1 per million persons with a worldwide distribution
22
.  The median 
age of the onset of the disease is between 57 and 62 years with an extensive age 
range between 14-92 years old
22
.  Patients with vCJD and iCJD are usually much 
younger which led to an earlier appreciation that the mode of transmission might be 
different.  Genetic CJD patients have only a slightly younger age of onset compared 
with sporadic CJD.   
 
1.4.2.1 Sporadic CJD (sCJD) 
 
Sporadic CJD (sCJD) remains the commonest type of CJD with an annual mortality 
rate of approximately 1-2 per million persons per year worldwide
22
.  It is essentially 
a disease of the middle aged and elderly with a median age of onset 70 years
104
, 
although younger cases also occur
22
.  The cause of sCJD remains unknown despite 
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large scale epidemiological studies.  Despite its rarity, the clinical presentation has 
been well described.  The typical clinical picture consists of a rapidly progressive, 
short duration illness dominated by dementia with associated neurological decline 
that often includes myoclonus, visual symptoms and cerebellar ataxia, eventually 
leading to a state of akinetic mutism and death
105
.  In some cases, psychiatric 
symptoms, behavioural change and insomnia can occur
23
.  The disease progression is 
typically rapid with a median disease duration to death of 4.5 months
106
. The 
cognitive decline may manifest as a global dementia, although specific behavioural 
abnormalities or particular cognitive issues may be prominent in the early stages.  
The disease is fulminant and deterioration may be observed on a day to day basis 
with death ensuing sometimes in a matter of weeks
106
.  Myoclonus, especially 
provoked by startle, is present in more than 90% of patients at some point during the 
illness but may be absent at presentation, even when the dementia is profound
23
.  
Other recognised symptoms include visual symptoms including visual blurring or 
loss, diplopia or visual field defects which may progress to cortical blindness. Visual 
hallucinations and misperceptions are also common. Extrapyramidal signs (such as 
hypokinesia), cerebellar and corticospinal tract involvement may also occur.  The 
mode of death usually relates to a reduced conscious level and loss of the swallow 
reflex, frequently resulting in aspiration pneumonia
23, 106
.  
 
However, while almost 80% of cases follow this typical presentation, atypical cases 
are also recognised and often pose a diagnostic challenge.  Atypical presentations are 
less common but clinical heterogeneity in sporadic CJD is a recognised phenomenon 
and can be diagnostically challenging
23, 25
.  Two particularly well documented 
atypical forms include a predominantly cerebellar onset (Oppenheimer-Brownell 
variant)
107
, a predominantly visual onset (Heidenhain variant)
108
 and more rarely, a 
stroke-like onset has also been reported
109
. Cases of patients presenting with isolated 
aphasia and spastic paraparesis have also been reported
23
.  Younger patients with 
sporadic CJD have clinical features that are somewhat distinct from the more typical 
older patient
23
. Pocchiari et al conducted a collaborative study in 2004 and assessed 
some of the predictors of survival in sporadic CJD.  The group concluded that longer 
survival was associated with younger age at onset of illness and female gender, 
codon 129 heterozyosity (discussed below) and certain investigations results
110
.   
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Atypical presentations of sCJD differ not only by their clinical presentation but also 
in disease course, diagnostic test results and specific neuropathological 
characteristics.  This spectrum of clinico-pathological variation has been correlated 
with different genotypes at codon 129 of the prion protein gene (PRNP) on 
chromosome 20 and also different conformations of the abnormal prion protein, 
PrP
Sc
.  A clinico-pathological molecular classification of sCJD was suggested by 
Parchi et al dividing the disease into different subgroups according to the codon129 
genotype and PrP
Sc 
conformation
23
.  The PRNP genotype is homozygous or 
heterozygous for methionine (M) or valine (V) at codon 129 classifies cases into 
those with methionine homozygosity (MM), valine homozygosity (VV) or 
heterozygosity (MV).  For example, the ‘classical’ sCJD phenotype of advanced age 
at onset, rapidly progressive dementia, early and prominent myoclonus and ataxia 
with a short duration of illness is seen in MM or MV individuals with PrP
Sc
 Type 1 
(MM1 or MV1) whereas VV2 patients have a cerebellar variant, late dementia and 
longer duration of illness. In total, 6 clinical phenotypes have been described.  The 
following tables summarise the key subtypes and their clinical and neuropathological 
characteristics.  However, the mechanisms underlying the links between particular 
molecular and clinical findings are yet to be established.  At neuropathology, 
spongiform change, astrocytosis and neuronal loss are observed, with amyloid 
plaques present in the minority.  Typically, the cerebral cortex is involved, but the 
severity and distribution of neuropathological changes is variable although this is not 
discussed in detail here
23
.   
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1.4.2.1.1 The Molecular Classification of Sporadic CJD (Adapted from Parchi 
et al) 
 
Table 1 Disease duration and age for each molecular subtype 
sCJD Subtype Age at Onset (years) Disease Duration 
(months) 
MM1 or MV1 70.1 (48-86) 4 (1-24) 
VV2 64.5 (45-83) 6.3 (3-18) 
MV2 Kuru 65.4 (48-81) 15.8 (5-48) 
MM/MV2 cortical 67.8 (61-75) 20 (12-36) 
MM2 thalamic 52.3 (36-71) 15.5 (8-24) 
VV1 39.3 (24-49) 15.3 (14-16) 
MM/MV 1+2 cortical 68.6 (42-89) 4 (1-26) 
MV2 kuru NA NA 
VV2 +1 69.3 (59-85) 6.5 (3.5-13) 
 
 
Table 2 Typical Clinical Features of sCJD Molecular Subtype 
sCJD Subtype Clinical Features 
MM1 or MV1 Typically rapidly progressive dementia 
and myclonus 
Ataxia in 50% 
Visual impairment in 30% 
VV2 Ataxic onset with dementia developing 
later 
MV2 Kuru Duration can exceed 2 years 
Dementia and ataxia 
MM/MV2 cortical Myoclonus, pyramidal signs and 
dementia 
Ataxia less common 
MM2 thalamic Frequently insomnia 
Psychomotor hyperactivity and motor 
problems 
Ataxia 
VV1 Progressive dementia with pyramidal 
signs and myoclonus 
MM/MV1+2 cortical Similar as MM1 
Phenotype depends on the predominance 
of either PrP
Sc
 type 1 or 2 
MV2 Kuru +2 cortical NA 
VV2 + 1 Not dissimilar to VV2 
 
The Diagnostic Utility of RT-QuIC for the Diagnosis of Sporadic Creutzfeldt-Jakob Disease   
 Introduction 17 
 
1.4.2.2 Variant CJD (vCJD) 
   
Ten years after the recognition of the initial case of BSE, the first case of an atypical 
form of CJD termed ‘new variant’ CJD in humans was identified igniting concerns 
that BSE had now been transmitted to humans via consumption of infected meat 
products
111, 112
. Following a series of experimental studies in mice, striking 
similarities were found particularly in regard to lesion profile and incubation periods 
113,114.
 The definitive association between BSE and vCJD resulted from the 
characterisation of primary and secondary transmission of 10 cases of vCJD mice
115
.  
Both CNS and peripheral tissue was transmitted and in all cases, the transmission 
characteristics including incubation period and abnormal prion protein deposition 
patterns were identical to BSE
115
. 
 
Since the first identified cases of vCJD in 1996, there have been 178 probable or 
definite cases identified in the UK.  The annual number of deaths was maximal in 
2000 with 28 deaths but after 2006, deaths from vCJD have declined significantly
116
.  
Worldwide, the majority of the cases have occurred in the UK.  However, 51 cases 
have now been reported in other countries, with most of these occurring in France 
which is thought to be related to the level of importation of beef products between 
1985 and 1995
117
.   
 
In comparison to sCJD, these patients have been much younger with a mean age of 
onset of 28 years old
118
.  In addition, their presentation, disease duration and 
neuropathological findings are distinct from those seen in other human prion 
diseases
112
.  The median survival post diagnosis is 14 months
118
.  The heterogeneity 
of sCJD has been partly related to PRNP 129 genotype and PrP protein type. Variant 
CJD is more homogenous with the majority codon 129 MM
25
. Definite and probable 
cases of vCJD have been predominantly codon 129 MM genotype which is in 
contrast to the normal distribution (42% MM, 47% MV and 11% VV) suggesting an 
association between vCJD susceptibility and/or incubation period and genotype. 
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However, there has been one definite and one possible case that were both codon 129 
MV
25, 112, 116
.   
Transmission studies using gene targeted mice expressing human PrP
C
 and carrying 
each of the codon 129 genotypes have suggested that there is potential for human to 
human transmission of vCJD and that this may be feasible in all genotypes
112, 114
.  
Further studies by Bishop et al demonstrated that the transmission efficiency varied 
in the order of MM>MV>VV with differing pathological characteristics for each 
genotype
112,119
.  The greatest transmission efficiency occurred in mice expressing 
codon 129 MM and these mice demonstrated the earliest onset of the disease.  In 
contrast, MV mice were shown to have longer incubation times
119
.  This suggests 
that in humans, all genotypes have the potential to be affected with different 
genotypes manifesting disease in different ways
112
. Of concern is that MV and VV 
individuals may display long asymptomatic or subclinical incubation periods that 
may exceed normal lifespan or even remain permanently subclinical which obviously 
has public health implications.   
In humans, PrP
Sc
 was discovered in the spleen and cervical lymph node of a PRNP 
129 heterozygote asymptomatic individual who died of non-neurological disorder 5 
years after receiving a blood transfusion
119
. The donor of the blood later went on to 
die from vCJD (vCJD and blood transfusion will be described in more detail under 
‘Iatrogenic CJD’).  Transmission studies using the PrP
Sc
 from this individual’s spleen 
were successful
119
.  In addition, in 2009, a possible case of vCJD in a codon 129 
heterozygote was not confirmed due to a lack of post mortem
120
.  Retrospective 
studies of anonymised tonsil and appendix samples have demonstrated PrP
Sc
 in all 3 
genotypes providing further support that all genotypes can be affected and add 
further concern to the possibility of subclinical infection and long incubation 
times
121, 122
.  The concept of asymptomatic carriers of prion infectivity will be 
discussed further later in the chapter. 
In addition to age at onset and duration illness, the clinical symptoms and signs are 
different in comparison to sCJD.   Early in the illness, patients usually experience 
prominent psychiatric features or behavioural problems and painful sensory 
symptoms which often dominate for the initial 6 months.  Psychiatric manifestations 
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including apathy, depression, anxiety are often the sole symptom for several months.  
Other neurological signs appear later and included cerebellar signs and gait ataxia, 
myoclonus, cognitive decline, involuntary movements followed by akinetic mutism 
in the end stages of the disease
25
. 
There are no completely reliable non-invasive tests to diagnose vCJD with the gold-
standard continuing to be neuropathology.  However, the presence of abnormal prion 
proteins in a variety of tissues other than the brain has been exploited by a number of 
studies with some promising results.  Moda et al used a PMCA assay technique to try 
and amplify minute amounts of PrP
Sc
 in the urine of variant, sporadic and genetic 
forms of CJD as well as a host of controls which included both healthy individuals 
and those with a non-prion neurodegenerative disease.  13/14 confirmed cases of 
vCJD returned a positive test and none of the 224 non vCJD cases were positive.  No 
cases of genetic CJD or sporadic CJD returned a positive result.  This produced a 
sensitivity of 92.9% and specificity of 100% although it was acknowledged by the 
authors that a larger study was needed in order to provide statistical significance.  
Similar studies have been employed using blood
123
.  Collinge et al developed a 
prototype assay that exploited the affinity PrP
Sc
 has for metal surfaces.  The assay 
included a stainless steel powder combined with direct immunodetection. Results 
indicated a sensitivity of 70% and specificity of 100% although it was acknowledged 
that it remains unclear whether this sensitivity is high enough to detect abnormal 
prion protein in suspected asymptomatic carriers of the condition who are considered 
at risk.  The levels of abnormal prion protein are thought to be even lower in these 
individuals than those who actually have the condition and so the assays reliability in 
this regard remains uncertain without a larger cohort study
124
.   Soto et al examined 
the blood from a cohort of patients that included 14 confirmed vCJD cases and 153 
non prion neurological cases.  They employed a PMCA technique to amplify small 
amounts of PrP
Sc
 to detectable levels.  The PMCA study had a sensitivity and 
specificity of 100%
125
.  Bougard et al produced similar findings using a PMCA 
technique, including a positive result in two subclinical cases that later went on to 
develop vCJD
126
.  Although promising as a non-invasive screening and diagnostic 
test, it has been recognised by authors that larger studies are required in this area.   
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Tonsillar biopsy can also be useful, reflecting the lymphoid involvement in vCJD, 
although this test is invasive and not without risk
122
.  The EEG typically shows non-
specifically slow-wave abnormalities or is normal
127
.  MRI brain imaging 
characteristically shows symmetrical hyperintensity of the pulvinar nucleus of the 
thalamus, changes which in the correct clinical context are highly sensitive and 
specific for vCJD
118
.  In addition, CSF 14-3-3 analysis is less useful in vCJD in 
comparison to sCJD being less sensitive with approximately 50% of cases returning 
a positive result
128
. Highly sensitive and specific diagnostic criteria, encompassing 
the core clinical features, results of MRI imaging and neuropathological features 
have been formulated and validated
118
. 
 
1.4.2.3 Iatrogenic CJD (iCJD) 
 
Iatrogenic transmission of CJD has occurred in many countries across the world. 
However, cases of iatrogenic CJD have significantly declined with occasional cases 
with exceptionally long incubation periods emerging.  The majority of these 
outbreaks were related to contaminated growth hormone and dura mater grafts 
derived from human cadavers with undiagnosed CJD infections
129
.  A small number 
of cases were caused by neurosurgical instrument contamination, corneal grafts, 
gonadotrophic hormone and secondary infection with variant CJD transmitted by 
transfusion of blood products
130
. No new sources of disease have been identified.  
Although blood and blood product transmission has been reported with vCJD, the 
cases are really not classed with iCJD and the modes of transmission have not been 
reported with other forms of human prion disease (details are discussed in 1.4.2.4.1.3 
below).  Current practices focus on improved recognition of potentially infected 
persons until a blood or other simple screening test for the detection of preclinical 
infection is validated for human use.   
The first case of iatrogenic CJD was reported in 1974 when a 55 year old patient 
received a corneal transplant from an infected cadaver and died 18 months post 
exposure
131
.  Other sources of infection later emerged including stereotactic depth 
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electrodes, neurosurgical instruments, cadaveric dura mater and pituitary glands
132
.  
Some incubation periods have been exceptionally long (years, sometimes decades) 
which poses a significant challenge for public health teams whose introductory 
measures may help prevent transmission of further cases but are redundant when it 
comes to preventing cases of an already infected individual in the asymptomatic 
phase of the disease. The incubation periods in the worldwide cohort of iCJD cases 
are markedly variable.  The shortest incubation periods occur on those exposed to 
neurosurgical instruments on the CNS (1-2.3 years).  The longest incubation periods 
occur in human dura mater recipients (1.3-30 years) and cadaver derived growth 
hormone and gonadotrophin recipients (5-42 years).  These prolonged incubation 
periods are not dissimilar of those occurring in Kuru where incubation periods of 
greater than 40 years have been reported
129, 132
. 
 
1.4.2.3.1.1 Human Growth Hormone 
 
The current worldwide total of growth hormone associated cases of CJD is 226.  
Most cases occurred in France, the United Kingdom and the United States. The use 
of pituitary-derived hGH in the treatment of primary and secondary growth hormone 
deficiency in the United Kingdom began as a clinical trial in 1959 and became a 
centrally administered National Health Service (NHS) activity in 1976
132
. The first 
case of iCJD secondary to hGH derived from cadaveric pituitary glands was reported 
in 1985 in the United States of America and in the UK
133, 134
. The mean incubation 
period in the United Kingdom was 20 years
135
.  However, predicting incubation 
periods in cases of human pituitary hormone related CJD is difficult as patients are 
frequently treated over a period of years
132
.  The use of cadaveric growth hormone to 
treat growth hormone deficiency was widespread from the late 1950s to the 1980s, 
with little or no screening of donors
132
.   
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1.4.2.3.1.2 Dura Mater 
 
The worldwide total of dura mater associated cases of CJD is 228 and new cases 
continue to emerge. However, in contrast to hGH cases, only 8 recipients of hDM 
have developed iCJD in the UK with incubation periods ranging from 3.8-14.8 
years
132, 136
. The majority of cases were reported in Japan where the use of such 
grafts during neurosurgery was particularly common.  The most recent cases 
occurred in Austria, South Korea and the Netherlands in 2011.  Incubation periods 
ranged between 1.3 to 30 years
137
 
 
1.4.2.3.1.3 Blood 
 
The UK has the highest incidence of vCJD in the world as described
112
.  During the 
initial stages of the vCJD epidemic, transmission via blood transfusion from infected 
individuals was considered a minimal risk
112
.  Despite this however, significant 
efforts were made to trace the fate of all blood components used for transfusion from 
donors known to have CJD
12
.  In addition, a number of transmission studies were 
conducted to assess the ability of prion infection to transfer via blood.  Sheep studies 
initially demonstrated that blood components collected either in the subclinical or 
clinical phase of the disease contained titres of infectivity that were sufficient for 
transmission to recipients after a single blood transfusion.  In addition, the number of 
recipients that developed disease supported that blood was a very efficient means of 
transmission
12, 112
.  From 2004, 4 cases of blood transfusion related vCJD infection 
have been documented in the UK
11, 138.
  The transfusions occurred between 1996 and 
1999.  All donors of the blood components were asymptomatic at the time of 
donation although it was later confirmed that they all died from vCJD.  Of the 4 
blood component recipients, 3 developed clinical signs supportive of vCJD and this 
was later confirmed on post mortem examination.  These cases were all codon 129 
MM in the PRNP gene
138
.  Interestingly, the remaining case was heterozygous at 
codon 129 and did not display any signs of a neurological disorder including vCJD.  
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There was also no evidence of vCJD in the individual’s brain and the patient died of 
an unrelated condition
138, 139
.  However, disease associated prion protein was 
identified in the spleen and cervical lymph node as described earlier in chapter. 
 
1.4.2.3.1.3.1 Current Prevention Strategies 
 
The optimal method of abolishing secondary iatrogenic infections is to prevent 
primary infections.  In the mean-time, without a test to identify persons who are in 
the asymptomatic phase of the disease, it is impossible to entirely eliminate the risk 
between human to human tissue transfer which is of significant public health 
concern.  At present we are obliged to rely on default strategies which include: 
identification and donor deferral of persons considered at risk, inclusion of prion 
reduction steps in the sterilisation of penetrating instruments and the processing of 
therapeutic tissues and fluids
132
. 
 
1.4.2.3.1.3.2 Risks Posed by Asymptomatic vCJD Infection 
 
The possibility of iatrogenic infection resulting from the transfer of tissues and 
bodily fluids remains real despite the apparent decline in the epidemic of BSE and 
vCJD.  To date, vCJD has occurred in MM and MV PRNP genotypes although is 
more common in homozygous individuals.  Data already discussed has demonstrated 
that MV cases can be associated with a longer incubation time which raises concern 
about the possibility of subclinical or asymptomatic infectivity and thus potential for 
iatrogenic transmission.  This has prompted a series of studies aiming to establish the 
potential prevalence of asymptomatic individuals that are possibly in the subclinical 
phase of the condition and may be infectious.  Variant CJD differs from other human 
prion diseases due to the widespread involvement of lymphoid tissues. A small 
number of cases later confirmed to have had vCJD and previously had their 
appendices removed before the onset of clinical symptoms revealed that the disease 
associated prion protein was detectable up to 2 years prior to the onset of clinical 
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disease
139, 140
. This finding prompted a larger retrospective study of tonsils and 
appendices from laboratories throughout the UK in order to provide an estimate of 
asymptomatic carriers of the condition. A series of anonymous studies were carried 
out and in 2004, the first estimated prevalence of asymptomatic cases was reported 
as 237 per million. Further studies have demonstrated a prevalence of 493 per 
million
121, 140
. These findings identify a number of important implications and 
support the need for ongoing surveillance, particularly with regard to the risk of 
secondary transmission from asymptomatic subclinical cases via surgical instruments 
or blood transfusion. 
 
1.4.2.4 Variable Protease sensitive Prionopathy (VPSPr) 
 
A relatively recently identified, and presumably sporadic, human prion disease  
called Variable protease sensitive prionopathy or VPSPr was initially described in 
2008 with 11 cases reported by that national prion surveillance unit in Cleveland 
Ohio. A further two cases were reported with all initially codon 29 VV genotype
141
.  
In 2010, a further 15 cases were identified which included both MV and MM 
genotypes
142
.  This novel type of human prion disease harbours a distinct 
neuropathological and biochemical profile that differs from CJD although has some 
similarities to GSS
143
. The lack of risk factors for iatrogenic CJD and PRNP 
mutation support a sporadic form of prion disease and it has been suggested that this 
could be the sporadic form of GSS
143, 144
.  In comparison to sporadic CJD, the 
clinical differences include a slower disease progression and presentation with some 
of the more atypical forms of dementia such as Frontotemporal lobe dementia, Lewy 
body disease and normal pressure hydrocephalus
145
.  Biochemical differences 
include the fact that the abnormal form of the prion protein is much less resistant to 
protein digestion.  In addition, the neuropathological features are unusual and include 
microplaques within the cerebellum and thalamus
142, 144
. 
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Human to human transmission of prion diseases is of significant concern, particularly 
in relation to public health.  Studies on transgenic mice have shown that sporadic 
CJD is readily transmitted in the presence of human PrP with the development of the 
recognisable clinical signs and the typical neuropathological hallmarks of the 
condition
146
.  Studies have demonstrated the transmissibility of VPSPr is much less 
efficient than sCJD
147, 148 
but not entirely negligible
144
. These findings support the 
need for ongoing surveillance to fully establish the expanding spectrum of human 
prion disease. 
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1.5 Inherited CJD 
 
Inherited CJD is historically classified into three forms according to their 
clinicopathological features.  These include genetic CJD (gCJD), Gerstmann 
Strӓussler Scheinker syndrome (GSS) and familial fatal insomnia (FFI). Inherited 
CJD is an autosomal dominant condition related to underlying mutations of the prion 
protein gene (PRNP). Genetic analysis of the sCJD and vCJD cohort is important as 
genetic prion disease cannot always be distinguished from clinically from other 
forms of prion disease and a family history is absent in approximately 50%.  For 
example genetic CJD can also present with a rapidly progressive dementia and motor 
syndrome with similar neuropathological features
21
. 
 
1.5.1 Genetic CJD 
 
Genetic prion diseases were initially recognised in at the turn of the 20
th
 century
21
. 
Genetic CJD (gCJD) presents in a similar fashion to sCJD with a rapidly onset 
dementia with death occurring within a few months of symptom onset. This supports 
the importance of genetic testing in all cases of sCJD as gCJD has the potential to 
masquerade as sCJD
21, 149
. The first mutation discovered to cause prion disease was 
the 6- octapeptide repeat insertion (6-OPRI)
150,151
.  The identification of several other 
point and insertional mutations were identified shortly after this and new mutations 
are still be discovered. Over 20 mutations have been identified in the opening 
reading frame (ORF) that have been linked to genetic disease phenotypes, the 
commonest being E200K which accounts for over 70% of families worldwide
21, 149
.  
 
The clinicopathological phenotype can vary significantly, with differences reported 
in families with the same mutation.  As with sCJD, the influence of PRNP codon 129 
polymorphisms has a major influence on upon the specific manifestations of the 
disease
21, 18
. 
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1.5.2 Gerstmann Strӓussler Scheinker Syndrome (GSS) 
 
GSS is an autosomal dominant form of inherited prion disease with several point 
mutations in the PRNP gene
152
.  In 1936, J. Gerstmann, E. Sträussler, and I. 
Scheinker reported an Austrian kindred that presented with slowly progressive 
cerebellar ataxia and late dementia, with an autosomal dominant pattern of 
inheritance, which is now considered the first known GSS family (PRNP P102L 
mutation identified later)
153
.  The clinical phenotype shows marked heterogeneity, 
even amongst family members with the same mutation which can make the diagnosis 
challenging and sometimes missed
21, 153
.  The commonest mutation is the P102L 
mutation cases typically presenting with a slowly progressive cerebellar ataxia and 
late onset dementia.  There are often pronounced cognitive and psychiatric features 
and some clinical presentations are not dissimilar to sCJD
154
. The age of onset of 
GSS is relatively early but the disease progresses slowly, with an average disease 
duration of 3-10 years although this can be shorter
21
.  A GSS case attributable to 
A133V mutation resulted in a rare clinical phenotype similar to that of progressive 
supranuclear palsy. Several other pathological mutations that result in GSS have also 
been described
21
. 
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1.5.3 Fatal Familial Insomnia (FFI) 
 
FFI is a subtype of genetic CJD. They are both linked to the same mutation of codon 
178 of the prion protein gene but remain two clinically and pathologically distinct 
diseases
21
.  FFI is the third most common inherited prion disease and the most 
common inherited prion disease in Germany
152
.  The term FFI was first used by 
Lugaresi et al. in 1986, in the description of an Italian family with progressive 
insomnia, dysautonomia, motor signs, and thalamic degeneration
155
. The 
neuropathological findings suggested FFI was a prion disease, but confirmation of it 
being genetic did not occur until 1992, when a PRNP D178N-codon 129M mutation 
was identified in the kindred
156
.  Since this time >100 FFI pedigrees have been 
identified
21
.  The genetic difference between FFI and genetic CJD lies in a 
polymorphism at codon 129.  FFI occurs when an individual has a D178N mutation 
and methionine at codon 129 of the mutated allele.  If the mutated allele carries 
valine then the disease phenotype resembles genetic CJD
157
.  Usually the diagnosis is 
made around the 5
th
 decade although a wide range age of onset has been reported
21, 
158
.  The core features are related to thalamic dysfunction and include profound 
disturbance of the sleep-wake cycle and dysautonomia
159
.  However, clinical 
variability in the clinical phenotype is well recognised amongst mutation carriers
160
.  
Interestingly, cases of sporadic fatal insomnia (SFI) have a clinical phenotype that is 
indistinguishable from its genetic counterpart but there is no detectable PRNP 
mutation.  This form is considered part of the sCJD spectrum
159
. 
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1.5.4 Codon 129 
 
The PRNP codon 129 M/V polymorphism has potential effects on susceptibility to 
prion diseases, the incubation period in infectious forms and, as has been discussed 
above, the clinic-pathological manifestations of the disease
23
. The polymorphic 
residue at codon 129 of the prion protein gene (methionine/valine) has been studied 
extensively
23
. There is variation in genotype frequencies according to geographical 
region with a pattern of increasing homozygosity extending from Western to Eastern 
countries
161-163
.  In the majority of countries studied, MM and MV frequencies are 
approximately 40-50% 
161-163
.  A study in Poland reported 45% MM, 39% MV and 
16% VV
164
. However, a study in a Turkish population demonstrated a slight increase 
in homozygosity with 57% of the normal population being MM, 34% MV and 
9%VV
165
.  In Korea, it was even higher with MM 94%, MV 5%, VV 0.19%
166
.  
Studies in Japan have also demonstrated a large difference where the normal 
population frequencies are MM 92%, MV 8% and VV 0%
167
. 
Codon 129 homozygosity is considered a risk factor for the development of human 
prion disease
162, 168
.  70% of sporadic CJD and the majority of variant CJD cases are 
MM as previously discussed
169
.  Homozygosity has also been shown to be a risk 
factor and reduce the incubation time for human growth hormone associated CJD, 
iatrogenic CJD and Kuru
170, 171
.  A French/UK study found an excess of VV CJD in 
iatrogenic CJD compared to sCJD
170
.  A further study of dura mater graft associated 
CJD in Japan divided cases into ‘typical’ and ‘atypical’ cases.  All cases were 
classified as MM apart from one case of atypical dura mater CJD which was 
documented as MV.  This raised the possibility of different strains
137
.   
In addition, analysis of the prion protein gene and codon 129 has produced some 
important findings as discussed earlier in the chapter.  Given that the majority of 
clinically probable and neuropathologically confirmed cases of variant CJD have 
been MM genotype provides good evidence that this genotype is classified as a risk 
factor.  With regard to the 4 cases of vCJD related to blood transfusion (discussed 
earlier in the chapter), 3 of these cases were MM and 1 was found to be MV.  
However, in the MV case, there was no clinical or neuropathological evidence of 
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vCJD in the recipient but disease related abnormal prion protein was found in the 
spleen and one lymph node
11
.  It is suspected that the recipient was therefore in the 
preclinical phase of the condition and therefore impossible to know whether they 
would have proceeded to the clinical phase of CJD if they had lived longer
11, 162 
.  In 
addition, 2 or 3 samples in an anonymous appendix study in the UK, were positive 
for deposition of prion disease associated with PrP
Sc
 were genotyped as VV 
suggesting that these polymorphisms are potentially associated with longer 
incubation periods and opens up the possibility that a second wave of vCJD may 
occur in the future
162, 172
 . 
Currently, the diagnosis of sCJD is based on the clinical presentation in addition to 
conventional diagnostic tests that include EEG, MRI and CSF 14-3-3
173
.  The 
influence of polymorphisms at codon 129 on the results of these tests is well 
recognised with growing concern that these tests may miss uncommon variants of the 
condition
174
.  One study analysed the value of these commonly used clinical tests for 
the clinical diagnosis of all 6 subtypes of sCJD.  Results demonstrated that EEG was 
reliable for MM1 and MV1 subtypes only.  14-3-3 held a high sensitivity for all 
subgroups but not MV2.  However, MRI was especially reliable for MV2 and overall 
had a sensitivity of 70% irrespective of subgroup
174
.  These studies were further 
supported by a study in Catalonia
175
.  In 2006, a further paper found EEG to be a 
useful test in the more classic presentations of sCJD (i.e. MM and MV but not 
VV)
176
.  A further study included a cohort of 2451 definite cases of sCJD of which 
743 underwent molecular subtyping.  Results found that illness duration significantly 
influenced the result of 14-3-3, however, MRI was not influenced by this and had an 
increased sensitivity to VV2 cases
177
. EEG was also influenced by age at onset and 
illness duration and was reliable in MM1 subtypes but less so in MV1, MV2 and 
VV2
177
.  Overall, 14-3-3 was the most reliable test of all 3 but less likely to be 
positive in the less common subtypes such as MV2 and MM2
177
.  However, a further 
paper contradicts this finding and reports that in fact 14-3-3 is very useful in 
identifying cases of MV2 and MM2
178
.  A further paper has shown that the MRI 
lesions vary across different subtypes.  Pathologically confirmed sCJD cases with 
codon 129 genotype (MM, MV, and VV), PrP(Sc) type, and fluid-attenuated 
inversion recovery (FLAIR) or diffusion-weighted imaging (DWI) were collected in 
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seven countries. MRI scans were evaluated in 211 CJD patients (98 MM1, 23 MM2, 
19 MV1, 30 MV2, 9 VV1, and 32 VV2). Basal ganglia hyperintensities occurred 
most frequently in MV2, VV2, and MM1 subtypes (79, 77, and 70%). Wide cerebral 
cortical signal increase was most common in VV1, MM2, and MV1 subtypes (86, 
77, and 77%). Thalamic hyperintensities occurred most often in VV2 (45%) and 
MV2 (43%). The most consistent finding across most subtypes was high signal in 
basal ganglia, with these abnormalities found in 63% (FLAIR) and 71% (DWI) .
179
  
 
1.5.5 PrPSc Glycotype 
 
In addition to the polymorphism at codon 129, the specific glycotype of PrP
Sc 
that 
accumulates in the brain also bears relevance to the clinic-pathological 
characteristics of prion disease.  Two major glycotypes have been validated for 
sCJD, Type 1 and Type 2 
23, 180
.  The glycotypes are mainly distinguished by the 
electrophoretic migration of the unglycosylated fragments.  The unglycosylated PrP
Sc
 
Type 1 fragment migrates at 19 kilodaltons whereas Type 2 migrates at 21 
kilodaltons.  These PrP
Sc
 types are presumed to reflect the differences in the 
susceptibility of distinct PrP
Sc
 strains to protease digestion due to accessibility to 
different cleavage sites
180
.  Codon 129 genotype and PrP
Sc 
glycotype have been 
shown to be associated with the clinical heterogeneity of sporadic CJD with 6 
classifications reported by Parchi et al as previously described in the chapter. 
Overall, codon 129 genotype, age at onset, glycotype and sex act as prognostic 
indicators for sporadic CJD
110
. 
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1.6 Classification and Diagnosis of Sporadic CJD 
 
Currently, there is not a disease specific, non-invasive test available for the diagnosis 
of sporadic CJD.  Post mortem examination of brain tissue demonstrating the 
presence of the abnormal prion protein PrP
Sc
 remains the definitive means of 
diagnosis
173
.  Brain biopsy is a feasible option although carries risk for the patient 
and is infrequently performed
181
.  Atypical presentations can prove a diagnostic 
challenge and there can be a delay in diagnosis which can be distressing for family 
members.  In addition, identifying potentially treatable alternative diseases and also 
preventing secondary transmission are both important.   
In 1979, Masters et al developed diagnostic criteria to aid the diagnosis of CJD
182
.  
These have been modified over the years, most recently in 2009
173
. The current 
diagnostic criteria rely on the clinical presentation in association with investigations 
including electroencephalogram (EEG), MRI brain and 14-3-3 protein in the 
cerebrospinal fluid (CSF)
173
.  Although these tests are useful, they do not provide the 
necessary degree of sensitivity and are not specific to prion disease and therefore 
lack diagnostic accuracy
173, 176, 177, 178, 179, 183, 184, 185
.  In addition, strict compliance of 
the criteria has the potential to result in failure to recognise cases, particularly in the 
early phases of the disease when non-specific features predominate and the 
traditional signs have not yet developed
186, 187
.  The differential diagnosis of rapidly 
progressive dementia is broad and it is important to confirm or exclude CJD early so 
that potentially treatable conditions that may present in similar ways to sporadic CJD 
are not missed. In addition, a wide range of focal signs at onset have been reported in 
patients with sporadic CJD that may suggest alternative diagnoses
186
.  Examples of 
focal signs include cerebellar ataxia
187
, visual symptoms
188
, aphasia
189
, alexia 
without agraphia
190
 and alien limb phenomenon
191
.  Motor weakness such as 
hemiparesis, monoparesis and focal seizure activity may also occur
192, 193
.  In many 
of these cases, the presenting focal manifestation can be of acute onset, often leading 
to an incorrect initial diagnosis of stroke
194
.  More global presentations may suggest 
autoimmune encephalitis, paraneoplastic disorders or toxic and metabolic 
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disorders
186
.  A diagnosis of sporadic CJD requires the exclusion of other potentially 
treatable disorders. 
Supportive investigations such as EEG, MRI and 14-3-3 have relatively low general 
diagnostic sensitivity and specificity although they may be very useful in specific 
clinical contexts
173, 176, 177, 178, 179, 183, 184, 185
.  The inclusion of certain MRI brain 
imaging sequences including fluid-attenuated inversion recovery (FLAIR) and 
diffusion weighted imaging (DWI) has improved the diagnostic yield and helped 
differentiate from other causes of rapidly progressive dementia although even these 
are not absolutely specific for sCJD
179, 184
.  The characteristic findings on EEG in 
sCJD are periodic sharp wave complexes (PSWCs) although these are non-specific: 
they can be present in a wide variety of other conditions
195
.  In the early stages of 
sCJD, it is not uncommon for the EEG to demonstrate non-specific slowing, 
lateralised abnormalities such as periodic lateralised epileptic discharges (PLEDs) or 
focal abnormalities
176,186, 195, 196
.  It can take days or weeks for PSWCs to manifest, if 
at all
186
.  Elevated CSF 14-3-3 levels, while have a reasonable sensitivity for sCJD, 
have a relatively low specificity (for example, it can be positive if the patient is 
suffering from seizures or indeed any neurological condition that can lead to acute 
neuronal damage)
185, 197
.   
Unfortunately, regardless of the criteria, sCJD with early focal features or atypical 
manifestations and sCJD in the early phases of the illness with no characteristic EEG 
or MRI changes may escape an early diagnosis
186
.  This may result in repeated or 
unnecessary investigations and a subsequent delay in diagnosis. This of great 
importance given the public health implications of this, potentially transmissible and 
incurable disease.  There is thus a need for a relatively simple, disease specific, 
reliable diagnostic test that can provide an earlier and more accurate diagnosis. 
The unique feature of prion disease is the presence of the abnormal prion protein and 
its ability to replicate and aggregate. This seeded conversion of PrP
C
 to PrP
Sc
 has 
been exploited by a variety of assay techniques to detect the abnormal prion protein  
with sufficient sensitivity to enable the detection of PrP
Sc
 in biological tissues such as 
CSF, blood, urine and olfactory mucosa in patients with prion disease
198-206
. 
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Protein amplification techniques have revolutionised the diagnosis of prion diseases 
and provide a platform for accurate antemortem diagnosis for prion diseases.  They 
exploit the ability of PrP
Sc
 to induce conformational change in PrP in a continuous 
fashion.  This allows the small amount of PrP
Sc
 found in biological fluids such as 
blood and CSF to be amplified to a threshold where conventional laboratory 
techniques can detect it.  The most widely used protein amplification techniques 
include Protein Misfolding Clyclic Amplification Assay (PMCA) with western 
blotting detection or alternatively surround optical fibre immunoassay (SOFIA)
198, 
199, 200, 201
 and Real Time Quaking Induced Conversion (RT-QuIC) which uses 
thioflavin-T immunofluorescence to detect PrP
Sc
  or western blotting
202, 203
. 
 
1.6.1 Protein mis-folding amplification assay (PMCA) 
 
PMCA assays exploit the fundamental replication mechanism of prions as detailed 
above.  Test samples are combined with homogenates of brain tissue or cells that 
contain PrP
C
 which act as the source of PrP
C 
.  Disease associated PrP
Sc 
found in 
brain and peripheral tissues (blood, urine, spleen, saliva) is added, thus inducing a 
seeding reaction and amplifying the level of PrP
Sc 198-201, 204, 205, 206
. To optimise the 
sensitivity of PMCA, the mixture undergoes a series of sonication and rest cycles 
which breaks up the aggregated or seeded PrP
Sc
 into several smaller fragments that 
will also start to seed and amplify further leading to more aggregation.  In addition, 
sensitivity is further improved by adding small amounts of the reaction products to 
fresh sources of substrate
207
.   
However, there are limitations that have been identified with this technique. The use 
of multiple cycles of sonication can induce spontaneous aggregation of substrate in 
the absence of any seed
208
.  In addition, the requirement of multiple sonication cycles 
to maintain adequate sensitivity is time consuming and labour intensive
205
.  The need 
for brain material as a substrate also has limitations.
  
For example, having a 
consistent and continuous substrate supply can be difficult 
209, 210
.  The lack of 
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consistency between laboratories despite using similar protocols has also been an 
issue
109
.  
 
1.6.2 Real Time Quaking Induced Conversion 
 
To address these practical short-comings, a further assay was introduced and 
developed based on the PrP
Sc
 seeding process called Real Time Quaking Induced 
Conversion (RT-QuIC)
202, 203
. The RT-QuIC test has been adapted since its initial 
development and now has the ability to detect many types of prion seeding activity in 
multiple host species and specimen types including those of particular diagnostic 
significance such as CSF, blood, saliva and nasal brushings
202, 203, 2011-219
 .  This test 
has shown considerable promise as a highly specific diagnostic test for the diagnosis 
of sporadic CJD
211-219
.   
 
In the RT-QuIC assay, recombinant prion protein is used as a substrate (rPrP
Sen
) and 
is mixed, or seeded, with a small amount of PrP
Sc
 from CSF or brain tissue and is set 
up in a 96 well microtitre plate thus facilitating a high throughput assay.  The 
reaction mixture leads to PrP aggregate formation and these are broken up by using 
intermittent shaking rather than sonication cycles as employed by PMCA. Another 
superior feature of RT-QuIC is the ‘built-in’ detection facility.  The reaction mixture  
contains Thioflavin-T (ThT), a dye that binds to amyloid aggregates.  As the 
aggregates form, the kinetics of fibril formation can be monitored in real-time using 
standard fluorescent spectrophetometers ThT fluorescence is measured in relative 
fluorescence units (rfu) with saturation occurring at 65 000. After an initial ‘lag 
phase’ of 5-10 hours with seeded brain tissue and 30-40 hours with CSF tissue, there 
is a rapid increase in the fluorescent signal until it reaches a maximum at 40 hours 
for brain tissue and 90 hours for CSF
211
. A positive response was considered to have 
occurred if the average of the two highest readings at 90 hours was 10 000 rfu or 
greater.  A cut off value of 10 000 rfu was chosen based on the mean of the first 20 
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non-CJD CSF samples analysed. A more detailed description of RT-QuIC analysis is 
given in the Methodology section
211
. 
 
Applications of RT-QuIC to panels of CSF from patients with and without the 
condition have shown sensitivities for the detection of sporadic CJD of 80-90% and 
specificities of 99-100%.  These studies have indicated that RT-QuIC can achieve 
greater diagnostic performance than other CSF biomarkers for sporadic CJD
203, 211, 
216
.  Current alternatives for the definitive diagnosis of sporadic CJD involve invasive 
techniques such as brain biopsy for neuropathological confirmation of the disease in 
living patients
181
.  As a much less invasive test with a high degree of diagnostic 
accuracy, RT-QuIC is now being implemented as a key diagnostic test.   
 
1.6.3 Sporadic CJD Diagnostic Pathways  
 
Within the United Kingdom, there is a national referral system for suspected cases of 
CJD in which clinicians notify the National CJD Research and Surveillance Unit 
(NCJDRSU) of patients who may or may not have the condition but in whom it is 
being considered a possibility. Cases are discussed in detail and initial investigations 
advised according to the EuroCJD diagnostic criteria, as previously described earlier 
in this chapter.  Further description of the role of the NCJDRSU is provided in the 
Methodology section. 
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1.7 Rationale for Current Study 
 
An early and accurate diagnosis of sCJD is important due to the aforementioned 
public health implications, to exclude CJD as a potential diagnosis early so that 
treatable neurological conditions are not missed and to ease distress of family 
members.  Provisional studies have shown that RT-QuIC has the potential to identify 
cases of sCJD that conventional techniques such as 14-3-3 may miss and thus 
contribute to an early and more accurate diagnosis.  At the time of writing, there had 
not been a prospective analysis of how useful RT-QuIC is in routine clinical practice 
and whether it has any added benefit over current antemortem diagnostic methods. 
The aim of this study is to prospectively assess the diagnostic utility of RT-QuIC in 
routine clinical practice and determine the value in RT-QuIC in cases where there is 
diagnostic uncertainty using current diagnostic techniques and establish whether it 
can provide an earlier diagnosis.  In addition, I will assess if certain clinical factors 
affect the RT-QuIC result, including codon 129 genotype, age at onset, symptoms at 
onset and duration of disease.  Throughout the course of the study, I will also review 
the operational parameters (for example CSF volume, timing of lumbar puncture) of 
RT-QuIC and contribute to the optimisation and development of this new diagnostic 
test. 
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Chapter 2 
 
 
 
Methodology 
 
 
 
 
 
 
 
 
 
 
 
 
 
The Diagnostic Utility of RT-QuIC for the Diagnosis of Sporadic Creutzfeldt-Jakob Disease   
 Methodology 39 
 
2 Methodology 
 
2.1 The National CJD Research and Surveillance Unit 
(NCJDRSU) 
 
‘To monitor the characteristics of all forms of CJD, to identify trends in incidence 
rates, to study risk factors for the development of the disease and to contribute to 
improving the quality of care for those with CJD
116
 
 
The National CJD Research and Surveillance Unit (NCJDRSU) was established in 
1990 and has two principle functions which include surveillance of prion disease 
within the United Kingdom and research into the condition. It is comprised of a team 
of specialists which include clinical neurologists, neuropathologists and a variety of 
scientists. The NCJDRSU relies on the referral of clinically suspected cases by 
clinicians from throughout the United Kingdom.  Notification is predominantly from 
neurologists, although we also receive referrals from other specialists including 
geriatricians and pathologists.  As part of surveillance, the unit has a number of other 
roles including analysis of CSF for 14-3-3 protein, genetic analysis, molecular 
biological studies, review of MRI scans and neuro-pathological examination of tissue 
received from clinically suspected cases.  There is a national referral system for 
suspected cases of CJD in which clinicians notify the NCJDRSU of patients who 
may or may not have the condition but in whom it is being considered a possibility.  
In addition, clinicians send CSF fluid to the 14-3-3 laboratory located within the 
NCJDRSU for analysis.  These samples are from clinically suspected cases as 
discussed above, but also from patients who are being investigated by local 
physicians although not yet regarded as a suspected case for formal referral.  
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2.2 Assessment of Cases 
 
The data period for this study was January 2012 to January 2013.  During this time, I 
was the clinical registrar at the NCJDRSU.  I played a pivotal role in the assessment 
and review of all referrals to the NCJDRSU.  In addition, I was responsible for 
overseeing all requests for 14-3-3 analysis, reviewing all 14-3-3 results and re-
assessing each individual case by discussing with the referring clinician to establish 
whether a formal referral is warranted. 
All cases referred to the NCJDRSU that were being considered potential cases of 
CJD were offered a visit by the clinical registrar.  Permission was sought from the 
patient’s family and local consultant for an assessment to take place.  During the 
visit, the patient (where possible) was interviewed and examined.  A semi-
standardised questionnaire was used to interview the family to obtain detailed 
clinical and epidemiological data.  This included an accurate history of the illness, 
past medical history and previous operations relevant family history and 
occupational history.  The results of relevant investigative findings were also 
recorded.  Copies of medical records, neuroimaging and EEG were obtained 
following written consent from the next of kin.  If the patient was referred after their 
death, then the family were contacted (with the permission from the local clinician or 
the general practitioner) and visited to complete the questionnaire,  obtain the clinical 
history and obtain consent  to review the medical records and relevant investigations.  
GP notes were also obtained after the patient had died. 
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2.3 Clinical Presentation 
 
Data about the age at onset, date of symptom onset, clinical symptoms and signs at 
presentation and throughout the course of the illness were extracted from the 
available information from the questionnaire and medical notes.  The onset was taken 
as the earliest date when symptoms that were deemed likely to be related to prion 
disease were noted by the patient’s family, local clinician or general practitioner.  
Where the exact date of symptom onset could not be provided (e.g. the month was 
given), then the 15
th
 day of the month was used.  Therefore, a certain amount of error 
will be present regarding the exact date of onset.  The disease duration was 
calculated using the date of onset and the date of death inclusive.  The presenting 
symptoms were extracted from the questionnaire.  The mode of symptom onset was 
determined using EuroCJD definitions (Mrs Terry Lindsey, personal communication, 
www.cjd.ac.uk)
116
. 
The presence or absence of clinical symptoms and signs as stipulated by the 
EuroCJD Diagnostic Criteria 2009 were recorded
173
.  
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2.4 Investigations 
 
The investigations conducted for each case were chosen as clinically indicated by the 
referring clinician. Some cases were discussed with clinical team at the NCJDRSU in 
advance and advice provided regarding the most appropriate tests.  Not all patients 
underwent CSF examination, EEG and neuroimaging, either because the patient was 
too unsettled for such investigations or because they were not felt to be clinically 
indicated. 
 
2.4.1 CSF Analysis 
 
The CSF laboratory within the NCJDRSU provides a national and international 
diagnostic service for the analysis of CSF 14-3-3 and other brain specific proteins. 
Since 2012, the laboratory has helped establish the RT-QuIC technique in many 
European countries.  The NCJDRSU receives approximately 300 CSF samples for 
14-3-3 analysis per annum. 
For the purposes of this study, all CSF samples accepted for 14-3-3 analysis between 
January 2012 and January 2013 were also tested using RT-QuIC.  RT-QuIC analysis 
was conducted by Dr Lynne McGuire and Dr Alison Green, post doctorate research 
scientists.  Both of these tests were performed according to previously established 
methodology
203
. Few samples of CSF 14-3-3 were conducted in the National 
Hospital for Neurology and Neurosurgery in London.   
During the course of this study, the RT-QuIC assay has been adapted and improved 
with the development of, a so called, ‘second generation’ RT-QuIC.  For the 
purposes of this study, the ‘first generation’ RT-QuIC assay was employed.  The 
differences between the two assays are discussed in Chapter 4. 
The first generation RT-QuIC assay employed the standard reaction mixture of 
recombinant substrate, seed and buffer.  In this study, the buffer composition 
included a10mM phosphate buffer (pH 7.4), 170mM NaCl (total 300mM including 
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phosphate buffer), 10µM Thioflavin-T (ThT) and 10µM ethylenediaminetetracetic 
acid tetrasodium salt (EDTA). This was mixed with the recombinant substrate which 
in this study was 0.1mg/ml of full length hamster PrP (23-231).  Reactions were 
prepared in a black 96 well, optical bottom plate in volumes of 98µl for brain 
homogenate (BH) seeded reactions and 85µl for CSF seeded reactions.  2µl of 
diluted brain homogenate or 15µl of diluted CSF were added to the wells for a final 
reaction volume of 100µl.  Each sample was run in quadruplicate, allowing 4 control 
samples (unseeded, non-neurological brain homogenate, Alzheimer’s disease brain 
homogenate, sCJD MM1 brain homogenate) and 20 CSF samples to be tested on one 
plate.  The plates were sealed and incubated in a BMG OPTIMA FLUOstar plate 
reader at 42ºC for 90-120 hours with intermittent shaking cycles.  ThT fluorescence 
measurements were taken every 15 minutes. 
The plate reader measures ThT fluorescence in relative fluorescence units (rfu) with 
saturation at 65 000.  The average fluorescence for each quadruplicate sample was 
measured against time.  Following a lag phase of 5-10 hours for sCJD BH and 40 
hours for sCJD CSF, a positive sample displayed a rise in rfu.  A positive response 
was considered if the average of the two highest readings at 90 hours was 10 000 rfu 
or greater.  A cut off value of 10 000 rfu was chosen based on the mean of the first 
20 non-CJD CSF samples analysed
211
. 
 
2.4.2 EEG Analysis 
 
If an EEG was performed, copies of the representative pages were obtained either 
during the visit or after.  Each EEG was independently reviewed by either Professor 
Richard Knight or Professor Robert Will. These were classified as either showing 
typical changes consistent with sporadic CJD or not typical changes.  In the cases 
where a copy was not obtained and therefore not reviewed at the NCJDRSU, the 
local report was used. 
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2.4.3 Neuroimaging 
 
If a MRI brain was performed, hard copies of the images were obtained either at the 
time of the visit or following assessment.  The timing of the MRI scan in relation to 
the onset of the symptoms was also documented. The images were reviewed by an 
experienced consultant neuro-radiologist, Dr David Summers.  Details of any 
abnormalities were documented with particular reference made to the presence of the 
typical findings accepted by the EuroCJD diagnostic criteria for sporadic CJD
165
.  
These included basal ganglia high signal +/- cortical high signal in three or more 
brain regions on Fluid Attenuated Inverse Recovery (FLAIR) or Diffusion Weighted 
(DWI) Sequences. In the instances where a hard copy of the MRI scan was not 
received, the report from the local radiologist was used.  
 
Cases that did not meet the EuroCJD neuroimaging criteria, but demonstrated other 
recognised features of sporadic CJD such as multiple areas of isolated cortical 
ribboning were examined in detail.  If the case was strongly suggestive of sporadic 
CJD clinically and the imaging showed cortical ribboning, with all other potential 
diagnoses excluded, then the MRI brain was considered a positive scan.  This was 
based on the expert and experienced opinions of both the clinical team at the 
NCJDRSU and neuro-radiologist, Dr David Summers.  However, for the benefit of 
classification, the EuroCJD criteria was strictly adhered to. 
 
2.4.4 Genotyping 
 
Provided the family of the patients who have been assessed have provided written 
consent, PRNP sequencing and codon 129 analysis was performed according to 
previously published methodology. Data was also obtained from genetic testing 
performed by the National Prion Clinic, London. Either blood or frozen brain tissue 
was used according to what was available. 
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2.4.5 Neuropathology 
 
In cases that were reviewed and underwent a post-mortem, neuropathological brain 
tissue was examined at the NCJDRSU following provision of written consent from a 
relative.  In some cases, tissue was not available and the post mortem was conducted 
at the National Prion Clinic in London, in which instance, a copy of the written post 
mortem report was obtained.   
During the study period, immune-histological examination and prion protein typing 
was conducted by Dr Mark Head’s team.  Prion protein typing was carried out using 
Western Blot Analysis to determine the size and abundance of the different PrP
Sc 
glycoforms.  Protein typing was classified according to their molecular weight into 
either Type 1 (non-glycosylated form with a molecular weight of 19kDa) or Type 2 
(non-glycosylated with a weight of 21 kDa).  If the di-glycosylated band 
predominates in Type 2 then it is termed Type 2B.  If the di-glycosylated band does 
not predominate then it is classified as Type2A
218, 219
. 
During the study period, neuropathological analysis was performed by Professor 
James Ironside
220
. 
 
 
2.5 Case Assessment and Data Extraction 
 
Between July 2011 and March 2014, I was the NCJDRSU clinical registrar.  The 
study period extended between January 2012 and January 2013 and was a 
prospective study throughout this time period.  I played a pivotal role in the 
assessment and review of all referrals to the NCJDRSU.  In addition, I was 
responsible for overseeing all requests for 14-3-3 analysis, reviewing all 14-3-3 
results and reassessing each individual case by discussing with the referring clinician 
to establish whether a formal referral was warranted.  For the purposes of this study, 
all CSF samples accepted for 14-3-3 analysis during the study period were also tested 
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for RT-QuIC. Relevant clinical and investigation information was noted at referral 
and the patient was classified according to the current EuroCJD diagnostic criteria 
for sporadic CJD at that time.  All formal referrals were offered a visit and the family 
interviewed (and the patient, where possible) using a semi-standardised 
questionnaire, obtaining detailed clinical and epidemiological data.  Neurological 
examination of the patient was also carried out.  As previously detailed, hospital and 
GP notes in addition to relevant investigations were requested and reviewed. 
Following the visit and review of the relevant investigations, each case was then re-
classified according the current diagnostic criteria. 
All cases were followed up by contacting the referring clinician.  This included cases 
that did not meet criteria at initial referral.  If the 14-3-3 or RT-QuIC were 
unexpectedly positive in this group, these cases were examined in further detail and a 
visit was offered if it was considered necessary. I created an Excel database and 
recorded the following data. 
 
 
Table 3 Data Collection 
ID Number Location Growth Hormone 
Case 
Family Interviewed 
after death 
Age at Onset Date of Symptom 
Onset 
Genetic Case Date of Visit 
Date of Birth Disease Duration Formal Referral  
Sex CSF Referral Date of Formal 
Referral 
 
CSF ID Number Date of CSF 
Referral 
Reviewed During 
Life 
 
 
I also recorded the mode of onset for each case using the following EuroCJD 
definitions (Mrs Terri Lindsay, NCJDRSU, personal communication) as illustrated in 
Table 3
116
.  Where ‘Other’ was the designated mode of onset, details were recorded 
in free hand in the Excel database. 
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Table 4 Definition of Modes of Onset
Mode of Onset Definition 
Rapidly Progressive Dementia The precise presenting symptom will vary from case to case, but the picture is an encephalopathic illness with 
dementia (and other neurological features), progressing rapidly over weeks to a few months, with no individual 
cognitive or physical deficit being present alone for more than two weeks. 
Slowly Progressive Dementia These cases present with a slowly progressive dementia, developing over months to years, without any other 
significant neurological features for the first six months. 
Cortical Blindness (Heidenhain) These cases present with impairment of visual acuity and/or field, progressing onto cortical blindness, without other 
significant clinical deficit for the first two weeks of illness. The visual symptoms might include visual loss, visual 
inattention, visual illusions and visual hallucinations. It is essential that the symptoms progress to cortical blindness. 
Cases with other onsets that progress to include cortical blindness are NOT included in this category. 
Psychiatric Onset These cases present with psychiatric symptoms such as depression, anxiety, paranoia and delusions, without the 
presence of other features for a period of at least four weeks. Non-specific malaise or apathy do not count unless 
accompanied by some of the above symptoms. Visual or auditory hallucinations alone do not count, but may 
accompany the above features. It may be difficult to distinguish between the early features of dementia and a more 
specifically psychiatric onset. Behavioural change straightforwardly due to a developing dementia is not included in 
this category. The essential characteristics of  this presentation is that the patients present with a disturbance that 
suggests a psychiatric disturbance rather than an obvious dementia and that specifically neurological features are 
absent. 
Cerebellar Onset The presentation is with a progressive cerebellar syndrome without other significant features, for at least two weeks. 
Extrapyramidal Onset The presentation is with an extrapyramidal syndrome involving Parkinsonian features with or without chorea, 
athetosis or dystonia, but without other significant features for at least two weeks. 
Stroke-like Onset The presentation is abrupt enough for a diagnosis of stroke to be entertained in the initial stages. 
Other None of the above described presentations is applicable. 
Missing There is no clear clinical information available or the information does not allow a definite classification. 
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2.6 Clinical Criteria for Sporadic CJD Diagnosis 
 
The following is adapted from the EuroCJD diagnostic criteria 2009 and was used 
thoughout this study to classify cases of suspected sporadic CJD
113
. 
 
2.6.1 Definite (1.0S) 
Neuropathologically confirmed sporadic CJD 
 
2.6.2 Probable (2.0S) 
Rapidly progressive dementia AND at least two out of the following four clinical 
features: 
Myoclonus 
Visual or cerebellar signs 
Extrapyramidal or pyramidal signs 
Akinetic Mutism 
AND a positive result on at least one of the following investigations: 
A typical EEG (periodic sharp wave complexes) 
A positive 14-3-3 CSF result in patients with a disease duration of less than two 
years 
MRI brain high signal abnormality in the caudate nucleus and/or putamen on DWI or 
FLAIR imaging sequences 
 
2.6.3 Possible (3.0S) 
 
Rapidly progressive dementia and at least two of the following four clinical features: 
Myoclonus 
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Visual or cerebellar signs 
Pyramidal/extrapyramidal signs 
Akinetic mutism 
AND the absence of a positive result for any of the three investigations that would 
classify the case as probable (see above) AND disease duration less than two years. 
 
2.6.4 Uncertain (4.1S) 
 
Patients were classified as 4.1S if the case did not meet the WHO diagnostic criteria 
but in whom sCJD was still being considered a possibility.  Examples of this include 
patients who have clinical phenotype that follows a longer incubation period and 
therefore the relevant clinical symptoms and signs have not yet evolved. 
 
2.6.5 Non-CJD Case based on clinical evidence (4.2S) 
 
This classification applied to cases in whom the patient did not meet diagnostic 
criteria and where there was strong evidence clinically to support an alternative 
neurological condition. 
 
2.6.6 Non-CJD Case based on pathological evidence (4.3S) 
 
Applied to patients where there was neuropathological confirmation of an alternative 
diagnosis 
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2.7 Statistical Analysis 
Statistical analysis was performed using StatsDirect software package Version 
3.1.21. 
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Chapter 3 
 
 
 
Results 
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3  Results 
 
Between the 1st of January 2012 and the 30th of June 2013 inclusive, 192 of 
clinically suspected cases of CJD were notified to the NCJDRSU.  30 of these cases 
were excluded either because they were notified out with the data period or because 
they were confirmed genetic or iatrogenic cases at notification.  The exclusion 
criteria are detailed in the methodology section.  162 cases of clinically suspected 
CJD were included in this study. 
 
3.1 Data Overview: case demographics 
 
The median age at symptom onset was 67.1 years (range 43 to 87 years).   The 
median duration of illness from symptom onset to death was calculated in 143 
(88.3%) and was 6.3 months (range 0.69 to 42.5 months).  Duration of illness could 
not be calculated in 19 (11.7%) due to missing date of symptom onset (n= 2), 
missing date of death (n= 3) and cases that are still alive (n= 14).  The overall sex 
distribution is shown in Figure 1. 
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Figure 1 Overall Sex Distribution 
 
Figure 2 illustrates the initial and final classification of each case according to the 
EuroCJD diagnostic criteria
113
.  The details of the classification criteria are given in 
the methodology section. 
 
Figure 2 Classification using EuroCJD Criteria 
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The majority of initial classifications were either 3.0S (possible sporadic CJD) or 
4.1S (diagnosis uncertain but CJD still considered to be a possibility).  The majority 
of final classifications were either 1.0S (definite sporadic CJD) or 2.0S (probable 
sporadic CJD) as illustrated in Figure 2 and Figure 3.  10 cases received a final 
classification of 3.0S.  Of these, 7 were initially classified as 4.1S and 3 as 3.0S.  All 
6 cases that were given a final classification of 4.1S were initially classified as 4.1S.  
11 cases were given a final classification of 4.2 (sporadic CJD unlikely).  2 of these 
were initially classified as 3.0S and 9 classified as 4.1S.  6 cases received a final 
classification of 4.3 (definitely not sporadic CJD). 3 were initially classified as 3.0S 
and 3 as 4.1S.  1 case was initially classified as 4.1N where the diagnosis was 
uncertain, although there was a suspicion of new variant CJD.  The final 
classification for this case was 2.0N (probable new variant CJD).  2 cases received a 
final classification of 1.0F (definite familial CJD) and 2.0F (probable familial CJD), 
both of which were initially classified as 4.1S.  1 case received a final diagnosis of 
1.0I (definite iatrogenic CJD) and was initially classified as 2.0I (probable iatrogenic 
CJD). 
 
 
 
Figure 3 Final Classification n=162 
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The mode of onset for each case is detailed in Table 5.  The definitions of each mode 
of onset were defined by the EuroCJD criteria and are detailed in the methodology 
section.  All cases that had RT-QuIC analysis have been included for comparison 
(n=115; 71%).  Fisher’s exact statistical analysis was employed to determine whether 
there were any statistically significant differences in the mode of onset between cases 
who did and did not have RT-QuIC.  There were no statistically significant 
differences found. 
 
Table 5 Mode of Onset 
 
 
As detailed in the methodology section, the ‘Other’ mode of onset, were cases that 
could not be categorised by the more common presenting features.  Examples include 
limb pain, status epilepticus, insomnia and depression, isolated speech disturbance, 
systemic symptoms such as lethargy and weight loss as we all as personality change. 
 
 
 
 
 
Mode of Onset Total Cases 
N=162 
Cases Tested 
for  RT-QuiC  
N=115 
Cases not 
tested for 
RT-QuIC 
N=47 
P Value 
Rapidly Progressive 
Dementia 
74 (45.7%) 49 (42.6%) 25 0.2295 
Slowly progressive 
Dementia 
2 (1.2%) 2 (1.2%) 0 >0.9999 
Stroke-Like Onset 3 (1.9%) 2 (1.2%) 1 >0.9999 
Psychiatric Onset 11 (6.8%) 8 (7.0%) 3 >0.9999 
Other 46 (28.4%) 36 (31.3%) 10 0.2505 
Heidenhain 9 (5.6%) 4 (3.5%) 5 0.1228 
Cerebellar 16 (9.9%) 13 (11.3%) 3 0.4019 
Data Missing 1 (0.6%) 1 (0.9%) 0 - 
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Table 6 shows the median age for each final classification for all cases.   
 
 
Table 6 Median age for each classification n=162 
Final 
Classification 
Total 
No. of 
Cases 
No. of cases 
with known 
age at onset 
Median Age at 
Onset (years) 
Age Range (years) 
Definite 
Sporadic 1.0S 
71 71 (100%) 67.5 43-81 
Probable 
Sporadic 2.0S 
54 54 (100%) 66.8 45-86 
Possible 
Sporadic 3.0S 
10 10 (100%) 68.3 58-76 
Diagnosis 
Uncertain 
4.1S 
6 6 (100%) 62.3 48-75 
Sporadic CJD 
Unlikely 4.2S 
11 11 (100%) 69.4 52-87 
Definitely not 
Sporadic CJD 
4.3S 
6 6 (100%) 73.2 63-85 
Definitely 
Genetic CJD 
1.0F 
1 1 (100%) 55.0 - 
Probable 
Genetic CJD 
2.0F 
1 1 (100%) 70.0 - 
Definite 
Iatrogenic 
CJD 1.0I 
1 1 (100%) 46.0 - 
Probable New 
Variant CJD 
2.0N 
1 1 (100%) 46.0 - 
Total 162 162 (100%) 67.1 43-87 
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Table 7 demonstrates the sex distribution within each final classification. 
 
Table 7 Sex distribution for each final classification n=162 
Final 
Classification 
Total Number of 
Cases 
Female (%) Male (%) 
Definite Sporadic 
1.0S 
71 36 (50.7) 35 (49.3) 
Probable Sporadic 
2.0S 
54 27 (50.0) 27(50.0) 
Possible Sporadic 
3.0S 
10 2 (20.0) 8 (80.0) 
Diagnosis 
Uncertain 4.1S 
6 1 (16.7) 5 (83.3) 
Sporadic CJD 
Unlikely 4.2S 
11 6 (54.5) 5 (45.4) 
Definitely not 
Sporadic CJD 4.3S 
6 1 (16.7) 5 (83.3) 
Definite Genetic 
CJD 1.0F 
1 1 (100.0) - 
 Probable Genetic 
CJD 2.0F 
1 1 (100.0) - 
Definite Iatrogenic 
CJD 1.0I 
1 - 1 (100.0) 
Probable New 
Variant CJD 2.0N 
1 - 1 (100.0) 
Total 162 75 87 
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Table 8 demonstrates the median disease duration for each final classification for all 
cases.   
Table 8 Median disease duration for each final classification n=162 
Final Classification Total 
Number of 
Cases 
No. of cases with 
known/calculated 
disease duration 
Median 
disease 
duration 
(months) 
Disease 
duration 
range 
(months) 
Definite Sporadic 
1.0S 
71 69 6.2 1.1-32.9 
Probable Sporadic 
2.0S 
54 53 4.7 0.7-15.3 
Possible Sporadic 
3.0S 
10 8 8.8 1.5-31.7 
Diagnosis Uncertain 
4.1S 
6 5 21.3 7.4-42.5 
Sporadic CJD 
Unlikely 4.2S 
11 0 - - 
Definitely not 
sporadic 4.3S 
6 4 7.1 1.2-19.7 
Definite Genetic CJD 
1.0F 
1 1 2.8 - 
Probable Genetic 
CJD 2.0F 
1 1 3.5 - 
Definite Iatrogenic 
CJD 1.0I 
1 1 4.3 - 
Probable New 
Variant CJD 2.0N 
1 1 11.6 - 
Total 162 143 6.31 0.7-42.5 
 
 
Disease duration could be calculated in 69 (97.2%) of the cases that were classified 
as 1.0S.  The date of disease onset was not available for one case and date of death 
not available for the other.  Neither of these cases had RT-QuIC performed.  A value 
could not be calculated in one 2.0S case as the patient is still alive. For those cases 
that received a final classification of 3.0S, disease duration could not be calculated in 
2 (20%).  Both cases were still alive at the time of writing.  Disease duration could 
not be calculated in 1 of the cases that received a final classification of 4.1S.  This 
case was a UK resident but returned to their native Africa and so it remains unclear 
as to whether this case is still alive.  Disease duration could not be calculated in any 
of the 4.2S cases as 9 are still alive and data is missing for 2 other cases.  The disease 
duration for those classified as 4.3S could not be calculated in 2 cases as the date of 
onset was unknown in one case and the other is still alive. 
The Diagnostic Utility of RT-QuIC for the Diagnosis of Sporadic Creutzfeldt-Jakob Disease   
 Results 60      60 
 
 
3.2 Data Overview: Investigations 
 
The current EuroCJD diagnostic criteria internationally employed to diagnose CJD is 
detailed in the methodology section.  It encompasses the clinical features in 
association with investigation results that include MRI, EEG, CSF 14-3-3 and 
neuropathological examination of brain tissue.  The following section provides an 
overview of the available data collected on each of these investigations for the entire 
cohort.  Additional relevant information such as codon 129 is also included.  Table 9 
demonstrates the available MRI data for the entire cohort of patients, n=162. 
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Table 9 Neuroimaging: what proportion of cases underwent a MRI? 
N= 162 MRI 
Performed 
MRI Sent 
to 
NCJDRSU 
MRI 
Reviewed 
at 
NCJDRSU 
MRI 
Positive 
According 
to 
NCJDRSU 
MRI 
Positive 
According to 
European 
CJD 
Criteria 
(also 
reviewed by 
NCJDRSU) 
MRI Positive 
According to 
Local Team 
Radiologist 
(not reviewed 
by 
NCJDRSU) 
Yes 154 96 95 70 57 14 
No 8 58 1 25 38 42 
Data 
Missing 
- - - - - 2 
Total 162 154 96 95 95 58 
 
 
154/162 (95.1%) cases had a MRI performed.  96/154 (62.3%) of those who had a 
MRI performed had copies of the imaging sent to the NCJDRSU for review.  Of 
these, 1 could not be assessed due to problems with software compatibility.  Of those 
that had a MRI performed but not sent to the NCJDRSU for assessment, the results 
of the MRI were missing in 2 cases.  As detailed in the methodology section, 
consultant neuro-radiologist, Dr David Summers based classified the imaging 
according to the EuroCJD diagnostic criteria, but also gave an overall opinion based 
on clinical experience, whether the scan was radiologically suggestive of sporadic 
CJD. This included scans that demonstrated isolated cortical ribboning which is the 
explanation as to why the number of positive scans differs between the EuroCJD 
diagnostic criteria and the NCJDRSU. 
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Table 10 shows the number of cases that had an EEG performed during their illness 
and what proportion of these had a copy of the representative pages of the EEG 
reviewed at the NCJDRSU. 
 
 
Table 10  Electroencephalogram: what proportion of cases underwent an EEG? 
N=162 EEG 
Performed 
EEG Sent 
to 
NCJDRSU 
EEG 
Reviewed 
at 
NCJDRSU 
EEG 
Positive 
According 
to 
NCJDRSU 
EEG 
Positive 
According 
to 
Referring 
Hospital 
(not 
reviewed by 
NCJDRSU) 
Yes 150 91 91 29 15 
No 6 59 0 62 43 
Data 
Missing 
6 - - - 1 
Total 162 150 91 91 59 
 
 
An EEG was performed in 150 cases in total.  Of these, 91 (60.7%) were sent to the 
NCJDRSU and all were reviewed.  59 (39.3%) were not sent to the NCJDRSU for 
assessment and the local report is shown for these.  Data was missing in 1 case.  
Figure 4 illustrates the proportion of the cohort who underwent a lumbar puncture 
and subsequent cerebrospinal fluid analysis. 
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Figure 4 Proportion of cases that underwent cerebrospinal fluid analysis 
 
 
145/162 (89.5%) of the study cohort had a lumbar puncture.  Figure 5 illustrates the 
proportion of cerebrospinal fluid samples that were analysed at the NCJDRSU.  A 
proportion of cases were discussed with the NCJDRSU for 14-3-3 and RT-QuIC 
analysis but samples were not sent as they were unsuitable due to insufficient volume 
or bloodstained.  Other samples were analysed locally for routine CSF constituents 
but the local clinicians did not refer for 14-3-3 and RT-QuIC.  The remaining 
samples were analysed at the National Hospital for Neurology and Neurosurgery in 
London, although this was only for 14-3-3. 
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Figure 5 Proportion of CSF samples analysed at NCJDRSU n=128 
 
 
 
128/145 samples of CSF were received by the NCJDRSU of which 121 were 
analysed for 14-3-3 +/- RT-QuIC, as shown in Figure 5.  The remaining 7 samples 
could not be analysed as they were found to be of insufficient volume or because 
they were bloodstained. 
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Figure 6 Proportion of CSF samples analysed for RT-QuIC and 14-3-3 n=115 
 
 
12/145 cases were analysed for 14-3-3 and not RT-QuIC.  6/12 of these samples 
were analysed at the National Hospital for Neurology and Neurosurgery and we did 
not receive a sample.  6/12 cases were analysed by the NJCDRSU but there was not 
enough CSF for RT-QuIC to be performed in addition to 14-3-3. 
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The proportion of cases that had codon 129 analysis is illustrated in Figure 7.  A total 
of 105/162 (64.8%) were analysed for the codon 129 polymorphism. 
 
 
Figure 7 Proportion of cases with codon 129 analysis n=162 
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The proportion of cases that underwent a post mortem and subsequent neuro-
pathological analysis is shown in Figure 8. 
 
Figure 8 Proportion of cases in whom a post mortem was performed with subsequent 
neuropathological assessment 
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3.3 Case Referrals 
 
The proportion of cases formally referred to the NCJDRSU is illustrated in Figure 9. 
 
Figure 9 Proportion of cases formally referred to NCJDRSU n=162 
 
 
157 (96.9%) of the study cohort were formally referred to the NCJDRSU and 5 
(3.08%) were not.  Of the non-referred cases, the offer of a visit was declined in two 
cases by the local clinicians.  One case was genetic and the remaining two cases were 
for discussion only.  131 were referred and reviewed during life.  7 cases were 
reviewed after death.  19 cases were formally referred after death but not reviewed 
during the study period.  The families of 3 of the 19 cases declined a visit.  For those 
cases that were reviewed either during life or after death, the assessing clinician is 
illustrated in Figure 10 and shows that the author reviewed the majority of the cases. 
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Figure 10 Clinicians who reviewed formally referred cases 
 
 
For the purposes of this study, only the clinical characteristics of suspected cases of 
sporadic CJD with a RT-QuIC result will be analysed. 
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3.4 Clinical Characteristics of Definite Sporadic (1.0S) 
RT-QuIC positive and RT-QuIC negative cases 
 
 
The proportion of the cohort with a final classification of 1.0S was 43.8% (n=71).  
The total number of 1.0S cases who had cerebrospinal fluid analysis was n=60.  Data 
was missing in one case.  The number of cases with a final classification of 1.0S that 
had cerebrospinal fluid successfully analysed for both 14-3-3 and RT-QuIC was 
n=44.  There were no cases where RT-QuIC was successfully analysed without 14-3-
3.  The following series of tables compare the mean age of onset, median duration of 
illness, mode of symptom onset, codon 129 genotype, MRI, EEG and 14-3-3 results 
between the RT-QuIC positive and negative groups.   
 
Table 11 demonstrates the mean age of onset, median duration of illness and mode of 
symptom onset between the 1.0S RT-QuIC positive and RT-QuIC negative groups.  
Logistical regression analysis was used to assess the predictive value of age and 
disease duration on a positive RT-QuIC result.  Odds ratios with their corresponding 
P values are provided.  A longer duration of illness was more likely to be associated 
with a negative RT-QuIC result and this was found to be significant.  The age of 
onset within the positive group was relevant in the positive RT-QuIC group but this 
did not reach statistical significance. 
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Table 11 Mean age at onset, median duration of illness and mode of onset 
 RT-QuIC 
Positive n= 35 
RT-QuIC 
Negative n= 9 
Odds 
Ratio 
P Value 
Mean Age at 
Onset (Years) 
66.6 (range 43-
78) 
61.1 (range 51-
71) 
1.023 0.644 
Median Duration 
of Illness (months) 
 
4.47 (range 
1.1-19.9) 
 
13.0 (range 2.2-
32.4) 
 
       
      0.82 
 
 
0.014 
Mode of Symptom 
Onset 
- - - - 
Rapidly 
Progressive 
Dementia 
16 (45.7%) 4 (44.4%) - - 
Slowly Progressive 
Dementia 
0 (0%) 0 (0%) - - 
Heidenhain 2 (5.7%) 1 (11.1%)   
Cerebellar 4 (11.4%) 0 (0%)   
Stroke-Like Onset 1 (2.9%) 0 (0%)   
Psychiatric Onset 2 (5.7%) 0 (0%)   
Other 10 (28.5%) 4 (44.4%)   
 
The codon 129 status was known for 40/44 (90.9%) of the 1.0S cases with a RT-
QuIC result, the details of which are shown in Table 12 below. Logistic regression 
analysis was used to assess the predictive value of each genotype in producing a 
positive RT-QuIC result.  Odds ratios with corresponding P values are shown.  
Codon 129 MM and MV were more likely to produce a positive result than VV 
genotype, although neither of these reached statistical significance.   The specific 
isotype was known in 23/44 (52.3%) of cases and is illustrated in Table 13. 
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Table 12 Codon 129 status for definite (1.0S) RT-QuIC positive and RT-QuIC negative cases n=40 
 RT-QuIC 
Positive 
n=35 
RT-QuIC 
Negative 
n= 9 
Odds Ratio P Value 
Codon 129 
Analysed 
31/35 
(88.5%) 
9/9 (100%)   
MM 18 (58.0) 3 (33.3%) 1.90 0.531 
MV 6 (19.3%) 2 (22.2%) 6.05 0.301 
VV 7 (22.5%) 4 (44.4%) 0.69 0.745 
Total 31 9   
 
 
Table 13 Codon 129/Isotype for definite (1.0S) Rt-QuIC positive and RT-QuIC negative cases n=44 
 RT-QuIC Positive n= 35 RT-QuIC Negative n= 9 
Isotype Analysed 19/35 (54.2%) 4/9 (44.4%) 
MM1 9 (47.3%) 0 (0%) 
MV1 3 (15.7%) 0 (0%) 
VV1 0 (0%) 1 (25%) 
MM2A 0 (0%) 1 (25%) 
MV2A 1 (5.2%) 1 (25%) 
VV2A 4 (21.0%) 0 (0%) 
MM mixed 2 (10.5%) 0 (0%) 
MV mixed 0 (0%) 1 (25%) 
VV mixed 0 (0%) 0 (0%) 
Total 19 4 
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Table 14 Neuroimaging: MRI assessment for definite (1.0S) RT-QuIC positive and RT-QuIC 
negative cases n=44 
 RT-QuIC Positive n= 35 RT-QuIC Negative n= 9 
MRI Performed 31/35 (88.5%) 9/9 (100%) 
MRI Sent to NCJDRSU 20/31 (64.5%) 8/9 (88.8%) 
MRI Reviewed at 
NCJDRSU 
20/31 (64.5%) 8/9 (88.8%) 
MRI Positive According 
to NCJDRSU 
  
Yes 16/20 (80%) 5/8 (12.5%) 
No 4/20 (20%) 3/8 (37.5%) 
Basal Ganglia change only 0/16 (0%) 2/5 (40%) 
Basal ganglia change + 
Cortical Ribboning 
15/16 (93.7%) 3/5 (60%) 
Cortical Ribboning Alone 1/16 (6.25%) 0/5 (0%) 
MRI Positive According 
to WHO Criteria (also 
reviewed at NCJDRSU) 
  
Yes 15/20 (75%) 5/8 (12.5%) 
No 5/20 (25%) 3/8 (37.5%) 
Basal Ganglia change only 0/15 (0%) 2/5 (40%) 
Basal ganglia change + 
Cortical Ribboning 
15/15(100%) 3/5 (60%) 
Cortical Ribboning Alone 0/15 (0%) 0/5 (0%) 
MRI Positive According 
to WHO Criteria (not 
reviewed at NCJDRSU) 
11/31 (35.4%) 1/9 (11.1%) 
Yes 4/11 (36.3%) 0/1 (0%) 
No 6/11 (54.5%) 1/1 (100%) 
Data Missing 1/11 (9.09%) - 
Basal Ganglia Alone 2/4 (50%) 0/1 (0%) 
Basal Ganglia + Cortical 
Ribboning 
2/4 (50%) 0/1 (0%) 
Cortical Ribboning Alone 0/4 (0%) 1/1 (100%) 
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Table 15 EEG assessment for definite (1.0S) RT-QuIC positive and RT-QuIC negative cases 
 RT-QuIC Positive n= 35 RT-QuIC Negative n= 9 
EEG Performed   
Yes 33/35 (94.2%) 9/9 (100%) 
No 0/35 (0%) 0/9 (0%) 
Data Missing 2/35 (5.71%) 0/9 (0%) 
EEG Reviewed at 
NCJDRSU 
21 (63.6%) 5 (55.5%) 
Positive 8 (38.1%) 1 (20%) 
Negative 13 (61.9%) 4 (80%) 
EEG Reviewed Locally 12 (36.3%)  4 (44.4%) 
Positive 4 (33.3%) 1 (25%) 
Negative 8 (66.6%) 3 (75%) 
 
 
Table 16 Comparison of 14-3-3 and RT-QuIC results for definite (1.0S) cases 
 RT-QuIC Positive n= 35 RT-QuIC Negative n =9 
Median Time from 
Symptom Onset to LP 
(range in months) 
 
3.22 (0.62-9.4) 
 
6.81 (0.56-13.4) 
14-3-3   
Positive 31(94.2%) 5 (55.5%) 
Negative 4 (11.4%) 4 (44.4%) 
 
The median time to LP was calculated in 34/35 RT-QuIC positive cases and 9/9 RT 
QuIC negative cases.  Date of lumbar puncture was not available in one case.  The 
predictive value of the duration from symptom onset to LP on the RT-QuIC result 
was analysed using logistic regression.  This produced an odds ratio of 0.72 
suggesting that there is no influence of the timing of the LP on the RT-QuIC result.  
The Diagnostic Utility of RT-QuIC for the Diagnosis of Sporadic Creutzfeldt-Jakob Disease   
 Results 75      75 
 
This finding was significant (p= 0.0094).  The agreement between 14-3-3 and RT-
QuIC was assessed using Cohen’s Kappa returning a value 0.33 suggesting a fair 
agreement between the two tests (p= 0.011). 
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3.5 Clinical Characteristics of Probable Sporadic 
(2.0S) RT-QuIC positive and RT-QuIC negative cases 
 
The proportion of the study cohort with a final classification of 2.0S was n=54.  The 
number of cases that had cerebrospinal fluid analysis was 50/54 (93%).  Of these, the 
proportion of cases that had both 14-3-3 and RT-QuIC analysed was n=45.  Table 17 
illustrates the median age of onset, median duration of illness and mode of symptom 
onset for both 2.0S RT-QuIC positive and RT-QuIC negative cases.  Logistical 
regression was used to assess the predictive value of age and duration of illness on 
the RT-QuIC result.  Odds ratios and corresponding P values are shown.  Older age 
and shorter duration of illness were shown to be more likely to produce a positive 
result although statistical significance was not reached.    
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Table 17 Mean age of onset, median duration of illness and mode of onset for probable (2.0S) RT-
QuIC positive and RT-QuIC negative cases n=54 
 RT-QuIC 
Positive n= 38 
RT-QuIC 
Negative n= 7 
Odds 
Ratio 
P Value 
Mean Age at 
Onset (Years) 
70 (range 45-
84) 
66.9 (range 47-
86) 
1.023 0.628 
Median Duration 
of Illness 
(months) 
4.48 (range 
0.69-11.9) 
3.57 (range 
1.64-6.1)* 
1.33 0.274 
Mode of 
Symptom Onset 
- - - - 
Rapidly 
Progressive 
Dementia 
19 (50%) 2 (28.5%) - - 
Slowly 
Progressive 
Dementia 
0 (0%) 0 (0%) - - 
Heidenhain 1 (2.6%) 0 (0%) - - 
Cerebellar 6 (15.7%) 1 (14.2%)   
Stroke-Like Onset 0 (0%) 1 (14.2%)   
Psychiatric Onset 2 (5.3%) 2 (28.5%)   
Other 9 (23.6%) 1 (14.2%)   
Data Missing 1 (2.6%) 0 (0%)   
 
*The median duration of illness could not be calculated in one case as the patient was still alive at the time of 
writing.   
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Table 18 illustrates the PRNP codon 129 genotype.. 
 
 
Table 18 Codon 129 status for probable (2.0S) RT-QuIC positive and RT-QuIC negative cases 
 RT-QuIC Positive n=38 RT-QuIC Negative n=7 
Codon 129 
Analysed 
17/38 (44.7%) 2/7 (28.6%) 
MM 9 (52.9%) 1 (50%) 
MV 1 (5.9%) 0 (0%) 
VV 7 (41.2%) 1 (50%) 
Total 17 2 
 
Codon 129/Isotype for probable sporadic (2.0S) RT-QuIC Cases 
Not performed in either group due to absence neuropathological examination. 
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Table 19 Neuroimaging: MRI assessment of probable (2.0S) RT-QuIC positive and RT-QuIC 
negative cases 
 RT-QuIC Positive n= 38 RT-QuIC Negative n= 7 
MRI Performed 38/38 (100%) 7/7 (100%) 
MRI Sent to NCJDRSU 25/38 (65.8%) 5/7 (71.4%) 
MRI Reviewed at 
NCJDRSU 
25/38 (65.8%) 4/7 (57.1%) 
MRI Positive According 
to NCJDRSU 
  
Yes 21/25 (84%) 2/4 (50%) 
No 4/25 (16%) 2/4 (50%) 
Basal Ganglia change only 3/21 (14.3%) 2/2 (100%) 
Basal ganglia change + 
Cortical Ribboning 
16/21 (76.2%) 0/2 (0%) 
Cortical Ribboning Alone 2/21 (9.5%) 0/2 (0%) 
MRI Positive According 
to WHO Criteria (also 
reviewed at NCJDRSU) 
  
Yes 19/25 (76%) 2/4 (50%) 
No 6/25 (24%) 2/4 (50%) 
Basal Ganglia change only 3/19 (15.8%) 2/2 (100%) 
Basal ganglia change + 
Cortical Ribboning 
16/19 (84.2%) 0/2 (0%) 
Cortical Ribboning Alone 0/19 (0%) 0/2 (0%) 
MRI Positive According 
to WHO Criteria (not 
reviewed at NCJDRSU) 
  
Yes 5/13 (38.5%) 1/3 (33.3%) 
No 7/13 (53.8%) 2/3 (66.7%) 
Data Missing 1/13 (7.7%) - 
Basal Ganglia Alone 0/5 (0%) 1/1 (100%) 
Basal Ganglia + Cortical 
Ribboning 
5/5 (100%) 0/1 (0%) 
Cortical Ribboning Alone 0/5 (0%) 0/1 (0%) 
Data Missing 1/13 (7.7%) - 
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Table 20 EEG assessment of probable (2.0S) RT-QuIC positive and RT-QuIC negative cases 
 RT-QuIC Positive n=38 RT-QuIC Negative n=7 
EEG Performed   
Yes 36/38 (94.7%) 6/7 (85.7%) 
No 2/38 (5.3%) 1/7 (14.3%) 
EEG Reviewed at 
NCJDRSU 
23/36 (63.9%) 4/6 (66.7%) 
Positive 6/23 (26.1%) 2 (50%) 
Negative 17/23 (73.9%) 2 (50%) 
EEG Locally Reported 13/36 (36.1%) 2/6 (33.3%) 
Positive 5/13 (38.5%) 1 (50%) 
Negative 8/13 (61.5%) 1 (50%) 
 
Table 21 Comparison of 14-3-3 and RT-QuIC for probable (2.0S) cases 
 RT-QuIC Positive n= 38 RT-QuIC Negative n =7 
Median time from 
symptom onset to LP 
(months) 
 
3.48 (range 0.36-11.4) 
 
3.85 (range 1.08-13.1) 
14-3-3   
Positive 34/38 (89.5%) 6/7 (85.7%) 
Negative 4/38 (10.5%) 1/7 (14.3%) 
 
The influence of the duration between symptom onset and LP on producing a 
positive RT-QuIC result was analysed using logistic regression.  The odds ratio was 
0.93 suggesting that the timing of the lumbar puncture does not influence the 
outcome of the result although this finding was not significant (p= 0.632).  The 
agreement between 14-3-3 and RT-QuIC was analysed using Cohen’s Kappa 
returning a Kappa value of 0.04 suggesting a poor agreement between the two tests, 
although this was not found to be a significant result (p- 0.383). 
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3.6  Clinical Characteristics of possible sporadic 
(3.0S) RT-QuIC positive and negative cases 
 
The number of cases who received a final classification of 3.0S at the time of writing 
was n=10. The proportion of these cases that underwent a lumbar puncture and 
subsequent cerebrospinal fluid analysis was 9/10 (90%).  Of these, the number of 
cases who had both 14-3-3 and RT-QuIC analysed was 5/9 (55.6%).  The clinical 
details and investigation results for these cases are shown in the series of tables 
below (Tables 22-24 inclusive). 
 
Logistical regression was used to assess the predictive value of age and duration of 
illness on the likelihood of a positive result.  No significant findings were observed, 
although it is recognised by the author that the disease duration could not be 
calculated in the RT-QuIC negative group and that the case numbers within this 
diagnostic group are small. 
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Table 22 Mean age at onset, median duration of illness, mode of onset for possible (3.0S) RT-QuIC 
positive and RT-Quic negative cases n=5 
 RT-QuIC 
Positive n= 3 
RT-QuIC 
Negative n= 2 
Odds 
Ratio 
P Value 
Mean Age at 
Onset (Years) 
67 (no range) 64 (range 58-
70) 
77.32 0.999 
Median Duration 
of Illness 
(months) 
4.26 (range 
1.51-6.46) 
 *  
1 
>0.999 
Mode of 
Symptom Onset 
- - - - 
Rapidly 
Progressive 
Dementia 
1/3 (33.3%) 1/2 (50%)   
Slowly 
Progressive 
Dementia 
0 (0%) 0 (0%)   
Heidenhain 0 (0%) 0 (0%)   
Cerebellar 1/3 (33.3%) 0 (0%)   
Stroke-Like Onset 0 (0%) 0 (0%)   
Psychiatric Onset 0 (0%) 0 (0%)   
Other 1/3 (33.3%) 1/2 (50%)   
Data Missing 0 (0%) 0 (0%)   
*The median disease duration could not be calculated.  The disease duration of one case was 
11.5 months.  The other case, to date, is still alive.  The date of symptom onset for this case 
was 15
th
 November 2011. 
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Table 23 Codon 129 status in the possible (3.0S) RT-QuiC positive and RT-QuIC negative group 
 RT-QuIC Positive n=3 RT-QuIC Negative n=2 
Codon 129 Analysed 3/3 (100%) 2/2 (100%) 
MM 2/3 (66.7%) 0 (0%) 
MV 0 (0%) 1/2 (50%) 
VV 1/3 (33.3%) 1/2 (50%) 
Total 3 2 
 
Codon 129/Isotype for the possible sporadic (3.0S) RT-QuIC Positive and 
RT-QuIC Negative Cases 
Not performed in either group. 
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Table 24 Neuroimaging: MRI assessment of possible (3.0S) RT-QuIC positive and RT-QuIC 
negative cases 
 RT-QuIC Positive n= 3 RT-QuIC Negative n= 2 
MRI Peformed 3/3 100%) 2/2 (100%) 
MRI Sent to NCJDRSU 2/3 (66.6%) 1/2 (50%) 
MRI Reviewed at 
NCJDRSU 
2/3 (66.6%) 1/2 (50%) 
MRI Positive According 
to NCJDRSU 
  
Yes 2/2 (100%) 1/1 (100%) 
No 0/2 (0%) 0/1 (0%) 
Basal Ganglia change only 0/2 (0%) 0/1 (0%) 
Basal ganglia change + 
Cortical Ribboning 
0/2 (0%) 0/1 (0%) 
Cortical Ribboning Alone 2/2 (100%) 1/1 (100%) 
MRI Positive According 
to WHO Criteria (also 
reviewed at NCJDRSU) 
  
Yes 0/2 (0%) 0/1 (0%) 
No 2/2 (100%) 1/1 (100%) 
Basal Ganglia change only 0 (0%) 0 (0%) 
Basal ganglia change + 
Cortical Ribboning 
0 (0%) 0 (0%) 
Cortical Ribboning Alone 0 (0%) 0 (0%) 
MRI Positive According 
to WHO Criteria (not 
reviewed at NCJDRSU) 
1/3 (33.3%) 1/2 (50%) 
Yes 0/1 (0%) 0/1 (0%) 
No 1/1 (100%) 1/1 (100%) 
Data Missing - - 
Basal Ganglia Alone 0 (0%) 0 (0%) 
Basal Ganglia + Cortical 
Ribboning 
0 (0%) 0 (0%) 
Cortical Ribboning Alone 0 (0%) 0 (0%) 
Data Missing - - 
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Table 25 EEG assessment of possible (3.0S) RT-QuIC positive and RT-QuIC negative cases 
 RT-QuIC Positive n= 3 RT-QuIC Negative n= 2 
EEG Performed   
Yes 2/3 (66.7%) 2/2 (100%) 
No 1/3 (33.3%) 0 (0%) 
Data Missing - - 
EEG Reviewed at 
NCJDRSU 
1/2 (50%) 0 (0%) 
Positive 0 (0%) - 
Negative 1/1 (100%) - 
EEG Reviewed Locally 1/2 (50%)  2/2 (100%) 
Positive 0 (0%) 0 (0%) 
Negative 1/1 (100%) 2/2 (100%) 
 
Table 26 Comparison of 14-3-3 and RT-QuIC for possible (3.0S) cases 
 RT-QuIC Positive n=3 RT-QuIC Negative n=2 
Median time from 
symptom onset to LP 
(months) 
 
3.22 (range 1.05-5.38) 
 
4.98 (range 4.03-5.93) 
14-3-3   
Positive 0 (0%) 0 (0%) 
Negative 3 (100%) 2 (100%) 
 
The predictive value of the duration between symptom onset and LP was once again 
analysed using logistic regression to determine whether this influences the outcome 
of the RT-QuIC result.  The odds ratio was 0.44 suggesting that there is no influence 
although this finding was not found to be significant (p=0.327).  The agreement 
between 14-3-3 and RT-QuIC was analysed using Cohen’s Kappa.  The value 
returned at 0.33 suggesting a fair agreement although this result was not significant 
(p= 0.078). 
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3.7  Clinical characteristics of Uncertain (4.1S) RT-
QuIC positive and RT-QuIC negative cases 
 
The number of cases that received a final classification of 4.1S was 6.  All of these 
cases underwent a lumbar puncture and subsequent CSF analysis and all were 
assessed for 14-3-3 and RT-QuIC.  The clinical characteristics and investigation 
findings are detailed in the series of tables below.   
 
Logistical regression was used to determine the predictive value of age and disease 
duration on the likelihood of a RT-QuIC result but no statistically significant 
observations were made which, once again, is likely to reflect the small numbers of 
cases within this diagnostic group. 
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Table 27 Mean age of onset, median duration of illness, mode of onset for uncertain (4.1S) RT-
QuIC positive and RT-QuIC negative cases n-6 
 RT-QuIC 
Positive n= 2 
RT-QuIC 
Negative n= 4 
Odds Ratio P Value 
Mean Age at 
Onset (Years) 
70 (range 67-
73) 
58.5 (range 48-
75) 
0.006 0.999 
Median Duration 
of Illness 
(months) 
 
9.1 (range 7.4-
10.8) 
 
29.5 (range 
14.9-42.5) 
 
 
            0 
 
 
     0.999 
Mode of 
Symptom Onset 
- - - - 
Rapidly 
Progressive 
Dementia 
2 (100%) 1 (20%)   
Slowly Progressive 
Dementia 
0 (0%) 1 (20%)   
Heidenhain 0 (0%) 0 (0%)   
Cerebellar 0 (0%) 0 (0%)   
Stroke-Like Onset 0 (0%) 0 (0%)   
Psychiatric Onset 0 (0%) 3 (60%)   
Other - -   
*Disease duration could not be calculated in one case as the patient is still alive at the time of 
writing.  The date of symptom onset for this case was the 15
th
 January 2012. 
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Table 28 Codon 129 status for uncertain (4.1S) RT-QuIC positive and RT-QuIC negative cases 
 RT-QuIC Positive n= 2 RT-QuIC Negative n= 4 
Codon 129 Analysed 0/2 (0%) 2/4 (50%) 
MM - 1/2 (50%) 
MV - 1/2 (50%) 
VV - 0 (0%) 
 
 
Codon 129/Isotype for the uncertain (4.1S) RT-QuIC Positive and RT-QuIC 
Negative Cases 
Not performed in either group. 
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Table 29 Neuroimaging: MRI assessment of unccertain (4.1S) RT-QuIC positive and RT-QuIC 
negative cases 
 RT-QuIC Positive n= 2 RT-QuIC Negative n= 4 
MRI Performed 2/2 (100%) 4/4 (100%) 
MRI Sent to NCJDRSU 1/2 (50%) 4/4 (100%) 
MRI Reviewed at 
NCJDRSU 
1/2 (50%) 4/4 (100%) 
MRI Positive According 
to NCJDRSU 
  
Yes 1/1(100%) 3/4 (75%) 
No 0/1 (0%) 1/4 (25%) 
Basal Ganglia change only 0 (0%) 1/3 (33.3%) 
Basal ganglia change + 
Cortical Ribboning 
1/1 (100%) 1/3 (33.3%) 
Cortical Ribboning Alone 0 (0%) 1/3 (33.3%) 
MRI Positive According 
to WHO Criteria (also 
reviewed at NCJDRSU) 
  
Yes 1/1 (100%) 2/4 (50%) 
No 0 (0%) 2/4 (50%) 
Basal Ganglia change only 0 (0%) 1/2 (50%) 
Basal ganglia change + 
Cortical Ribboning 
1/1 (100%) 1/2 (50%) 
Cortical Ribboning Alone 0 (0%) 0 (0%) 
MRI Positive According 
to WHO Criteria (not 
reviewed at NCJDRSU) 
  
Yes 0/1 (0%) 0/1 (0%) 
No 1/1 (100%) 1/1 (100%) 
Data Missing - - 
Basal Ganglia Alone 0 (0%) 0 (0%) 
Basal Ganglia + Cortical 
Ribboning 
0 (0%) 0 (0%) 
Cortical Ribboning Alone 0 (0%) 0 (0%) 
Data Missing - - 
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Table 30 EEG assessment of uncertain (4.1S) RT-QuIC positive and RT-QuIC negative cases 
 RT-QuIC Positive n=2 RT-QuIC Negative n=4 
EEG Performed   
Yes 2/2 (100%) 4/4 (100%) 
No 0 (0%) 0 (0%) 
Data Missing - - 
EEG Reviewed at 
NCJDRSU 
1/2 (50%) 1/4 (25%) 
Positive 0 (0%) 0 (0%) 
Negative 1/1 (100%) 1/4 (100%) 
EEG Reviewed Locally 1/1 (100%) 3/4 (75%) 
Positive 0 (0%) 0 (0%) 
Negative 1/1 (100%) 3/3 (100%) 
 
Table 31 Comparison of 14-3-3 and RT-QuIC for uncertain (4.1S) cases 
 RT-QuIC Positive n= 2 RT-QuIC Negative n =4 
Median Time to LP from 
Symptom Onset 
 
5.1 (range 4.7-5.4) 
 
14.7 (range 2.5-27.3)* 
14-3-3   
Positive 0 (0%) 0 (0%) 
Negative 2/2 (100%) 4/4 (100%) 
*Time from symptom onset to LP could not be calculated in one case as the date of the LP was 
missing. 
 
Logistic regression analysis was used to assess the predictive value of the duration 
between symptom onset and LP on the RT-QuIC result.  This produced an odds ratio 
of 0.87 suggesting that there is no influence although this finding was not significant, 
presumably due to the small numbers, p- 0.315.  The agreement between 14-3-3 and 
RT-QuIC was also assessed using Cohen’s Kappa.  The Kappa value was 0.33 
suggesting a fair agreement but this was not significant (p=0.0786). 
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3.8  Clinical characteristics of unlikely sporadic (4.2S) 
and definitely not sporadic (4.3S) RT-QuIC cases 
 
The number of cases with a final classification of 4.2S was 10 and all of these had 
CSF analysis performed.  7/10 had both 14-3-3 and RT-QuIC performed.  All were 
RT-QuIC negative.  The mean age at onset was 74.4 years.  The number of cases that 
received a final classification of 4.3S was 5 and all underwent CSF analysis.  4/5 had 
both 14-3-3 and RT-QuIC assessed.  Given that both 4.2S and 4.3S classifications 
are considered to be not CJD, these groups have been assessed together.  The 
following series of tables demonstrates the clinical characteristics and investigations 
for the 4.2S and 4.3S RT-QuIC negative cases. 
 
Table 32 Mean age at onset, median duration of illness, mode of onset for unlikely (4.2S) and 
definitely not (4.3S) RT-QuIC negative cases n=12 
 RT-QuIC Positive (n=0) RT-QuIC Negative 
(n=12) 
Mean Age at Onset 
(Years) 
- 72 (range 52-87 years) 
Median Duration of 
Illness (months) 
- 9.1 (range 3.1-19.7)* 
Mode of symptom onset   
Rapidly progressive 
dementia 
- 2/12 (16.7%) 
Slowly progressive 
dementia 
- 1/12 (8.3%) 
Heidenhain - 0 (0%) 
Cerebellar - 0 (0%) 
Stroke-like onset - 0 (0%) 
Psychiatric onset - 2/12 (16.7%) 
Other - 7/12 (58.3%) 
Data missing - 0 (0%) 
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Table 33 Codon 129 status for unlikely (4.2S) and definitely not (4.3S) RT-QuIC negative cases 
 RT-QuIC Positive n=0 RT-QuIC Negative n=12 
Codon 129 Analysed - 4/12 (33.3%) 
MM - 3/4 (75%) 
MV - 1/4 (25%) 
VV - 0 (0%) 
Total - 4 
 
 
Codon 129/Isotype for the unlikely (4.2S) and definitely not (4.3S) RT-QuIC 
Positive and RT-QuIC Negative Cases 
Not performed in either group. 
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Table 34 Neuroimaging: MRI assessment of unlikely (4.2S) and definitely not (4.3S) RT-QuIC 
negative cases 
 RT-QuIC Positive n= 0 RT-QuIC Negative n= 12 
MRI Performed - 10/12 (83.3%) 
MRI Sent to NCJDRSU - 7/10 (70%) 
MRI Reviewed at 
NCJDRSU 
- 7/7 (100%) 
MRI Positive According 
to NCJDRSU 
  
Yes - 0/7 (0%) 
No - 7/7 (100%) 
Basal Ganglia change only - 0 (0%) 
Basal ganglia change + 
Cortical Ribboning 
- 0 (0%) 
Cortical Ribboning Alone - 0 (0%) 
MRI Positive According 
to WHO Criteria (also 
reviewed at NCJDRSU) 
  
Yes - 0/7 (0%) 
No - 7/7 (100%) 
Basal Ganglia change only - 0 (0%) 
Basal ganglia change + 
Cortical Ribboning 
- 0 (0%) 
Cortical Ribboning Alone - 0 (0%) 
MRI Positive According 
to WHO Criteria (not 
reviewed at NCJDRSU) 
-  
Yes - 0/3 (0%) 
No - 3/3 (100%) 
Data Missing - - 
Basal Ganglia Alone - 0 (0%) 
Basal Ganglia + Cortical 
Ribboning 
- 0 (0%) 
Cortical Ribboning Alone - 0 (0%) 
Data Missing - - 
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Table 35 EEG assessment of unlikely (4.2S) and definitely not (4.3S) RT-QuIC negative cases 
 RT-QuIC Positive n=0 RT-QuIC Negative n=12 
EEG performed   
Yes - 12/12 (100%) 
No - 0 (0%) 
Data missing - 0 (0%) 
EEG Reviewed at 
NCJDRSU 
- 9/12 (75%) 
Positive - 1/9 (11.1%) 
Negative - 8/9 (88.9%) 
EEG Reviewed Locally - 3/12 (25%) 
Positive - 0/3 (0%) 
Negative - 3/3 (100%) 
 
 
Table 36 Comparison of 14-3-3 and RT-QuIC for unlikely (4.2S) and definitely not (4.3S) cases 
 
 
 
 
 
 RT-QuIC Positive n= 0 RT-QuIC Negative n =12 
Median Time to LP from 
Symptom Onset 
- 9.2 (range 0.6-35.2)* 
14-3-3   
Positive - 2/12 (16.7%) 
Negative - 10/12 (83.3%) 
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Table 37 demonstrates the final diagnosis in the 4.2S and 4.3S sub-cohort. 
 
Table 37 Final diagnosis of the unlikely (4.2S) and definitely not (4.3S) cases 
 RT-QuIC Negative n=12 
Final Diagnosis  
Neuro-metabolic 1 
Neuro-inflammatory 2 
Diagnosis Unclear 2 
Diagnosis Unclear; patient improved 3 
Neurodegenerative- Alzheimer’s disease 
Vascular dementia 
Mixed dementia 
1 
1 
1 
Primary psychiatric 1 
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3.9  Summary of the clinical characteristics and 
investigations for RT-QuIC positive and RT-QuIC 
negative cases for all classifications 
 
Table 38 provides an overview of the clinical characteristics and investigation 
findings for RT-QuIC positive and RT-QuIC negative cases for all classifications.  
MRI imaging was considered positive only if results were in concordance with the 
EuroCJD diagnostic criteria (i.e. Basal ganglia signal change +/- cortical ribboning 
and not isolated cortical ribboning). 
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Table 38 Summary of the clinical characteristics and investigations for RT-QuIC positive and negative cases for all classifications 
 Total N 
 
Mean Age 
(years) 
Median 
Duration 
(months) 
RCD 
(%) 
Myoclonus 
(%) 
Cerebellar 
(%) 
Visual 
Symptoms 
(%) 
Mutism 
(%) 
Pyramidal/ 
Extrapyramidal 
(%) 
MRI Positive 
(%) 
EEG 
Positive 
(%) 
14-3-3 
Positive 
(%) 
1.0 
 
RT-QuIC + 
 
RT-QuIC – 
 
Data Missing 
 
 
35 
 
9 
 
- 
 
 
66.6 
 
61.1 
 
- 
 
 
4.47 
 
13.0 
 
- 
 
34/35 (97.1%) 
 
8/9 (88.9%) 
- 
 
33/34 
 (97.1%) 
 
7/9 
 (77.8%) 
 
1 
 
31/35 (88.6%) 
 
7/9  
(77.8%) 
 
0 
 
23/32 (71.9%) 
 
6/9  
(66.7%) 
 
3 
 
17/33 (51.5%) 
 
3/8  
(37.5%) 
 
3 
 
22/32  
(68.8%) 
 
3/8  
(37.5%) 
 
4 
 
19/31 (61.3%) 
 
5/9 
 (55.6%) 
 
1 
 
12/33 (36.4%) 
 
2/9 
(22.2%) 
 
2 
 
31/35 (88.6%) 
 
5/9 
(55.6%) 
 
0 
2.0 
 
RT-QuIC + 
 
RT-QuIC – 
 
Data Missing 
 
 
38 
 
7 
 
- 
 
 
70 
 
66.9 
 
- 
 
 
4.48 
 
3.57 
 
- 
 
38/38 (100%) 
 
7/7  
(100%) 
 
0 
 
37/38 
(97.4%) 
 
7/7 
(100%) 
 
0 
 
32/32 
(100%) 
 
5/7 
(71.4%) 
 
6 
 
26/38 
(68.4%) 
 
3/7 
(42.9%) 
 
0 
 
21/36 
(80.8%) 
 
2/6 
(33.3%) 
 
3 
 
29/36 
(80.6%) 
 
4/6 
(66.7%) 
 
3 
 
24/38 
(63.2%) 
 
3/7 
(42.9%) 
 
0 
 
11/38 
(28.9%) 
 
3/7 
(42.9%) 
 
0 
 
34/38 
(89.5%) 
 
6/7 
(85.7%) 
 
0 
3.0 
 
RT-QuIC + 
 
RT-QuIC – 
 
 
3 
 
2 
 
 
67 
 
64 
 
 
4.26 
 
* 
 
3/3  
(100%) 
 
2/2  
(100%) 
 
3/3  
(100%) 
 
1/2 
(50%) 
 
3/3 
 (100%) 
 
2/2 
 (100%) 
 
1/3  
(33.3%) 
 
1/2 
(50%) 
 
0/3  
(0%) 
 
0/3  
(0%) 
 
1/3  
(33.3%) 
 
1/2 
(50%) 
 
0/3  
(0%) 
 
0/2 
(0%) 
 
0/2  
(0%) 
 
0/2 
 (0%) 
 
0/3  
(0%) 
 
0/2  
(0%) 
4.1 
 
RT-QuIC + 
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3.10  Review of the operational parameters of RT-
QuIC and influence on result 
 
3.10.1  Influence of timing of lumbar puncture on the RT-QuIC 
result 
 
Figures 11 and 12 demonstrate the influence of the timing of the LP on the RT-QuIC 
result for each classification. 
 
 
 
Figure 11 Effect of Timing of LP on a Positive RT-QuIC Result 
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Figure 12 Effect of Timing of LP on a Negative RT-QuIC Result 
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3.10.2  Influence of CSF volume on RT-QuIC Result 
 
During the initial data period, 15µl of CSF was used although over the course of the 
study, it was found that 30µl gave better discrimination between positive and 
negative RT-QuIC results.  However, some CSF samples from cases of suspected 
sporadic CJD had a negative RT-QuIC response at 30µl but a postive RT-QuIC 
response was obtained using 15µl.  Therefore, CSF samples were tested at both 15µl 
and 30µl. 
 
3.10.3  Timing of RT-QuIC result in comparison to other 
investigations 
 
Below are a series of figures illustrating the timing of the LP , EEG and MRI results 
for 1.0S and 2.0S cases.  This is followed by Table 4.35 which provides a summary 
of the timing of all of the investigations for each classification.  
Figure 13 Definite Cases (1.0S) Time from LP to RT-QuIC Result 
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Figure 14 Definite Cases (1.0S) Time from LP to 14-3-3 Result 
 
 
 
Figure 15 Definite Cases (1.0S) Time from Symptom Onset to RT-QuIC Result 
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Figure 16 Definite Cases (1.0S) Time from Symptom Onset to 14-3-3 Result 
 
 
Figure 17 Definite Cases (1.0S) Time from Symptom Onset to a Positive EEG Result 
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Figure 18 Definite Cases (1.0S) Time from Symptom Onset to a Positive MRI Result 
 
 
Figure 19 Probable Cases (2.0S) Time from LP to RT-QuIC Result 
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Figure 20 Probable Cases (2.0S) Time from LP to 14-3-3 Result 
 
 
Figure 21 Probable Cases (2.0S) Time from Symptom Onset to RT-QuIC Result 
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Figure 22 Probable Cases (2.0S) Time from Symptom Onset to 14-3-3 Result 
 
 
Figure 23 Probable Cases (2.0S) Time from Symptom Onset to a Positive EEG 
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Figure 24 Probable Cases (2.0S) Time from Symptom Onset to a Positive MRI Result 
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Table 39 Summary of timing of investigations for all classifications
 Total Number Time from Symptom 
Onset to Positive 
MRI 
(Range in months) 
Time from Symptom 
Onset to Positive 
EEG 
(Range in months) 
Time from Symptom 
Onset to 14-3-3 
Result 
(Range in months) 
Time from Symptom 
Onset to RT-QuIC 
Result 
(Range in months) 
Time from LP to 14-
3-3 Result 
(Range in months) 
Time from LP to 
RT-QuIC Result 
(Range in months) 
1.0S 44 24/44 (54.5%) 
3.6 
(0.2-8.9) 
14/42 (33.3%) 
2.9 
(0.6-6.9) 
40/44 (90.9%) 
4.2 
(1-13.7) 
41/44 (93.2%) 
5.9 
(1.5-37.7) 
40/44 (90.9%) 
0.5 
(0.1-2) 
40/44 (90.9%) 
1.4 
(0.5-5) 
2.0S 45 27/45 (60%) 
4.2 
(0.2-15.1) 
11/45 (24.4%) 
3.4 
(1.2-11.2) 
44/45 (97.8%) 
3.9 
(0.8-13.4) 
44/45 (97.8%) 
4.9 
(1.3-13.7) 
44/45 (97.8%) 
0.4 
(0.2-1.2) 
44/45 (97.8%) 
1.3 
(0.5-5) 
3.0S 5  
None positive 
 
None positive 
4/5 (80%) 
4.5 
(1.5-6.1) 
5/5 (100%) 
5 
(2.6-6.5) 
4/5 (80%) 
0.4 
(0.1-0.7) 
5/5 (100%) 
1.1 
(0.5-1.7) 
4.1S 6 3/6 (50%) 
11.1 
(2.3-26.3) 
 
None Positive 
6/6 (100%) 
12.4 
(2.7-27.6) 
6/6 (100%) 
12.8 
(3.3-28.2) 
5/6 (83.3%) 
0.4 
(0.2-0.5) 
5/6 (83.3%) 
0.8 
(0.6-0.9) 
4.2/4.3S 12  
None Positive 
1/12 (8.3%) 
2.8 
(1 positive) 
12/12 (100%) 
9.4 
(1.2-35.5) 
12/12 (100%) 
9.8 
(2.3-35.8) 
11/12 (83.3%) 
0.53 
(0.2-1.2) 
11/12 (91.7%) 
1 
(0.4-1.8) 
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3.10.3.1 Definite sporadic (1.0S) Group 
 
The time from symptom onset to RT-QuIC result could not be calculated in 3 cases 
as the date of the RT-QuIC result was missing. The time taken from LP to RT-QuIC 
result was prolonged at 24.5 months in one case.  This case was referred for CSF and 
formal referral out with the data period but reviewed during the data period and the 
RT-QuIC performed retrospectively.  This case was therefore not included in the 
median duration to result.   The time between symptom onset to 14-3-3 result could 
not be calculated in 4 cases as the date of the 14-3-3 result was missing. 42/44 cases 
had an EEG performed and data was missing for the remaining 2 cases.  14 were 
positive.  The time from symptom onset to a positive EEG result could be calculated 
in 12/14.  24/44 cases had a positive MRI of which the duration from symptom onset 
to a positive MRI result could be calculated in 21/24.  The remaining 3 cases could 
not be calculated as the date of the MRI result was missing.  
 
 
3.10.3.2 Probable Sporadic (2.0S) Group  
 
The time from symptom onset to the RT-QuIC result could not be calculated in one 
case as the date of the RT-QuIC result was missing.  The time taken from the LP to 
the 14-3-3 result could not be calculated in one case as the date of the 14-3-3 result 
was missing.  The duration from symptom onset to RT-QuIC result could not be 
calculated in one case as the date of the RT-QuIC result was missing.  Duration 
between symptom onset and 14-3-3 result could not be calculated in one case as the 
date of the 14-3-3 was missing. EEG was performed in 42/45 cases and was positive 
in 14/42.  The time to positive result could not be calculated in 3 cases as the date of 
the positive EEG was missing. 27/45 cases had a positive MRI. Data was missing in 
one case.  The time to a positive result could not be calculated in one case as the date 
of the MRI result was missing. 
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3.10.3.3 Possible sporadic (3.0S) Group 
 
The time from LP to 14-3-3 result could not be calculated one case as the 14-3-3 
result date was missing.  Time from symptom onset to 14-3-3 result could not be 
calculated in one case for the same reason.  All 5 cases underwent a MRI, none of 
which were positive. 4/5 cases had an EEG, none of which were positive. 
 
3.10.3.4 Diagnosis uncertain (4.1S) Group 
 
The time from LP to the RT-QuIC result was calculated in 5/6 cases.  The date of LP 
was missing in one case.  The time from LP to 14-3-3 result was calculated in 5/6 
due to one case with a missing date of LP.  All 6 underwent an EEG, none of which 
were positive.  All 6 underwent a MRI with half of these positive. 
 
3.10.3.5 Unlikely sporadic or definitely not sporadic (4.2S/4.3S) Group 
 
The time from LP to RT-QuIC result was calculated in 11/12.  The date of the LP 
was missing in one case.  This was similar for the time from the LP to 14-3-3 result.  
All 12 underwent an EEG with only one case reported as positive.  10/12 had a MRI, 
none of which were positive. 
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3.11 Overall Sensitivity and Specificity of RT-QuIC 
 
The following tables illustrate the investigation results for each classification and 
also the specificity, sensitivity and positive predictive value of each test. 
 
Table 40 Investigations results by classification 
Classification 
(EuroCJD 
Criteria) 
Total RT-
QuIC 
positive 
14-3-3 
Positive 
EEG 
Positive 
MRI 
Positive 
(Basal 
ganglia 
change) 
MRI 
Positive 
(Cortical 
ribboning 
only) 
Definite 44 35 (80%) 36 (82%) 14 (32%) 24 (55%) 6 (14%) 
Probable 45 38 (84%) 40 (89%) 14 (31%) 27 (60%) 4 (9%) 
Possible 5 3 (60%) 0 (0%) 0 (0%) 0 (0%) 3 (60%) 
Uncertain 7 2 (29%) 2 (29%) 0 (0%) 3 (43%) 2 (29%) 
Non Case 
Clinically 
7 0 (0%) 2 (29%) 0 (0%) 0 (0%) 0 (0%) 
Non Case 
Pathologically 
4 0 (0%) 0 (0%) 1 (25%) 0 (0%) 0 (0%) 
 
 
Table 41 Sensitivity, specificity and positive predictive value of all tests 
Definite 
Sporadic 
CJD 
RT-QuIC  14-3-3 EEG MRI 
(Basal 
Ganglia 
change) 
MRI 
(Cortical 
ribboning 
only) 
Sensitivity 80% 82% 32% 55% 14% 
Specificity 100% 82% 91% 100%  
Positive 
Predictive 
Value 
100% 95% 93% 100%  
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3.12 Case Vignettes 
 
Below are a series of case vignettes where the RT-QuIC result was particularly 
useful.  These are divided into RT-QuIC negative and RT-QuIC positive cases. 
 
3.12.1 Cases where RT-QuIC was Positive 
 
3.12.1.1 Case 1 
 
A 47 year old male patient presented with a 1 year history of prominent 
neuropsychiatric features and painful limbs.  Initial MRI brain and CSF 14-3-3 were 
not supportive although the RT-QuIC test was positive. The clinical course 
progressed to a clinical phenotype supportive of sCJD and repeat MRI brain and 14-
3-3 later became positive.  Post mortem and codon 129 genotyping was not 
performed and the final classification based on the WHO criteria was a Probable case 
(2.0S). 
 
3.12.1.2 Case 2 
 
A 75 year old female presented with a neurological syndrome of rapidly progressive 
dementia and progressed to develop cerebellar signs and akinetic mutism.  However, 
the MRI brain and EEG were not supportive.  CSF 14-3-3 and RT-QuIC were both 
positive.  However, the clinical picture was complicated by a possible malignant 
lesion of the pancreas identified on CT imaging suggesting the possibility of a 
paraneoplastic process.  In addition,  a significantly raised anti-thyroid peroxidase 
antibody was found suggesting the possibility of Hashimoto’s thyroiditis.  This 
patient underwent a course of steroid treatment although continued to progress and 
died.  The final WHO diagnostic classification during life was Uncertain (4.1S) due 
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to the fact that an alternative cause could not be fully excluded.  Post mortem 
examination confirmed sCJD and the classification was upgraded to a definite (1.0S) 
case. Genotyping and PrP
Sc 
type was not available. 
 
3.12.1.3 Case 3 
 
A 77 year old female presented with bilateral deafness and later developed rapidly 
progressive dementia, pyramidal signs and myoclonus.  MRI, EEG and 14-3-3 were 
not supportive and the highest classification during life was a Possible case (3.0S).  
Post mortem examination confirmed sCJD and this case was re-classified as definite 
(1.0S).  Data on genotype and PrP
Sc
 type was not performed. The RT-QuIC test was 
positive in this case. 
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3.12.2 Cases where RT-QuIC was negative 
 
3.12.2.1 Case 1 
 
A 73 year old male presented with weight loss and insomnia followed by rapidly 
progressive dementia, ataxia, myoclonus and visual symptoms.  MRI and EEG were 
not supportive of sCJD but the 14-3-3 test was positive.  It was the impression of the 
local team that this was a case of sCJD.  Based on the ongoing progression of the 
patient’s condition and following the WHO diagnostic criteria, this case was initially 
classified as 2.0S.  However, at alter date the anti-voltage gated potassium channel 
antibody was returned as significantly positive confirming the diagnosis of 
autoimmune encephalitis. The patient is still alive and the case was re-classified as 
4.2S.  RT-QuIC was negative in this case. 
 
3.12.2.3 Case 2 
 
An 85 year old male presented with rapid cognitive decline and progressed to 
akinetic mutism and myoclonus.  The case was complicated by subdural haematomas 
and subsequent seizure activity.  The 14-3-3 and MRI were not supportive of sCJD 
but the EEG was positive and overall this was thought to be a case of sCJD.  
However, post mortem examination demonstrated changes consistent with 
Alzhemier’s disease and not sCJD.  The RT-QuIC result was negative in this case.   
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3.13 Diagnostic outcome for cases that were referred 
for CSF only 
 
As detailed in the methodology section, the NCJDRSU receives a large proportion of 
CSF for analysis of 14-3-3 in whom CJD is being considered a possibility although 
not yet regarded as a suspected case for formal referral.  The clinical details provided 
by the local clinicians at initial referral were reviewed along with the 14-3-3 and RT-
QuIC results for all of the non-referred cases within the data period.  All local 
clinicians were written to requesting the final diagnosis.  Within the data period, 221 
samples of CSF were sent to the NCJDRSU requesting analysis for 14-3-3 for 
patients in whom CJD was being considered a possibility.  122 responses were 
received from the local clinicians detailing the overall progress of the patient and 
diagnosis where possible.  These are shown in table 41.  5 cases were categorised as 
‘other’.  Diagnoses included: nephrogenic diabetes insipidus and an extrapyramidal 
syndrome secondary to long term valproate use; resection of an ependymoma 
complicated by hydrocephalus and ventriculitis; post-flu immunisation 
encephalopathy and segmental dystonia. 
Three cases of CJD were identified.  One case was an iatrogenic case of CJD 
confirmed by post mortem examination.  One case was labelled as sporadic CJD on 
the death certificate but this was not confirmed by post mortem and was not formally 
referred.  This case was RT-QuIC negative.  The final case was RT-QuIC positive 
and was confirmed at post mortem.  This patient was not formally referred to the 
NCJDRSU for review. 
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Table 43 Final outcome for non-referred cases in whom CJD considered a possibility 
Diagnosis/Overall Outcome Case Number n=122 (%) 
Dementia 
Vascular 
Frontotemporal 
Corticobasal Degeneration 
Parkinson’s Disease with Dementia 
Lewy Body Dementia 
Alzheimer’s Disease 
Mixed Dementia 
Unclassified  
 
5 (4.1%) 
9 (7.4%) 
2 (1.6%) 
1 (0.8%) 
9 (7.4%) 
13 (10.7%) 
5 (4.1%) 
2 (1.6%) 
Inflammatory/Autoimmune 13 (10.7%) 
Infection 7 (5.7%) 
Metabolic/Alcohol related 7 (5.7%) 
Diagnosis Unclear- Not CJD 20 (16.4%) 
Malignant/Paraneoplastic 4 (3.3%) 
Motor Neuron Disease 3 (2.5%) 
Huntington’s Disease 2 (1.6%) 
Progressive Supranuclear Palsy 1 (0.8%) 
Vascular/Stroke 3 (2.5%) 
Psychiatric/Functional 8 (6.6%) 
Other 5 (4.1%) 
CJD 
PM confirmed Sporadic 
Non PM Confirmed Sporadic 
PM confirmed iatrogenic CJD 
 
1 (0.8%) 
1 (0.8%) 
1 (0.8%) 
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Chapter 4 
 
 
 
Discussion 
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4 Discussion 
 
4.1 Structure of Discussion 
 
Human prion diseases are highly heterogenous and invariably fatal neurological 
disorders.  The commonest form is sporadic CJD which accounts for approximately 
85% of cases
103
. The exact infectious mechanism remains unknown although the 
most widely accepted theory is the protein hypothesis where a normal cellular 
protein, PrP
C
 undergoes post conformational misfolding thus resulting in the disease 
associated form of the protein, PrP
Sc 2, 4
. This abnormal prion protein subsequently 
aggregates to form amyloid fibrils and although the pathological mechanism is not 
yet fully understood,  the recognised pathological hallmarks of the disease which 
includes astrocytosis, gliosis and neuronal cell loss
5
.   The clinical heterogeneity of 
sCJD results from the influence of the host PrP genotype and the conformational 
pattern of the pathological PrP
Sc
 as described
22
. The variation in clinical and 
pathological phenotype has led to difficulties with making an early and accurate 
diagnosis
24, 25
.  Although sCJD is not infectious per se, it is transmissible and concern 
has been raised about subclinical cases who remain asymptomatic although may be 
infectious and therefore pose a risk from a public health perspective
27
.  Preventative 
measures have been useful in dramatically reducing the incidence of iatrogenic 
transmission of variant CJD although these measures do not always apply to sporadic 
CJD which arises spontaneously. In addition, an early diagnosis alleviates family 
distress and will confirm or refute the diagnosis thus allowing a potentially treatable 
condition to be diagnosed earlier.  Confirming sCJD at an early stage provides 
greater opportunity to identify potential therapeutic treatments.     
The development and revision of diagnostic criteria over the years has proven to be 
very useful in diagnosing sCJD.  The EuroCJD criteria is based on a recognisable 
clinical presentation combined with diagnostic tests that include EEG, MRI and CSF 
biomarkers including 14-3-3
165
.  However, diagnostic criteria was mainly developed 
for epidemiological purposes and does not take into account the clinical 
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heterogeneity of the condition which poses as a major diagnostic challenge in 
differentiating prion diseases from other neurological disorders
178
.  CJD is 
increasingly recognised as in the differential diagnosis of rapidly progressive 
neurological syndromes, highlighting the need for reliable tools to make an early and 
accurate diagnosis.   The ageing population, improved awareness of the clinical 
heterogeneity of sCJD and the identification of potentially treatable disorders that 
manifest as rapidly progressive neurological syndromes have all contributed to this 
problem.    
Currently at least 6 major subtypes of sCJD are recognised based on the PRNP codon 
129 genotype and PrP
Sc
 Type. The number and variety of clinical symptoms, rate of 
disease progression and underlying brain pathology vary significantly amongst these 
individual subtypes and therefore challenge the accuracy and of the diagnostic 
criteria
22, 24, 25,178
. However, the definitive means of diagnosis remains 
neuropathological confirmation of brain tissue obtained either by post mortem or 
brain biopsy
165
.  The latter is invasive with many patients considered to be unfit for 
the procedure due to the nature of the condition as well as the iatrogenic risk to 
others from the operation
173
.  The diagnostic accuracy of the criteria has been 
challenged particularly in relation to potentially missing cases that present atypically 
where early symptoms can be non-specific and conventional tests may be normal
174-
184
. 
This identified the need for a more accurate and robust test that is based on the 
disease process itself.  A number of bioassays have been developed with the most 
recent named RT-QuIC
196-204
.  This test exploits the seeding process of the abnormal 
prion protein and has been demonstrated in preliminary studies to diagnose sCJD 
with a high degree of sensitivity and specificity
194, 195
.  This study aimed to assess the 
diagnostic accuracy of RT-QuIC via a prospective study over an 18 month period by 
evaluating the sensitivity and specificity.  In addition, it aimed to look at the utility of 
the test in comparison to more conventional techniques as stipulated by the 
EUROCJD criteria and assess the ability of this novel test to identify cases that may 
have been missed by conventional diagnostic techniques.  These cases will be 
examined in detail. The influence of age of onset, disease duration, codon 129 and 
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timing of lumber puncture will also be discussed and their influence on the outcome 
of RT-QuIC in comparison to current literature.   
During the course of this study, certain operational parameters and limitations of the 
test in our centre have been reported and will be discussed.  Since the onset of this 
study, further studies have been carried out in attempt to improve the accuracy of the 
test. There have also been large multicentre studies that have improved the 
standardisation, validation and overall reproducibility and accuracy of the test. 
Finally, the future of RT-QuIC in the diagnoses of other neurodegenerative disorders 
where the molecular mechanism of disease is thought to be based on misfolding of a 
host protein in to a disease associated form will be considered as part of the role of 
RT-QuIC in future research.   
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4.2 Sensitivity and Specificity of RT-QuIC 
 
This study has demonstrated that RT-QuIC is a robust test with a high degree of 
sensitivity and specificity which is in concurrence with other studies.  Several 
research groups have now conducted large studies in which CSF samples collected 
from sCJD cases and controls were evaluated using RT-QuIC assays
24
. Collectively, 
these studies provide hundreds of sCJD cases and an even larger number of controls.  
Diagnostic sensitivities observed range from 77-97% and specificities 99-100%
195, 
203-208, 212
. 
 
It has been demonstrated that there is no apparent correlation between the RT-QuIC 
response obtained in confirmed sCJD cases and any of the clinical features such as 
age at onset of the disease, disease duration or timing of the lumber puncture.  The 
lack of influence timing of lumber puncture has on the test suggests that CSF 
samples tested early in the disease course are unlikely to yield false positive 
results
203, 212
. 
 
A large number of non-CJD CSF samples have been analysed in these studies and 
only two have returned a positive RT-QuIC result
212
.  One of these cases had a 
working diagnosis of frontotemporal dementia and was lost to follow up.  The 
second case was given a diagnosis of a paraneoplastic syndrome although it remains 
unclear as to whether this was confirmed at autopsy.  Overall, the specificity of RT-
QuIC is approaching 100% and has been demonstrated to be significantly better than 
other surrogate markers such as 14-3-3
212
. 
 
However, RT-QuIC does not have perfect sensitivity and fails to identify 10-20% of 
cases of sCJD.  PrP
Sc
 accumulates in the olfactory epithelium in patients with 
sporadic CJD which suggests that evaluation of these tissues may be useful in 
providing another strategy for antemortem diagnosis of sCJD
24, 208
.  One study has 
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shown that the use of RT-QuIC using nasal brushings has the ability to provide a 
diagnosis with a high degree of sensitivity and specificity
208
.  Samples of the 
olfactory epithelium can be collected by a simple and gentle brushing technique 
although does involve directly visualising the nasal vault with a rigid, sheathed 
fibroscope. Three-four brushings per nostril are obtained to maximise the liklihood 
of contacting the olfactory mucosa as adjacent respiratory mucosa is low in PrP
Sc
.   
To date, nasal brushings from a total of 43 patients and a total of 43 non CJD 
controls were assessed and indicated an overall diagnostic sensitivity of 97.5% and 
specificity of 100%
208
.  This sensitivity was superior to that achieved using CSF 
samples from the same patients.  It was suggested that olfactory mucosa specimens 
provide a significantly stronger RT-QuIC response than CSF samples obtained from 
the same patient with an overall higher sensitivity than CSF.  However further 
validation via this means of testing is still required to establish the overall diagnostic 
performance of the test especially with regard to how early in the course of the 
disease the infectivity can be detected
208
.   
 
In a more recent study, the diagnostic sensitivity of RT-QuIC was assessed using 
CSF and olfactory mucosa from 86 patients classified as probable, possible or 
suspected sCJD.  The CSF was tested using standard and improved RT-QuIC 
conditions whereas the olfactory mucosa was tested using standard conditions only.   
Sensitivity in the CSF samples was 95% and olfactory mucosa 97% and 100% 
specific.  However, if both samples were tested together then this is improved to an 
overall sensitivity and specificity of 100%.  This led to the recommendation that both 
CSF and olfactory mucosa should be tested for RT-QuIC to optimise diagnostic 
accuracy
213
. 
 
Despite these encouraging findings, olfactory epithelial testing is invasive and is not 
part of the routine diagnostic work up for a patient suffering from a rapidly 
progressive dementia.  In addition, the stronger result suggests possible infectivity 
and therefore may have biosafety implications
24, 208
.  Therefore CSF remains a 
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primary diagnostic sample for RT-QuIC sampling.  However, if the CSF RT-QuIC is 
negative or a lumbar puncture has not been feasible and there is still a high degree of 
suspicion of that sCJD is the diagnosis then testing olfactory mucosa may be a 
feasible option if this test undergoes adequate validation and standardisation
24
. 
 
This study has shown that RT-QuIC has a high degree of sensitivity and specificity 
in line with other studies.  Since the onset of this current study, two international 
studies have demonstrated that this is a robust and reproducible test amongst 
laboratories in different countries using a range of recombinant PrP
C
 sources and 
instrumentation produced identical results when analysing the same set of CSF 
samples
205, 214
. The WHO have recognised the usefulness of this test and now 
included it into the diagnostic criteria as of January 2017 which has now replaced the 
diagnostic criteria that this study was based on and is detailed below
113
: 
 
Diagnostic criteria for surveillance of sporadic CJD from 1 January 2017 
1.1 DEFINITE: 
            Progressive neurological syndrome AND 
  Neuropathologically or immunohistochemically or biochemically 
confirmed 
  
1.2 PROBABLE: 
  1.2.1 I + two of II and typical EEG* 
           OR 1.2.2 I + two of II and typical MRI brain scan** 
OR 1.2.3 I + two of II and positive CSF 14-3-3  
OR 1.2.4 Progressive neurological syndrome and positive RT-QuIC in 
CSF or other tissues 
  
1.3 POSSIBLE: 
  I + two of II + duration < 2 years  
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I Rapidly progressive cognitive impairment 
  
II A   Myoclonus 
 B    Visual or cerebellar problems 
 C    Pyramidal or extrapyramidal features 
 D   Akinetic mutism 
 
 
*Generalized periodic complexes 
**High signal in caudate/putamen on MRI brain scan or at least two cortical regions 
(temporal, parietal, occipital) either on DWI or FLAIR 
 
 
 
4.3 Definite and Probable Cases 
 
A total of 115 cases formally referred to the NCJDRSU during the study period 
underwent CSF testing for both RT-QuIC and 14-3-3.  44 of these were classified as 
definite cases according to the EUROCJD diagnostic criteria 2009. 35 cases were 
RT-QuIC positive and 9 were negative.  There was no significant difference between 
age at onset between the positive and negative groups.  However the negative group 
had a longer median disease duration of 13 months (range 2.2-32.4) and longer 
disease duration was significantly more likely to produce a negative RT-QuIC result.  
The majority of both groups presented with a rapidly progressive dementia process 
although the RT-QuIC negative group were more likely to present with an ‘Other’ 
mode of presentation.  In comparison, 45 cases were classified as probable of which 
38 were positive for RT-QuIC and 7 were negative. There was no observed 
difference in terms of age or disease duration between these groups and no 
significant influence of either of these factors on the outcome of the RT-QuIC result.  
However, the positive group were more likely to present with a rapidly progressive 
dementia, 50% and 28.5% respectively.  The RT-QuIC negative group were more 
likely to present with a psychiatric presentation or stroke-like presentation, 28.5% 
and 14.2% respectively. 
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4.3.1 Influence of Codon 129 and PrPSc Type 
 
As previously discussed, patients with sporadic CJD can be characterised according 
to the PRNP codon 129 genotype and the biochemical characteristics of PrP
Sc
 into 6 
molecular subtypes
22
.  The subtypes MM1 and MV1 represent the classic clinical 
phenotype and subtypes MM2 and VV1 are less typical
22
.  
 
In the definite group, the RT-QuIC positive cases were more likely to have a MM 
codon 129 genotype than the negative group, 58% and 33.3% respectively. The 
negative cases were more likely to be VV genotype compared to the RT-QuIC 
positive group, 44.4% compared to 22.5% respectively.  These findings did not reach 
statistical significance.  In the instances where it was possible to fully classify the 
definite cases by codon 129 genotype and PrP
Sc
 type (as described by Parchi et al), 
the majority of the RT-QuiC positive group were of a MM1 subtype.  The RT-QuIC 
negative group were more likely to be of the less common subtypes including VV1, 
MM2A, MV2A and MV mixed. None of the RT-QuIC negative group had a MM1 
subtype.  Due to lack of post mortem in the probable group, PrP
Sc 
cannot be assessed.  
In terms of codon 129 genotype, 17/38 (44.7%) of the positive RT-QuIC group 
underwent genotyping.  9 (52.9%) were MM, 1 (5.9% was MV and 7 (41.2%) was 
VV.  In the RT-QuIC negative group, 2/7 (28.6%) underwent genotyping.  1 (50%) 
was MM and 1 (50%) was VV. 
 
The numbers in this study are too small to draw any strong conclusions from, 
however there have been recent larger studies that have investigated the relationship 
between codon 129 genotype and PrP
Sc 
Type
 
on the outcome of the RT-QuIC 
response and overall result as detailed below. 
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Peden et al (2012)- reported that rapid and early seeding was seen with the most 
commonly occurring phenotypes of sCJD (MM1/MV1, VV2 and MV2).  In addition, 
Atarashi et al also reported (2011) that human recombinant PrP converted equally 
well in the presence of of sCJD MM1 and MM2 brain seeds. Peden et al (2012) did 
however find lower seeding efficiency and less reproducible responses when using 
MM2C and VV1 brain samples
221
.  
 
Cramm et al (2015) conducted a CSF study to determine the effects of codon 129, 
prion disease type and PrP
Sc
 type and other disease related factors on the RT-QuIC 
response. The effect of codon 129 genotype or PrP
Sc 
type in CSF was assessed 
separately by performing a comparative analysis of three sCJD genotypes (MM, MV, 
VV) and two PrP
Sc
 types (1 and 2).  By using this approach, they assessed both 
variables separately and assessed the impact of codon 129 genotype on the patient 
groups of the same PrP
Sc
 type. Similarly, sCJD cases with the same codon 129 
genotype but different PrP
Sc
 type were examined. Results indicated that neither the 
PrP
Sc 
type or the codon 129 genotype alone had a significant impact on the RT-QuIC 
response. However, it was found that codon 129 genotype within Type 1 patients was 
associated with a faster result in MM patients than MV and VV. This effect was not 
observed in Type 2 candidates.  When analysing subgroups of patients the other way, 
patients exhibiting the same genotype but different  PrP
Sc
 type (i.e. MM1 vs MM2, 
MV1 vs MV2), no difference was observed.  In terms of what other factors could 
influence the kinetics of the RT-QuIC response, this study also reported that disease 
duration had an impact on the seeding efficiency of PrP
C
.  For example, those with a 
shorter disease course showed higher seeding efficiency in the RT-QuIC response.  
As demonstrated in this study, the disease duration in the definite RT-QuIC negative 
group was more prolonged and this may be relevant to the seeding efficiency of RT-
QuIC
206
. 
 
Foutz et al (2016) reported a recent study assessing the sensitivity and specificity of 
RT-QuIC with a second generation version of the test on CSF.  They performed a 
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blinded retrospective study and prospective analysis of a cohort of patients suffering 
from diverse rapidly progressive neurodegenerative disorders but suspected of 
having prion disease.  The results were compared with detailed neuropathological 
and genetic assessments. The influence of age at onset, disease duration, phenotype 
and molecular characteristics were assessed.  Neuropathological confirmation was 
performed on 272 cases.  The first retrospective cohort was blinded and tested for 
RT-QuIC and then unblinded and pathology evaluated.  It was found that the 
neuropathologically verified cases that were RT-QuIC positive were associated with 
an older age, shorter disease course and higher frequency of ataxia.  The RT-QuIC 
was more frequently negative in the MM2 and no correlation was observed between 
the RT-QuIC result and codon 129 polymorphism alone, gender, EEG or MRI.  It 
was also found that RT-QuIC was superior to 14-3-3
25
. 
 
The overall specificity was 98.5%.  The reason it was not 100% was due to 1 case 
which repeatedly tested positive to CSF RT-QuIC but neuropathology demonstrated 
lewy body dementia.  However, on further examination of the brain homogenate, low 
levels of PrP
Sc 
were identified.
 
 Taking into account the 50 year incubation time of 
prion diseases and the high sensitivity of RT-QuIC, it is possible that this was a case 
of dual pathology with the patient in the subclinical phase of the condition but died 
of an alternative diagnosis. The prospective study revealed a specificity of 100% and 
sensitivity of 95% with a 100% positive predictive value.  CSF 14-3-3 had a much 
lower specificity of 42.9% and sensitivity of 81% in comparison.  Overall the high 
diagnostic specificity compares well with the results of other studies. The second 
generation RT-QuIC missed only 5-8% of cases compared to 11-23% reported in the 
first generation assay. 
 
Lattanzio et al (2017)-  recently reported a large study including 1062 patients who 
presented with a rapid neurological disorder in which CJD was considered a 
possibility. The number of pathologically confirmed sCJD cases was 186. The 
overall test sensitivity of RT-QuIC was 82.1% and specificity 99.4% with a PPV of 
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99%.  RT-QuIC sensitivity varied according to the codon 129 genotype and was 
higher in MM (84.2%) than in MV (72.2%) or VV (79.5%). The specificity was 
substantially better than 14-3-3. In addition, there was convincing evidence that 
sensitivity was lowered by atypical subtypes of the disease characterised by PrP
Sc
 
Type 2 (VV2, MV2K and MM2C).  This variability in seeding activity between 
subtypes remains unclear.  In addition, it remained unclear as to why some 
neuropathological confirmed cases returned a negative RT-QuIC result.  There was 
no significant correlation between age at onset, disease duration.  These results also 
consolidate the importance of establishing codon 129 genotype in every patient who 
is being worked up for CJD given the implications it has on clinical phenotype and 
also prognosis.  In addition, it allows for accurate interpretation of investigations that 
also now include RT-QuIC
212
. 
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4.4 Possible and Uncertain cases 
 
Five cases were classified as possible under the EUROCJD 2009 diagnostic criteria 
that had both CSF 14-3-3 and RT-QuIC assessed.  Of these 3 were positive for RT-
QuIC and 2 were negative.  Of the RT-QuIC positive group, 1 case presented with 
rapidly progressive dementia, 1 with cerebellar onset and 1 with an ‘Other’ 
presentation (sensory symptoms).  Of the negative group, 1 presented with rapidly 
progressive dementia and 1 with ‘Other’.  There was no difference in mean age at 
onset and median disease duration could only be calculated in the positive group 
(4.26 months).  In the negative group, one case was still alive at the time of writing 
and the other had a disease duration of 11.5 months.  All cases underwent codon 129 
genotyping.  In the positive group, 2 cases were MM and 1 case MV.  In the negative 
group, 1 was MM and the other VV.  With regard to investigations, 2 cases in the 
positive group had a MRI which was reviewed at the NCJDRSU and showed cortical 
ribboning in isolation which does not support a positive scan by the 2009 diagnostic 
criteria.  The remaining case that was RT-QuIC positive was not sent for review but 
was considered negative by local services.  With regard to the RT-QuIC negative 
possible cases, 1 case underwent a MRI which showed isolated cortical ribboning.  In 
all possible cases, where EEG and 14-3-3 were performed, these were all negative. 
 
To highlight the usefulness of RT-QuIC in these scenarios, it is of benefit to consider 
the RT-QuIC positive group on a case by case basis.  The first case was a 67 year old 
patient who presented with a rapidly progressive dementia and later developed other 
relevant signs such as pyramidal signs, myoclonus and cerebellar signs.  The EEG, 
14-3-3 were both negative and MRI brain showed cortical ribboning in isolation.  
The second case was a 68 year old patient with a disease duration of 6.46 months.  
They presented with sensory symptoms affecting an upper limb and then later 
developed more typical symptoms including rapidly progressive dementia, 
myoclonus, visual symptoms and cerebellar signs.  MRI revealed isolated cortical 
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ribboning and 14-3-3 and EEG were both negative.  The final case was a 68 year old 
patient with a disease duration of 4.82 months.  This was a cerebellar onset followed 
by myoclonus and dementia. The MRI was suspicious but not diagnostic of basal 
ganglia change and both 14-3-3 and the EEG were negative. 
 
By applying the new diagnostic criteria to these possible cases, all of the RT-QuIC 
positive cases would be classified as probable and one of the negative cases would be 
classed as probable based on the MRI. 
 
With regard to the cases that were classified as uncertain or 4.1S, 6 underwent CSF 
analysis for 14-3-3 and RT-QuIC.  Two cases were positive for RT-QuIC and 4 
negative.  The mean age of the negative group was younger (58.5 years) than the 
positive group (70 years).  The duration of illness was also longer in the RT-QuIC 
negative group with a median disease duration of 29.5 months.  
 
The two RT QuIC positive patients will be discussed separately and in more detail.  
The first case presented with a rapidly progressive dementia and later developed 
visual symptoms.  MRI brain showed cortical ribboning only and the 14-3-3 was 
positive but EEG negative.  The disease duration was 7.38 months although the 
patient died without fulfilling the clinical signs required by the WHO diagnostic 
criteria.  However, based on the new WHO diagnostic criteria, this would now be 
considered a probable case of sporadic CJD and this was considered the most likely 
diagnosis at the time.  The second case was a 73 year old patient who also presented 
with a rapidly progressive dementia syndrome and went to develop pyramidal signs.  
CSF 14-3-3 analysis was positive as was the MRI brain but EEG negative.  The 
disease duration was 10.75 months and similar to the last case, the reason this patient 
did not fulfil the then current diagnostic criteria was due to the lack of development 
of other relevant clinical signs and symptoms.  However, if we follow the new 
diagnostic criteria, this would also now be considered a probable case.   
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Obviously one of the limitations of this study is that the final classification was based 
on the clinical symptoms and signs at review.  It was difficult to follow up on the 
evolvement of other signs, especially in cases that followed a longer duration of 
illness as no follow up visits.  However, the key point is that in the above cases, the 
RT-QuIC test was positive before the patient developed the required signs as set out 
by the old diagnostic criteria and therefore made an earlier and more accurate 
diagnosis.  These cases highlight the usefulness of RT-QuIC in routine clinical 
practice where conventional measures of diagnosis failed to support a diagnosis at an 
early stage despite the high level of clinical suspicion. 
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4.5 Timing of Investigation Results 
 
Diagnostic delay in sCJD is well recognised. The more classic presentations are 
typically rapid and patients present at different stages of their illnesses.  As we have 
previously discussed, the initial stages of the illness can be non-specific and initial 
efforts and preliminary investigations are concentrated on identifying a potentially 
reversible condition. In our centre, the median time between symptom onset and 
diagnosis is 3-4 months (Professor Richard Knight, personal communication).  
During the early stages of the illness, it may be that an alternative cause other than 
sCJD how is being considered a possibility at that time.  In some circumstances, it 
can be reasonable to adopt a ‘watch and wait approach’ with the evolvement of more 
typical features of sCJD becoming more apparent later on in the illness.  In addition, 
sCJD is in invariably fatal condition and providing a diagnosis that is as secure as 
possible is important.  
 
The timing of investigations varies between patients depending on how they have 
presented.  Although less specific for sCJD, in vivo tests such as MRI, EEG and CSF 
are still important in the work up of a patient suffering from a progressive 
neurological illness as they may offer an alternative diagnosis that could potentially 
be treatable.  Newer bioassays such as RT-QuIC has been shown to offer a higher 
degree of diagnostic accuracy as demonstrated by the high sensitivity and specificity 
indicated by this study and several other larger studies as discussed.  However, 
providing an earlier diagnosis where possible also relies on providing test results in a 
timely manner once they have been performed. 
 
With regard to MRI and EEG, there were some cases in this study where these 
investigations were considered negative in local centres but upon review by the 
NCJDRSU, were considered positive. The timing of the lumbar puncture varied 
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between patients during the course of the illness.  Delays in providing a result from 
the date of lumbar puncture were largely related to logistical delays in transferring 
the sample from other centres around the United Kingdom.  In addition, lumbar 
punctures were often performed initially to exclude or look for alternative 
neurological diagnoses with sCJD not yet considered a possibility.  During this 
study, it was not uncommon for samples to be sent at a later date for processing. 
 
However, it was recognised that our ‘turnaround time’ for providing RT-QuIC 
results is slower than some centres in comparison to more recent studies.  Since the 
onset of this study, further work has been published demonstrating updated versions 
(so-called second generation) of RT-QuIC that has resulted in an improved 
processing time and sensitivity.  A recent study demonstrated that increasing the 
temperature of the reaction mixture, longer shaking intervals with higher shaking 
speeds results in a faster RT-QuIC reaction without compromising sensitivity.  The 
most widely used version of RT-QuIC employed by many centres can process 
samples between 24-90 hours and this is the same in our centre.  However, under 
these newer conditions, this time has been shown to be reduced to between 4-14 
hours which is very promising for the future and would have the potential for this 
novel test to be more cost-effective and improve the efficiency of CJD surveillance if 
diagnoses can be made earlier
215
.  However, more data is required in this area before 
firm conclusions can be made. 
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4.6 Development and Implementation of the test 
 
4.6.1 Further development of RT-QuIC 
 
In addition to evaluating the measures that improve the speed of the RT-QuIC 
reaction, there are other variables that can influence the test outcome.  During this 
study, it became apparent that the CSF volume used in the reaction mixture 
influenced the test result.  By using a CSF volume of 30µl, we found that there was 
greater differentiation between a positive and negative result.  Therefore, all testing 
initially used 30µl of CSF and if this was negative, the test was repeated using 15µl. 
 
In addition, we found that CSF contaminated with blood had the ability to produce a 
false negative result and this has also been reported in other studies.  One recent 
study reported that contamination with blood cells may influence the RT-QuIC 
response.  In routine diagnostic practice, between 5 and 10% of the CSF samples are 
contaminated with blood during the lumbar puncture.  The findings of this study 
indicated that blood contamination higher than 1250 cells/µl may inhibit the RT-
QuIC reaction.  Levels below this were considered negligible. Fresh blood-
contaminated samples (3 days) can be rescued by removing the red cells
205
.   
 
4.6.2 Implementation and Reproducibility 
 
In order for a test to be implemented into routine clinical practice, it has to be 
demonstrated to be reproducible and undergo a comprehensive validation and 
standardisation.  Although many centres have developed their own protocols 
regarding RT-QuIC based on original studies, a recent study reported the first formal 
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multi-centre assessment of RT-QuIC, the outcome of which influenced the revision 
of the EuroCJD criteria and subsequent implementation of the test as previously 
discussed. 
 
110 prion disease patients were analysed and 400 control patients using the RT-QuIC 
method under various conditions.  In addition, ‘blinded’ ring trials between different 
centres were performed to estimate reproducibility. The study reported a sensitivity 
of 85% and specificity of 99%.  The multi-centre inter-laboratory reproducibility of 
RT-QuIC revealed a Fleiss’ kappa value of 0.83 indicating almost perfect 
concordance between centres. Two ring trials were performed between different 
laboratories.  The first was between two centres using a high number of samples (54 
sCJD and 32 controls) and indicated a substantial agreement with a Fleiss Kappa 
score of 0.75.  Despite the high concordance, it was aimed to also identify the 
optimal conditions and standard operating procedures for the RT-QuIC method.  The 
assay precision depends on various factors including inter-laboratory variations in 
staff, protocols and substrates, sensitivity of the assay to CSF sample storage and 
shipping temperatures and different fluorescence readers.  By minimising any 
variation, the second ring trial achieved almost perfect agreement with a Fleiss kappa 
score of 0.83 thus demonstrating a high reproducibility of the assay with improved 
standardisation.  A general problem with biomarker assays is that the sensitivity of 
the biomarker proteins to storage and shipment conditions.  For example, during 
shipment, samples are subjected to a variety of temperatures and following arrival, 
also frequently undergo cycles of thawing and freezing.  This study demonstrated 
that the PrP
Sc
 seed in the CSF of sCJD patients resisted the variations subjected to it 
with no impact on sensitivity or specificity. In addition, the study investigated 
various operational parameters including short term CSF storage at different 
temperatures long term storage, repeated freezing and thawing cycles and 
contamination of CSF by blood on the RT-QuIC seeding response. Overall, the study 
consolidated the reproducibility and high stability of RT-QuIC across various CSF 
storage conditions with a remarkable sensitivity and specificity supporting the 
current evidence that RT-QuIC is a robust and novel diagnostic method for sCJD
205
. 
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4.7 Non Cases 
 
Those cases classified as non-CJD cases either based on clinical grounds (4.2S) or 
neuropathological grounds (4.3S) were negative for all relevant tests including RT-
QuIC emphasising the high specificity of this new test. 
 
4.8 Conclusions  
 
This study has supported initial and new evidence that RT-QuIC is a highly sensitive 
and specific antemortem test for the diagnosis of sCJD.  It has been demonstrated via 
a series of case vignettes that it has advantages over more conventional tests in cases 
where the diagnosis has been particularly challenging. In addition, following the 
revision of the EuroCJD criteria during the course of the study, cases that were 
previously classified as possible or uncertain, have now been re-classified as 
probable based on the RT-QuIC result or MRI imaging. 
  
It has been demonstrated through this study and larger studies that RT-QuIC is 
positive in all molecular subtypes of sCJD. However, genotype may have an 
influence on the test result and it remains contentious as to whether RT-QuIC can 
provide a ‘definite’ answer on sporadic CJD.  Moreover, unlike brain specimens, RT-
QuIC whether performed using CSF or olfactory epithelium does not provide any 
information on PrP
Sc
 glycotype, distribution of lesions, pattern of deposition or 
associated pathologies such as additional dementia types. Therefore, 
neuropathological examination remains the definitive means of diagnosis at this 
present time.  As with other CSF protein biomarkers, the in vitro conversion reaction 
exploited by RT-QuIC is significantly affected by the neurobiological heterogeneity 
of prions.  Studies on nasal brushings have been encouraging, although further work 
is required in this area.   
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4.9 Future Research 
 
The data period for this study was 18 months.  However, data collection by the team 
at NCJDRSU regarding the diagnostic utility of RT-QuIC has been ongoing until 
2017 which provides 5 years of data analysing the usefulness of RT-QuIC in routine 
clinical practice in our centre and these findings will be published in the future. 
In addition, aggregation of misfolded proteins is also implicated in other 
neurodegenerative disorders such as Alzheimer’s disease and Parkinson’s disease.  In 
vitro amplification studies have shown that, similar to PrP
Sc
, these misfolded protein 
aggregates can seed the normal protein isoforms through prion-like processes of 
replication.  In addition, the olfactory bulb has been shown to be an early site of 
involvement in both Alzheimer’s disease and synucleinopathies.  Therefore, it seems 
possible that the development of highly sensitive seeding assays of olfactory mucosa 
brushings may assist the diagnosis of other proteinopathies and is an area of ongoing 
interest and research
216, 217
. 
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SECTION 1 
GENERAL INFORMATION 
 
1. 
 
 
IDENTIFICATION  INFORMATION   
 
ID Number:                  
 
 
 
1.1 
 
What is subject’s name? First name: 
  
     Surname:   
     Other name(s):   
    
 (if subject is female and is/has been married) 
record subject’s maiden name or previous married names if different from current surname  
 
_________________________________________________________________________ 
 
1.2 Sex of subject? 
1=male 
2=female 
 
 
1.3 
 
When was subject born? 
 
____/____/________ (dd/mm/yyyy) 
 
1.4 
 
What do you consider to be subject’s ethnic origin? 
1=Caucasian   
2=Mixed/multiple  
3=Asian 
4=Black/African/Caribbean 
5=Other 
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1.5 
What is subject’s marital status? 
1=single  4=divorced 
2=married 5=separated 
3=widowed 6=cohabitating 
1.6 What is subject’s present home address?  
(if subject is deceased) What was subject’s last home address before s(he) became ill?   
  House and street:   
  Town:   
  County:   
  Postcode: 
  
 
1.7 
 
Name of subject’s consultant: 
 
 
    
1.8 Hospital address Name of hospital:   
     Street:   
     Town:   
    Postcode:   
    Tel. number:   
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1.9 Subject’s hospital record number:   
    
1.10 Subject’s NHS number:   
    
1.11 Name of subject’s GP      Name/Practice:   
     Street:   
     Town:   
    Postcode:   
    Tel. number:   
    
    
1.12 Date of interview/examination: ____/____/________ (dd/mm/yyyy)  
1.13 Interview/examination performed by:   
    
1.14 What is your (respondent’s) name? 
                First name 
  
    Surname   
     Other names(s)    
    
1.15 What is your (respondent’s) relationship to 
subject? 
If other, specify:_____________________ 
 1=partner  5=cousin 
 2=son/daughter  6=father/mother 
 3=nephew/niece  7=subject themselves 
 4=sibling  8=other 
 
   
 
1.16 How long have you know subject? 
(record year since which subject known) 
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1.17 What is your (respondent’s) address?   
  House and street   
 Town   
 County   
 Postcode   
 Telephone  
 
    
1.18 Place of interview: 
 1=hospital 
 2=home 
 3=other 
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SECTION 2 
CLINICAL SURVEILLANCE AND EPIDEMIOLOGICAL REVIEW 
BACKGROUND HISTORY 
 
2.1 Surgical History 
Surgical history questions refer to subject’s history BOTH BEFORE AND AFTER ONSET OF ILLNESS 
 
 Has subject ever had any operations, including eye 
operations or stitching of wounds?  
     1= yes           
2= not to respondent’s knowledge 
 (If yes), record the year, hospital and type of operation: 
1. Year: 
     Accuracy code 
    (filled in at data entry stage) 
 Name of Hospital: 
  
 
Operation: 
  
Group Category 
  
  
2. Year: 
     Accuracy code 
    (filled in at data entry stage) 
 Name of Hospital: 
  
 
Operation: 
  
Group Category 
  
  
3. Year: 
     Accuracy code 
    (filled in at data entry stage) 
 Name of Hospital: 
  
 
Operation: 
  
Group Category 
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4. Year: 
     Accuracy code 
    (filled in at data entry stage) 
 Name of Hospital: 
  
 
Operation: 
  
Group Category 
  
  
5. Year: 
     Accuracy code 
    (filled in at data entry stage) 
 Name of Hospital: 
  
 
Operation: 
  
Group Category 
  
  
6. Year: 
     Accuracy code 
    (filled in at data entry stage) 
 Name of Hospital: 
  
 
Operation: 
  
Group Category 
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7. Year: 
     Accuracy code 
    (filled in at data entry stage) 
 Name of Hospital: 
  
 
Operation: 
  
Group Category 
  
  
8. Year: 
     Accuracy code 
    (filled in at data entry stage) 
 Name of Hospital: 
  
 
Operation: 
  
Group Category 
  
  
9. Year: 
     Accuracy code 
    (filled in at data entry stage) 
 Name of Hospital: 
  
 
Operation: 
  
Group Category 
  
  
10. Year: 
     Accuracy code 
    (filled in at data entry stage) 
 Name of Hospital: 
  
 
Operation: 
  
Group Category 
  
  
11. Year: 
     Accuracy code 
    (filled in at data entry stage) 
 Name of Hospital: 
  
 Operation: 
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Group Category 
  
  
12. Year: 
     Accuracy code 
    (filled in at data entry stage) 
 Name of Hospital: 
  
 
Operation: 
  
Group Category 
  
  
 
 
 
Record the total number of operations   88=not applicable 
 
 
Total no.of  
                      fracture  
operations  
(88=N/A 99=N/K) 
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2.2 Organ or Tissue Transplant 
Has subject ever received an organ or tissue transplant, 
including corneal or bone marrow transplant? 
(If yes), record year hospital and organ/tissue(s) received: 
   
  
  
 1=yes 
 2=not to respondent’s knowledge 
   
 Hospital  Organ:  
 Hospital  Organ:  
     
 
 
1=yes 
2=not to respondent’s knowledge 
If yes, record year 
If no, record 8888  
 Cornea        
 Bone Marrow        
 Kidney        
 Liver        
 Other        
         
 
2.3 Previous Medical History 
All further questions in this section refer to subject’s history PRIOR TO THE ONSET of the current illness 
 
 Does the subject have a record of previous hospital admissions 
EXCLUDING surgery AND unrelated to the present illness? 
            
1= yes 
2= not to 
respondent’s knowledge 
 (If yes,) on how many occasions has the subject been admitted to 
hospital (excluding surgery)? 
     
       88=not applicable 
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(If yes), record the hospital name, the date(s) of admission and the reason(s) for admission: 
 Hospital:   
 Date of Admission:   
 Reason:   
    
 Hospital:   
 Date of Admission:   
 Reason:   
    
 Hospital:   
 Date of Admission:   
 Reason:   
 
  
  
2.3   Previous Medical History (cont’d)  
    
 Hospital:   
 Date of Admission:   
 Reason:   
    
    
 Hospital:   
 Date of Admission:   
 Reason:   
    
The Diagnostic Utility of RT-QuIC for the Diagnosis of Sporadic Creutzfeldt-Jakob Disease   
 
 Hospital: 
  
 Date of Admission: 
  
 Reason: 
  
 
 
Total no.of fracture admissions  
           (non-surgical) 88=N/A 99=N/K) 
 
 
2.4 
Blood donation  
 
Has subject ever been a blood donor?      1=yes 
         2=not to respondent’s knowledge 
 
 
If yes, date(s) and place(s): 
 
  
 
  
 
  
 
  
 
  
2.5 
Blood/blood product transfusion  
 
Has subject ever received a transfusion of blood or blood products?     
For suspect cases do not include any transfusions related to current illness 
           
If yes, give year, hospital and reason:     1=yes 
         2=not to respondent’s knowledge 
 
 Year: 
 
 Hospital: 
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 Reason and product (if known) 
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2.5 
Blood/blood product transfusion (cont’d)  
 Year:  
 Hospital:  
 Reason and product (if known):  
   
 Year:  
 Hospital:  
 Reason and product (if known):  
   
2.6 Has subject ever been diagnosed with an inherited bleeding disorder or primary 
immunodeficiency disease (eg haemophilia, Von Willebrand’s) 
        1=yes 
        2=not to respondent’s knowledge 
If yes, give year, hospital and type of illness:       
   
 
 Year:  
 Treating hospital:  
 Type of illness:  
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2.7 Course of Injections 
Has subject ever received a treatment involving a course of injections, for example, human growth 
hormone, human gonadotrophin, insulin, fertility treatment? 
For suspect cases and controls do not include treatments related to current illness 
 
(If yes), record year, name of therapy, frequency and reason):  1=yes 
         2=not to respondent’s knowledge 
 
Year:  
Therapy: 
Frequency: 
Reason: 
 
Year:  
Therapy: 
Frequency: 
Reason: 
 
Year:  
Therapy: 
Frequency: 
Reason: 
 
Year:  
Therapy: 
Frequency: 
Reason: 
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2.8 Has subject ever been notified that they are at increased risk of CJD?   
                    1=yes 
                           2=not to respondent’s knowledge 
 
 
Risk category: 
  
 1=inherited prion disease (ie have been tested or a blood relative tested and have a mutation or 
     two or more blood relatives with prion disease; 
 
 2=recipients of blood components from vCJD donors;   
 3=donors of blood components to people who develop vCJD;   
 4=other recipients who received blood from donors to vCJD cases;   
 5=bleeding disorders who received UK sourced clotting factors; 
 6=plasma product recipients (non-bleeding disorder patients);   
 7=highly transfused; 
 
 8=human derived hormone recipients, ie growth hormone or gonadotrophin; 
 9=dura mater graft 
 10=surgical contacts of CJD cases; 
  
 88=not applicable 
 
 
Please give details _____________________________________________________________ 
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2.9 
 
Has subject ever been diagnosed with diabetes or bowel disease?        1=yes 
(If yes, please give details)              2=not to respondent’s knowledge 
 
 
  
 
 
 1=inflammatory bowel disease;  
 2=insulin-dependant diabetes;   
 3=other;   
 4=other bowel disease;   
 8=not applicable 
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2.10 Family history 
 
Pedigree (indicating years of birth and death) 
 
 
Subject’s grandparents 
(including names and dates of birth) 
 
 
 
 
 
 
 
Subject’s parents and parents’ siblings 
(including names and dates of birth) 
The Diagnostic Utility of RT-QuIC for the Diagnosis of Sporadic Creutzfeldt-Jakob Disease   
 
 
 
 
 
Subject and siblings 
(including names and dates of birth) 
 
 
 
 
 
 
 
 
Subject’s children 
(including names and dates of birth) 
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2.11 
Family History  
 
Have any of the blood relatives of the subject included in the pedigree above died with dementia (or 
remain alive with dementia)?         
         1=yes 
         2=not to respondent’s knowledge 
         3=respondent unsure 
 
Have any of these individuals been diagnosed as having Creutzfeldt-Jakob disease? 
 
         1=yes 
         2=not to respondent’s knowledge 
         3=respondent unsure 
 
(If yes), record the person’s name and the approximate date of illness: 
 
Name:  ___________________________________________________________________________ 
 
Date of illness:  __________________________ 
 
 
Confirmation of family history of CJD from surveillance database 
         1=definite case      4=unable to confirm 
         2=probable case    5=not a case 
         3=possible case     8=not applicable 
 
2.12 Social Contact 
 
 
Has subject had social contact, through family, friends or work, with someone else who developed CJD? 
  
         1=yes 
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         2=not to respondent’s knowledge 
         3=respondent unsure 
(If yes), record the person’s name and the approximate date of illness: 
 
Name:  ___________________________________________________________________________ 
 
Date of illness:  __________________________ 
 
Confirmation of social contact with case of CJD from surveillance database 
 
         1=definite case      4=unable to confirm 
         2=probable case    5=not a case 
         3=possible case     8=not applicable 
 
2.13 Dietary History                  
Has subject ever been a vegetarian for a period of one year or more?   
           
           1=yes; 
           2=not to respondent’s knowledge 
(If yes), during what period(s) was subject vegetarian, and did s(he) eat any meat or fish at all during this 
time? 
_____________________________________________________________________________ 
_____________________________________________________________________________ 
_____________________________________________________________________________ 
 
2.14 Education 
 
 
How many years of  full time education did subject complete? 
(including school, college and university) 
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2.15    RESIDENTIAL HISTORY (begin with the most recent and work backwards) 
 
  From 
(dd/mm/yyyy) 
 To  
(dd/mm/yyyy) 
  Street  Town   County  Postcode   OS grid reference 
  1 
     /      /      /      /            E       
N       
  2 
     /      / 
 
     /      /            E       
N       
  3 
     /      /      /      /            E       
N       
  4 
     /      /      /      /            E       
N       
  5 
     /      /      /      /            E       
N       
  6 
     /      /      /      /            E       
N       
  7 
     /      /      /      /            E       
N       
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  8 
     /      /      /      /            E       
N       
  9 
     /      /      /      /            E       
N       
  10 
     /      /      /      /            E       
N       
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2.15    RESIDENTIAL HISTORY (continued) 
 
  From 
(dd/mm/yyyy) 
 To  
(dd/mm/yyyy) 
  Street  Town   County  Postcode   OS grid reference 
  11 
     /      /      /      /            E       
N       
  12 
     /      / 
 
     /      /            E       
N       
  13 
     /      /      /      /            E       
N       
  14 
     /      /      /      /            E       
N       
  15 
     /      /      /      /            E       
N       
  16 
     /      /      /      /            E       
N       
  17 
     /      /      /      /            E       
N       
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  18 
     /      /      /      /            E       
N       
  19 
     /      /      /      /            E       
N       
  20 
     /      /      /      /            E       
N       
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2.16 Exposure to animals 
Since the beginning of 1980, has subject worked, lived or 
stayed for more than one week on a farm? 
 
  
  
 1=lived or worked 
 2=stayed 
 3=not to respondent’s knowledge 
 
(If lived, worked or stayed), which type of farm was it? 
Duration of stay? ____________________________ 
If livestock, please specify type ________________________ 
_________________________________________________ 
 
             1=arable 
           2=livestock  
 3=mixed arable and livestock 
       4=other 
 8=not applicable 
 
Has subject ever hunted deer? 
If so, give details of where and when 
 
__________________________________________________ 
 
__________________________________________________ 
 
__________________________________________________ 
 
  
 1=yes 
 2=not to respondent’s knowledge 
 
 
2.17 Occupational history of subject 
(NB if any categories below are coded 1, please complete further details on following page) 
                 1=ever 
                 2=never 
 
 
medical (medical/paramedical/nursing/dentistry) 
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laboratory (diagnostic/pharmaceutical/animal/other research) 
  
 
 
 
 
 
animal farming/veterinary medicine 
 
 
 
 
 
 
meat industry 
(butchers/abbattoir staff/slaughterhouse workers/renderers/workers handling MRM etc) 
 
 
 
 
 
 
hauliers/incinerator operators/landfill site workers/cleaning & waste disposal workers 
 
 
 
 
 
 
maintenance engineers (eg in abbattoirs, rendering plans, incinerators etc) 
 
 
 
 
 
 other occupation involving animal products (eg leather worker)   
 
catering industry (professional) 
     
 
 
 
 
 
workers in zoos and circuses 
     
 
 
 
 
The Diagnostic Utility of RT-QuIC for the Diagnosis of Sporadic Creutzfeldt-Jakob Disease   
 
 
 
 
The Diagnostic Utility of RT-QuIC for the Diagnosis of Sporadic Creutzfeldt-Jakob Disease   
 
2.17 OCCUPATIONAL HISTORY OF SUBJECT (cont’d) 
 
 From 
(dd/mm/yyyy) 
To  
(dd/mm/yyyy) 
Name of employer Town Description of work 
1      
2      
3      
4      
5      
6      
7      
8      
9      
10      
11      
12      
13      
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14      
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SECTION 3 
EXAMINATION REVIEW 
 
 Examination from notes 
State of subject at admission/first examination by a neurologist 
 
3.1 General Appearance: 
 
 
 
3.2 Mental state/speech function: 
 
 
 
3.3 Cranial nerves: 
 
 
 
3.4 Motor system: 
 
 Involuntary movements: 
 
3.5 Sensory system: 
 
 
3.6 Reflexes: 
 primitive: 
 tendon: 
 plantar: 
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3.7 Cerebellar function/co-ordination 
 
 
 
 NCJDSU Clinician – Examination of the subject 
3.8 General Appearance: 
 bed bound 
 NG/PEG 
 catheterised 
 akinetic mute 
 posture 
 myoclonus 
 startle 
 other involuntary movements 
 
3.9 Mental state/speech functions: 
 best motor response 
 best verbal response 
 eye opening 
 
3.10 Cranial nerves: 
 fields/response to menace 
 pupils 
 EOMs/Doll’s eyes 
  
3.11 Motor system: 
 tone 
 power 
 wasting 
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3.12 Sensory system 
 
 
 
 
 
 
3.13 Reflexes 
 primitive: 
  grasp 
  palmomental 
  pout 
  rooting 
 tendon (incl. jaw jerk): 
 plantar: 
 
3.14 Cerebellar function/co-ordination: 
 
 
 
3.15 General examination: 
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3.16 Detailed history of present illness: 
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3.16 Detailed history of present illness: 
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3.16 Detailed history of present illness: 
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 CLINICAL HISTORY 
 
 
3.17 
 
Note the source of information eg hospital notes, 
relatives, other.  
 
 
hospital notes 
 
relatives 
 
other 
 
 
 
 
 
 
  
  
 
1=yes 
2=no 
9=not known 
 
 
       
  If other, specify: _______________________ 
 
 
3.18 
 
What were the first symptoms of illness noted by the 
subject or their family? 
              
            
 
 
   
 
 
3.19 
 
When did these symptoms first occur?                 
                                        
     
                                       (dd/mm/yyyy) 
 
 
 
3.20 
 
When did the subject seek medical attention for the 
illness?                                                     (dd/mm/yyyy) 
 
 
 
3.21 When was the subject first referred to a neurologist?                          (dd/mm/yyyy) 
 
 
 
3.22 When was the subject seen by a neurologist?             (dd/mm/yyyy) 
 
 
 
3.23 
 
 
When was the subject first admitted for the current 
illness?                                                     (dd/mm/yyyy) 
 
 
 
3.24 
 
 
Since the start of the illness, has the subject been 
seen by a psychiatrist? 
   
 
  1=yes     
  2=no          
 
 
3.25 
 
If yes, record date of the first consultation:                          (dd/mm/yyyy) 
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3.26 SPECIFIC ILLNESS DETAILS Since the start of the illness, until the current time, has the subject exhibited 
the following neurological symptoms/signs: 
Symptoms: 1=Yes 
2=No 
8=NK 
9=Missing 
Date appeared 
(dd/mm/yyyy) 
Signs: 1=Yes 
2=No 
8=NK 
9=Missing 
Date appeared 
(dd/mm/yyyy) 
Forgetfulness/ memory 
impairment 
  Cognitive impairment   
Other higher function 
impairment 
  
Agnosia 
  
Apraxia 
  
Visuospatial impairment 
  
Language disturbance 
  Dysphasia 
  
Dyslexia 
  
Dysgraphia 
  
Psychiatric symptoms   Grasp reflex 
  
Depression    
  
Anxiety    
  
Behavioural disturbance    
  
Apathy/withdrawal    
  
Delusions    
  
Hallucinations 
Visual   
   
Auditory   
   
Other psychiatric symptoms   
   
Disturbance of gait 
  Cerebellar gait ataxia 
  
Spastic   
Lower motor neurone   
Other, specify 
......................................... 
  
Bedbound   Akinetic mutism   
Speech disturbance   Dysarthria   
Visual 
symptoms 
Diplopia   Ocular motor palsy   
Visual  
  Hemianopia   
impairment 
  Cortical blindness   
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Weakness or clumsiness of 
limbs 
 
 
 
  Pyramidal weakness   
Extrapyramidal signs   
Cerebellar signs/nystagmus   
Lower motor neurone   
Symptoms: 1=Yes 
2=No 
8=NK 
9=Missing 
Date appeared 
(dd/mm/yyyy) 
Signs: 1=Yes 
2=No 
8=NK 
9=Missing 
Date appeared 
(dd/mm/yyyy) 
Increased limb tone 
  Rigidity   
Spasticity   
Gegenhalten   
Hyperreflexia   
Extensor plantar 
responses 
  
Muscle wasting   
Fasciculation   
Hypo- or Areflexia   
Involuntary movements 
  Myoclonus   
Chorea   
Dystonia   
Other, specify 
......................................... 
  
Sensory 
symptoms 
Numbness/tingling/ 
paraesthesia 
  
 
1=yes 
2=no 
3=central origin 
4=peripheral origin 
9=uncertain 
Date appeared 
dd/mm/yyyy 
Pain /burning / 
discomfort 
  Sensory signs   
Seizures    
 
3.27    TREATMENT 
 
Specify drug therapy for TSE 
 
 
 0=No treatment 
 1=Quinacrine 
 2=Oral PPS 
 3=Intra-ventricular PPS 
 4=Tetracycline (doxycycline) 
 5=Other, specify: __________________________________________ 
 
 
Complications of surgery 
 
 
 
 1=yes 
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Complications of intra-ventricular catheter 
 
Complications of pump 
 2=no 
 9=missing 
 
 
 
 
Significant drug side effects 
  
 1=yes, withdrawal of drugs      
 2=yes, decrease of therapeutic dose     
 3=yes, but no change of the therapeutic dose 
 4=no 
 9=missing 
 
 
Significant evidence of benefit 
 
 
 
 1=clinical improvement 5=other improvement 
 2=EEG improvement 6=no 
 3=MRI improvement 8=Other, specify _______________________ 
 4=14-3-3 improvement 9=missing 
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SECTION 4 
REVIEW OF INVESTIGATIONS 
 
 INVESTIGATIONS 
 
4.1 EEG 
 
Has the subject undergone an EEG? 
       
(If yes), on how many occasions? 
 
 
  
 1=yes; 2=no; 9=not known 
   
 
 
 
 
(If yes), record date of most recent EEG 
   
 
  ____/____/_______(dd/mm/yyyy) 
 
 
Are EEG records/copies available in the Unit
  
Have the EEGs been examined by a Unit staff 
member?    
 1=yes 
 2=yes,some 
 3=no 
 8=not applicable 
   
 
Has the patient recorded an EEG characteristic 
of CJD (generalised triphasic periodic 
complexes with frequency about 1/s) 
 1=yes, confirmed by Unit staff 
 2=yes, reported by local staff, EEG not
     available for confirmation by Unit staff 
 3=no 
 8=no EEG performed 
 
(If yes), record the date on which the first 
characteristic EEG was recorded 
 
  ____/____/________ (dd/mm/yyyy) 
  
 
4.2 CT Scan 
 
 Has the subject ever had a CT scan? 
       
 
 
 1=yes; 2=no; 9=not known 
 
 
 
Has the patient ever had an abnormal CT scan?  1=yes, confirmed by Unit staff 
 2=yes, reported by local staff, scan not
     available for confirmation by Unit staff 
 3=no 
 8=no scan performed 
 
(If yes), record the date on which the first 
abnormal scan was performed? 
 
 
(If yes), specify what abnormalities have been 
observed 
 
 
  ____/____/________ (dd/mm/yyyy) 
 
 
  
 ________________________________________ 
 
  ________________________________________ 
 
  ________________________________________ 
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4.3 MRI Scan  
 Has the subject ever had an MRI scan? 
       
(If yes), on how many occasions? 
 
 1=yes; 2=no; 9=not known 
 
   
 
 
 
(If yes), record date of most recent scan 
   
  ____/____/_______(dd/mm/yyyy) 
 
Are MRI scans available in the Unit 
 
Have the MRI scans been examined by a Unit 
staff member?    
 1=yes 
 2=yes,some 
 3=no 
 8=not applicable 
   
 
Has the patient ever had an abnormal MRI 
scan? 
 1=yes, confirmed by Unit staff 
 2=yes, reported by local staff, scan not
     available for confirmation by Unit staff 
 3=no 
 8=no scan performed 
 
(If yes), record the date on which the first 
abnormal scan was performed? 
 
 
(If yes), specify what abnormalities have been 
observed  
 
 
 
 
 
 
  ____/____/________ (dd/mm/yyyy) 
 
 
  
 ________________________________________ 
 
  ________________________________________ 
 
  ________________________________________ 
 
Please complete MRI results sheet on page 31 when scan has been reviewed at NCJDRSU 
 
 
(If an abnormal MRI scan has been reported by someone outside the unit) who reported the 
abnormal scan? 
 
Name: ____________________________________________________________________ 
 
Address ___________________________________________________________________ 
 
___________________________________________________________________________ 
 
___________________________________________________________________________ 
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4.4 CSF findings (fill coding boxes with 8s if test results are not available) 
 Date of first CSF collection   
____/____/________ (dd/mm/yyyy) 
 Results:         protein 
          .       g/l 
 
CSF glucose 
serum glucose        .    mmol/l 
 
WBC 
RCC 
             count/mm3 
 14-3-3 
 1=negative     4=bloodstained 
 2=equivocal    5=not suitable/uninterpretable 
 3=positive       6=weak positive 
 S100b 
       .             ng/ml 
 RTQuIC 
 1=negative     4=blood-stained 
 2=equivocal    5=not suitable/uniterpretable 
 3=positive        
 Ig oligoclonal bands in:            CSF  1=positive, 2=negative       
 blood  1=positive, 2=negative       
 Date of second CSF collection   
____/____/________ (dd/mm/yyyy) 
 Results:         protein 
          .        g/l 
 
CSF glucose 
serum glucose        .    mmol/l 
 
WBC 
RCC 
             count/mm3 
 14-3-3 
 1=negative     4=bloodstained 
 2=equivocal    5=not suitable/uninterpretable 
 3=positive       6=weak positive 
 S100b 
       .             ng/ml 
 RTQuIC 
 1=negative     4=blood-stained 
 2=equivocal    5=not suitable/uniterpretable 
 3=positive        
 Ig oligoclonal bands in:            CSF  1=positive, 2=negative       
 blood  1=positive, 2=negative       
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4.5 Has the subject had neurophysiology studies done?  
    
 
 
 1=yes 
 2=no 
 9=not known 
4.6 Has the subject had any abnormalities on other routine 
biological/haematological investigations during this illness? 
  
 
 1=yes 
 2=no 
 9=not known 
 
 
(If yes), describe the investigation(s) and the abnormalities: 
 
____________________________________________________________________________ 
 
____________________________________________________________________________________ 
 
____________________________________________________________________________________ 
 
____________________________________________________________________________________ 
 
____________________________________________________________________________________ 
 
____________________________________________________________________________________ 
 
____________________________________________________________________________________ 
 
____________________________________________________________________________________ 
 
____________________________________________________________________________________ 
 
____________________________________________________________________________________ 
 
4.7  Has the subject undergone neuropsychological assessment?  1=yes 
 2=no 
 9=not known 
 Type of examination? 
 1=MMSE 
 2=Other, specify_______________________________ 
 3=Formal Neuropsychometry 
      4= Multiple 
 
 Result Score for MMSE __________________________________ 
 
Score from other test (score) 
__________________________________ 
(please specify other test) 
 
 
Is neuropsychology report 
available? 
 1=yes 
 2=no 
 9=not known 
   
4.8 Has the subject undergone a brain biopsy?  1=yes 
 2=no 
 9=not known 
 
(If yes), were there any complications? 
Result _____________________________________________ 
 1=yes 
 2=no 
 9=not known 
   
4.9 Has the subject undergone a tonsil biopsy?  1=yes 
 2=no 
 9=not known 
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(If yes), were there any complications? 
Result _____________________________________________ 
 1=yes 
 2=no 
 9=not known 
   
 
4.10 Specimens Collected 
  1=yes   
  2=no  Quantity (mls) 
 Blood: Frozen for general use 
  
 
  
  Separated and frozen  
 
  
 Urine   
 
  
 CSF 
 
  
 
4.11 Post Mortem 
 
 
 Date of death:  ____/____/________ 
 Was a post mortem performed? 
 1=yes    
  2=no   
 9=not known 
 (If yes), is neuropathological material available? 
 
 
(If material is available) is material available in Edinburgh? 
 
 1=yes 
 2=no 
 8=not applicable 
 9=not known 
  
 Are post mortem results available? 
 1=yes    
  2=no   
 9=not known 
 
   
4.12 PrP Genotype 
 
 
 Are PrP genotype data available? 
 1=yes    
  2=no   
 9=not known 
 (If yes), what was the subject’s codon 129 genotype 
 1=MM    
  2=MV  
 3=VV 
 (If yes), did the subject carry a mutation? 
 1=yes    
  2=no   
 8=not done 
 9=missing 
 (If mutation), specify: _______________________________________________________ 
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4.13 Subject Classification  
 On the basis of the available information, what is the 
classification of the subject? 
                   1.0=definite CJD 
                   2.0=probable CJD 
          .           3.0=possible CJD 
         4.1=diagnosis unclear 
         4.2=CJD thought unlikely  
          4.3=definitely not CJD 
                5.0=GSS 
                      0.0=unclassified 
 
 
(If subject is classified as at least possible CJD or 
GSS) which category of disease is suspected? 
 S=sporadic CJD 
 N=variant CJD 
 G=genetic/familial CJD 
  I=iatrogenic CJD 
 G=GSS 
 
  
Presenting symptoms  1=rapidly progressive dementia 
2=Heidenhain 
3=Pure psychiatric onset 
4=progressive dementia 
5=pure cerebellar onset 
6=stroke-like onset 
8=other, specify: __________________________________ 
9=missing 
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MRI DATA SHEET 
 
Patient name:  
NCJDRSU number:  
MRI date:  
 
 
Format:    CD / Films   Films loaded: Yes / No 
 
 
MRI sequences: T1/T2  C / S / A 
 
   Flair  C / S / A 
 
   DWI  C / S / A 
 
 
Quality of scan:  1=excellent; 2=good; 3=average; 4=sufficient; 5=insufficient; 
6=poor 
 
  RIGHT LEFT 
  FLAIR DWI FLAIR DWI 
Basal ganglia Caudate     
 Putamen     
 Globus pallidus     
Thalamus Anterolateral thalamus     
 Mediodorsal thalamus     
 Pulvinar     
Cortex Cingulate gyrus     
 Insular region     
 Hippocampi     
 Frontal     
 Parietal     
 Temporal     
 Occipital     
 
SUMMARY Pulvinar sign: Yes / No 
 Basal ganglia high signal: Yes / No 
 Number of areas of cortical high signal  
 
OVERALL IMPRESSION Inadequate scan  
 Not suggestive  
 Suspicious but not diagnostic  
 Positive scan  
   
Other findings: 
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